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ABSTRACT
STRUCTURE-BASED DESIGN OF INHIBITORS OF CXCR4
Jason Bradley Meier
November 17,2011
Metastasis is a complex process requiring directed migration of metastatic
cells to favorable microenvironments. Increased CXCR4 expression has been
implicated in more invasive, aggressive and metastatic tumor phenotypes and
poor patient survival in twenty-three forms of cancer. CXCR4 has been linked to
cancer metastasis and CXCR4 expression on the cell surface of tumor cells has
been linked to increased migration and homing of neoplastic cells to sites where
stromal cells express the chemokine CXCL 12 such as the lung and bone
marrow. In this dissertation, we will utilize structure based drug design to identify
inhibitors of CXCR4 targeting the extracellular surface of the receptor, as well as
the intracellular interface between the GPCR and G-protein. Our screens of the
extracellular surface identified one compound, ECLVS14, which inhibits
chemotaxis with an IC50 value of 5 j..IM, and is highly selective for CXCR4
without significant cytotoxicity. Subsequent QSAR analysis of the structure of this
inhibitor reveals the importance of the 1-[bis (phenyl methyl) amino] methyl moiety
and the fact that electronegative modifications of the terminal benzene enhance
activity. Subsequent Molecular dynamics simulations of the compound in
complex with CXCR4 reveal that the compound induces significant modifications
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of the receptor structure. Our intracellular screens represent a novel screening
strategy targeting the intracellular region of CXGR4 interacting with Gai, which
identified ten compounds selectively inhibiting GXGR4 with IG50 values of 10 IJM
or less. Three of the most active compounds from the extracellular and
intracellular screens were tested in an in vivo anti-metastatic animal model,
successfully demonstrating the anti-metastatic activity of these compounds. In
total this work demonstrates that structure based drug design utilizing in silico
analysis in combination with in vitro and in vivo testing can be utilized to develop
novel lead compounds which can function as anti-metastatics.
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CHAPTER I: INTRODUCTION
Metastasis presents an unresolved and difficult clinical problem
Tumor metastasis represents a significant portion of the morbidity and
mortality attributable to neoplasia [1]. Axillary lymph node micrometastasis or
occult metastasis of 2mm or less correlates poorly with disease-free and overall
survival [2]. Bone metastasis is present in 30-50% of patients with highly
metastatic cancers such as breast, prostate, and non-small cell lung cancer [3].
Development of metastases requires a complex process of cellular
evolution including several distinct transitions from primary carcinoma in situ to
cells capable of establishing new metastatic foci, (see Figure 1) [4, 5].
Neoplastic cells must proliferate and invade at the primary site. These cells must
then leave the primary tumor and enter the blood stream, in a process known as
intravasation. Neoplastic cells extravate from the blood stream and attach to
surfaces at foci of metastasis [6]. Established by Paget in 1889, the "seed and
soil hypothesis" stipulates that neoplastic cells only establish metastatic foci in
favorable microenvironments [6, 7].
The diffuse and systemic nature of metastatic disease renders many
conventional treatment modalities ineffective, presenting a particularly perplexing
predicament for treatment. Prior to metastasis, neoplasia can be
effectivelytreated by surgical excision with clear margins and localized radiation.
Once the neoplastic cell's metastatic capability is disabled, the disease reverts to
1

Figure 1: The process of metastasis of neoplastic cells from primary
tumors to target organs. Neoplastic cells proliferate and invade at their primary
locus. Selected cells gain the capability of leaving the primary tumor and entering
the systemic circulation. Tumor cells extravate in target organs such as the lung,
liver, bone marrow and brain. Once adherent, selected neoplastic cells will
survive in favorable microenvironments and proliferate to form metastatic foci.
Reproduced from [6].
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Figure 1: The process of metastasis of neoplastic cells from primary
tumors to target organs.
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an earlier stage, and becomes a cancer that is once again isolated to its primary
site and any metastatic foci. Neoplastic growth would continue in a linear fashion,
but without systemic spread, conventional surgery/chemoradiation could have a
greater probability of success. An anti-metastatic approach largely mirrors the
clinical reality. For example, 84% of newly diagnosed lung cancer has already
progressed past early stage disease upon time of diagnosis [8], making treating
and inhibiting the metastasis of the primary tumor a greater concern than
inhibition of the growth of the primary tumor. Unfortunately there are no primary
anti-metastatic treatments approved by the FDA or in clinical trials.
CXCR4 plays a key role in Tumor metastasis.
A wide number of molecules such as cytokines, chemokines and their
receptors and growth factors have been implicated in the metastatic properties of
cancer cells [9-15]. In 2001 the involvement of chemokine receptors in breast
cancer metastasis was reported [9]. In a seminal Nature paper, Muller et al
delineated a theory of metastasis which centered on chemoattraction, a process
illustrated in Figure 2. Metastatic breast cancer cells displayed increased cell
surface expression of CXCR4 and CXCR4's ligand CXCL 12 was highly
expressed in lung, lymph node, bone marrow and liver tissues. Muller found that
CXCL 12 induced more malignant and metastatic phenotypes with increased
actin modification and pseudopodia formation in cells expressing CXCR4.
CXCL 12 and CCL21 also were found to induce metastatic cell migration. Protein
extracts from several organs were found to induce chemotactic migration by the
cancer cells, with lung, lymph node, bone marrow and liver tissues inducing the
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Figure 2: Metastatic breast cancer cells migrate to regions of elevated
CXCL 12 concentration. Reproduced from [16]. MOiler et al. found that
metastatic breast cancer cells (patient samples and in the MDA-MB-231 cell line)
express elevated levels of cell surface CXCR4. CXCR4 ligand CXCL 12
expression was increased in sites of metastatic foci, including lymph nodes, lung,
liver and bone marrow. Metastatic cells migrated to regions of elevated CXCL 12
concentration, and cells with elevated CXCR4 surface expression formed stable
metastatic foci.
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Figure 2: Metastatic breast cancer cells migrate to regions of elevated
CXCL 12 concentration.
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most migration. Finally, metastasic models, using mammary fat pad or tail vein
injection of metastatic MDA-MB-231 cells, CXCR4 neutralization by antibody was
found to reduce lung metastasis with a rate of relative suppression of 61-68%.
CXCR4 has been demonstrated to playa critical role in angiogenesis [17]
and metastasis [18] of several tumors, including basal cell carcinoma [17], thyroid
cancer [18], squamous cell carcinoma [19], neuroblastoma [20], ovarian [21],
melanoma [22], renal cell carcinoma [23], hepatocellular carcinoma [24], breast
[25], colon [26], lung [25], pancreatic [27] and prostate cancers [25]. Chinni et al
expanded on the Muller theory by demonstrating that bone metastatic prostate
cancer cells express cell surface CXCR4, and the CXCR4/CXCL 12 interaction
was essential to migration and bone marrow invasion [28]. Additional research
has determined that knockdown or inhibition of CXCR4 impedes growth [29] and
metastasis [9, 30, 31] of neoplastic breast cancer cells. Phillips et al [32]
demonstrated that non-small cell lung cancer (NSCLC) tumor specimens and
NSCLC derived cell lines, (such as A549) express CXCR4 and that these cells
migrate towards CXCL 12, with increased intracellular signaling in the form of
increased intracellular calcium mobilization and MAPK activation. They also
demonstrated that NSCLC metastasis could be prevented in nude mice through
the application of a CXCR4-specific antibody, with rate of relative suppression of
around 50% for bone marrow and brain metastasis.
A recent publication by Karnoub et al [33] suggested an alternative
mechanism for metastasis. In this report, they demonstrated that mesenchymal
stem cells (MSCs) within the tumor stroma can induce increased metastasis in
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primary tumors. Their mechanism for this increased metastasis centered on
increased CCl5 production by MSCs inducing enhanced AKT phosphorylation
which resulted in increased tumor motility and invasiveness. While this paper
would seem to cast some doubt on CXCR4's role in metastasis, several factors
speak to the importance of CXCR4 in this process. Active MSCs have been
characterized as retaining enhanced expression of CXCR4 and CXCl12 [34].
Also, a more recent study using C090 high expressing cells (a common marker
for MSCs) found that co-culture or incubation in conditioned medium resulted in
increased CXCR4 expression in BPH-1 cells [35]. Muelberg et al [36] recently
demonstrated increased motility, invasion and metastasis in breast cancer cells
using Adipose tissue derived stem cells. They found this increased metastasis
was largely effected by BCCs inducing increased secretion of CXCl12 by the
Adipose tissue derived stem cells, and that the enhanced- metastasis phenotype
could be abolished by CXCR4 knockdown in tumor cells.
CXCR4 expression by the tumor cells allows for tumor cell migration, and
homing of the neoplastic cells to sites where non-malignant stromal cells express
CXCl12 [37]. This implies that tumor cell metastasis is not a random event, but
directed by the expression of chemokine receptors and adhesion molecules on
the neoplastic cells, and their respective ligands in the target organs [9, 16].
Tumor cells utilize this mechanism to access microenvironments, such as the
bone marrow, that provide factors that favor their growth. For example, the
importance of CXCR4 for breast cancer metastasis to different target organs has
been demonstrated in vitro and in vivo [9]. leukemia cells from patients with
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chronic lymphocytic leukemia (Cll) and acute lymphoblastic leukemia utilize
CXCR4 for homing to marrow stromal cells in vitro [38] and in vivo [39].
Moreover, CXCl12 has a direct growth and survival-promoting effect for various
cancer cells, such as breast cancer cells [40] or Cll cells [41]. CXCl12
promotes tumor progression by recruiting endothelial progenitor cells to tumors
for angiogenesis [40].
CXCR4 was originally characterized as a co-receptor for T-tropic strains of
HIV-1.

Originally dubbed "lESTR", or "leukocyte-derived seven-transmembrane
domain receptor" [42], CXCR4 was an orphan G-protein coupled receptor
(GPCR) when it was identified as the co-receptor for T-tropic strains of the
human immunodeficiency virus-1 (HIV-1) [43]. CXCR4 was offiCially named
following the identification of its cognate ligand CXCl12, (previously identified as
stromal derived factor-1) through experiments demonstrating that CXCR4
interaction with CXCl12 inhibited HIV-1 infection [44, 45]. It was found that the
N-terminal region of CXCR4 was essential to HIV-1 entry [46] and that complex
interactions between the N-terminus and second extracellular loop (ECl2) of
CXCR4, GP120 and CD4 and the V3 loop of HIV-1 are important for HIV-1
infection, as illustrated in Figure 3 [47-50]. Interaction between gp120 and CD4
results in a conformational change of gp120, allowing binding of the co-receptor,
in this case, CXCR4. Interactions between gp120 and CXCR4 induce further
conformational changes in the complex, resulting in insertion of the fusion
peptide of gp41 into the cell membrane of the host T-cell membrane [51].
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CXCR4 and CXCL 12 play essential roles in the physiology of the
developing embryo.
CXCR4 is constitutively expressed in many tissues including stomach,
small intestine, brain, lymphatics, thymus and spleen and serves to direct
migration for numerous cell types [52]. CXCR4 mediated migration serves a
variety of functions, from facilitating repair of damaged liver tissue [53] to
endochondral bone formation [54].
CXCR4 also plays an important role in development as CXCR4 deletions
are lethal in utero, with embryos displaying defects in neuronal and cardiac
development [55-57] as well as defects in neovascularization [24]. CXCR4
regulates the migration of primordial germ cells in the formation of the nervous
system [58]. CXCR4 and CXCL 12 are also essential to the proper migration of
cells associated with the cerebellum, dentate gyrus and dorsal root ganglia [5961]. Finally, CXCR4/CXCL 12 interaction controls cortical interneuron migration
and positioning [62].
CXCR4 mediated signaling is also essential to the formation of the
primordial gut, known as the cloaca, [63] as well as the formation of the vascular
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Figure 3: Complex interactions between CXCR4, gp120, CD4 and the V3
loop of HIV-1 guide fusion of the HIV-capsule to the host cell membrane.
Reproduced from Cohen et al [64]. Interaction between gp120 and CD4 results
alters the conformation of gp120 resulting in CXCR4 binding of gp120. CXCR4:
gp120 interaction induces insertion of the fusion peptide of gp41 into the cell
membrane of the host T-cell membrane [51].
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Figure 3: Complex interactions between CXCR4, gp120, CD4 and the V3
loop of HIV-1 guide fusion of the HIV-capsule to the host cell membrane.
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system of the GI tract [65, 66]. The CXCL 12/CXCR4 axis is also responsible for
maintaining mucosal barrier integrity in the gut by regulating epithelial cell
migration, barrier maturation, and reconstitution [67].
CXCR4 heterozygous mutation can lead to WHIM (warts,
hypogammaglobinemia, infections, and myelokathexis) syndrome [68]. The
structural basis of WHIM syndrome pathology stems from a C-terminus deletion
of CXCR4, most commonly at R334 [69]. This C-terminal deletion produces a
two-fold increase in signaling, while rendering the GPCR strongly resistant to
ligand-mediated downregulation [69].

Essential role of CXCR4 signaling in cell mediated immunity
CXCR4 and CXCL 12 signaling is essential to immune physiology. CXCR4
is widely expressed on leukocytes, and serves to regulate leukocyte
hematopoesis and trafficking [68] as well as anchoring developing cells to
specific regions of the bone marrow [70]. NaYve T-Iymphocytes express CXCR4,
and this expression is essential in directing T-cell migration to the thymus for
maturation. Once in the thymus, the interaction between CXCR4 and CXCL 12 is
critical to the intra-thymic migration of immature T-cells [71]. In the spleen, lymph
nodes, and tonsils, CXCR4 is essential to the formation of properly structured
lymphoid follicles and population of germinal centers by controlling the trafficking
of 8-cells, T-cells and plasma cells [72, 73]. In mature neutrophillic leukocytes,
increased CXCR4 expression has been associated with cell aging, and
sequestration in the liver, spleen and bone marrow before apoptosis [74]. While
increased CXCR4 expression and activation has been associated with increased
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migration in the leukocyte compartment, decreased CXCR4 expression and
activation has been associated with increased circulating active leukocytes [75],
and increased activation of T-cell receptors on T -lymphocytes [76].
One of the more interesting roles of CXCR4 in the immune compartment
involves its role in regulation of neutrophil mobilization. Petit et a/ demonstrated
that neutrophils are maintained in the bone marrow by CXCR4-CXCL 12
signaling. Specifically, it is the production of CXCL 12 by bone marrow stromal
cells which maintains the interaction between CXCL 12 and CXCR4, and when
factors such as granulocyte colony stimulating factor (G-CSF) decrease stromal
CXCL 12 production by inhibiting CXCL 12 mRNA expression, stem cells are
mobilized [77, 78]. This effect is seen in a variety of pathological situations,
including sepsis where depressed marrow CXCL 12 expression combined with
enhanced CXCL 12 expression in the spleen has been demonstrated to drive
neutrophil mobilization and leukocytosis in response to overwhelming infection
[79]. CXCR4's role in sequestration of hematological stem cells in the bone
marrow is also highlighted by CXCR4 inhibitor AMD3100. Inhibition of CXCR4
decreases CXCR4-CXCL 12 signaling, producing rapid mobilization of
hematopoietic stem cells [80-82], a finding that resulted in FDA approval of
AMD3100 as a mobilization agent for hematopoietic stem cells for autologous
transplantation in non-Hodgkin's lymphoma and multiple myeloma [80].
Because of CXCR4's critical role in immunity some may question the
wisdom of using it as a chemotherapeutic agent. They may suggest that
inhibition of immunity at a time when patients are already immunocompromised
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due to elevated tumor burden would be unwise. However, this really isn't the
case with cancer chemotherapy. One of the most common side effects of
common chemotherapeutic agents such as cisplatin, adriamycin,
cyclophosphamide and mercaptopurine is myelosuppresion, which results in a
nadir 21-28 days after treatment is begun when white blood count can drop to
almost zero. Several chemotherapy regimens include prednisone, a
corticosteroid which suppresses the immune system. The counter to
symptomatic myelosuppression has been treatment with G-CSF, which acts by
inhibiting CXCR4 signaling.
G-Protein Coupled Receptors: sensors of external and internal stimuli
CXCR4 is a seven-transmembrane-helix G-protein coupled receptor
(GPCR) which binds CXCl12, a CXC chemokine. Structurally, CXCR4 and other
GPCRs are characterized by seven membrane spanning helical domains, an
extracellular amino terminus, and an intracellular carboxyl terminus. The seven
transmembrane (TM) domains are joined by three extracellular (ECl) and three
intracellular (ICl) loops as illustrated in Figure 4. Humans express 750 GPCRs
which serve as sensors of external and internal stimuli by transmitting signals
through the cell membrane and activation of cytoplasmic signaling cascades [83].
As seen in Table 1, GPCRs are divided into 6 classes, based on the Vriend
classification system for GPCRs [84]. Class A GPCRs, which are rhodopsin-like,
encompass 80% of GPCRs [85]. CXCR4 is a Class A GPCR. Class B, secretinlike, class C, metabotropic glutamates, class 0, pheromones, class E, cAMP
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Figure 4: Linear structure of CXCR4. G-Protein coupled receptors are
characterized by seven transmembrane receptors joined by three extracellular
and three intracellular loops, with an extracellular N terminus and an intracellular
C terminus. Adapted from [86].
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Figure 4: Linear structure of CXCR4.
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Table 1: GPCR Classifications. Under the Vriend classification system [84] for
GPCRs, class A GPCRs, which are rhodopsin-like, encompass 80% of GPCRs.
CXCR4 is a Class A GPCR. Class B, secretin-like, class C, metabotropic
glutamates, class 0, pheromones, class E, cAMP receptors, and the class F
frizzled/smoothened family encompass the other 20% of these receptors.
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Table 1: GPCR Classifications.

GPCR Family

Family Description

Class A

Rhodopsin-Like

Class B

Secretin-Like

Class C

Metabotropic glutamates/pheromones

Class D

Fungal Pheromone

Class E

cAMP receptors

Class F

Frizzled/Smoothened
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receptors, and the class F frizzled/smoothened family encompass the other 20%
of these receptors. Phylogenetic analysis has allowed further subclassification of
the Class A GPCRs into distinct sub-families as depicted in Table 2 [87]. CXCR4
belongs to subfamily A2 in this classification system, which encompasses the CC
and CXC chemokines, as well as adrenomedullin and the Duffy antigen.
GPCR activation triggers coupling with heterotrimeric G-proteins
consisting of a,

~,

and V subunits. Upon interaction with an activated GPCR,

GOP bound to Ga will be exchanged for GTP, facilitating a separation of the
heterotrimer into Ga and

G~y

subunits. These subunits in turn activate

downstream signaling pathways until intrinsic GTP-ases in Go convert GTP to
GOP, facilitating the reformation of the G-protein heterotrimer.
Chemokines: small protein regulators of a variety of physiological
processes
Chemokines are a superfamily of small molecule chemoattractive
cytokines that mediate several cellular functions. Chemokines are classified by
the conformation of a conserved amino-terminal cysteine residue motif, as
depicted in Table 3 [88, 89]. Chemokines and their receptors regulate
chemotaxis and the transendothelial migration of leukocytes were recently
observed to play an important role in the metastasis of various cancers [90], as
well as homeostasis, cell proliferation, hematopoesis, angiogenesis and
neovascularization [88]. Chemokines also have important roles outside the
hematopoietic compartment, for example, GROa has been shown to be an
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Table 2: Subclassifications of Class A GPCRs. CXCR4 belongs to subfamily
A2 in this classification system, which encompasses the CC and CXC
chemokines, as well as adrenomedullin and the Duffy antigen. The BLT/LTB4
signaling pathway belongs to the A5 class of receptors. Rhodopsin is classified
as a class A 16 receptor with the rest of the Opsin receptors.
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Table 2: Subclassifications of Class A GPCRs.
Subfamily

Representative Receptors

A1

CC and CX3C Chemokines

A2

CC, CXC, and IL-8

A3

Angiotensin and Bradykinin

A4

Opiod, Somatostatin, Neuropeptides BIW

A5

Leukotriene B4 receptors, Relaxin, Galanin

A6

Cholecystokinin, Vasopressin, Orexin

A7

Bombesin, Endothelin, TRHR

A8

Anaphylatoxin receptor, Formyl peptide receptores

A9

Melatonin, Neurokinin, Neuropeptide Y

A10

FSH receptor, LH Receptor, Thyrotropin receptor

A11

GPR40 and P2 Purinoreceptor

A12

P2 Purinoreceptor, Platelet-activating factor

A13

Cannabinoid receptor, Lysophosphatidic acid receptor,
Melanocortin/ACTH receptor

A14

Eicosanoid receptor

A15

Protease-activated receptor, Proton-sensing GPCRs

A16

Opsins

A17
A18
A19

5-Hydroxytryptamine (5-HT) receptor, Adrenergic receptor,
Dopamine receptor, Histamine H2 receptor
Histamine Receptor, Adenosine receptor, Muscarinic
acetylcholine receptor
5-Hydroxytryptamine (5-HT) receptor
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Table 3: Chemokines are classified by the conformation of a conserved
amino-terminal cysteine residue motif. Chemokines serve a variety of
functions in the regulation of the immune system as well as in control of
homeostasis, cell proliferation, haematopoiesis, angiogenesis and
neovascularization in neoplasia. Adapted from [88].
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Table 3A: CXC, C, and CX3C Chemokines, and their receptors.
Human ligand

Receptor(s)

CXCL1

GROa/MGSAa

CXCR1, CXCR2

CXCL2

GROI3/MGSAI3

CXCR2

CXCL3

GROy

CXCR2

CXCL4

PF4

CXCR3B

CXCL5

ENA-78

CXCR2

CXCL6

GCP-2

CXCR1, CXCR2

CXCL7

NAP-2

CXCR2

CXCL8

IL-8

CXCR1, CXCR2

CXCL9

MIG

CXCR3, CXCR3B

CXCL 10

IP-10

CXCR3, CXCR3B

CXCL 11

I-TAC

CXCR3,CXCR3B,CXCR7

Chemokine
CXC Chemokine

a/l3

CXCR4, CXCR7

CXCL 12

SDF-1

CXCL 13

BLC/BCA-1

CXCR5

CXCL 14

BRAK, Bolekine

Unknown

CXCL 15

Unknown

Unknown

CXCL 16

SICB6

CXCR6

CXCL 17

DMC

Unknown

XCL1

Lymphotactin/ATAC/SCM-1 a

XCR1

XCL2

SCM-113

XCR1

Fractalkine

CX3CR1

C chemokines

CX3C Chemokines
CX3CL 1
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Table 38: CC Chemokines, and their receptors.
Human Ligand

Receptor( s)

CCl1

1-309

CCR8

CCl2

MCP-1/MCAF/TDCF

CCR2

CCl3

MIP-1a/lD78a

CCR1, CCR5

CCl3l1

lD78~

Unknown

CCl3l3

lD78~

Unknown

CCl4

MIP-1~

CCR5

CCl4l1

AT744.2

Unknown

CCl5

RANTES

CCR1, CCR3, CCR5

CCl7

MCP-3

CCR1, CCR2, CCR3

CCl8

MCP-2

CCR1, CCR2, CCR3, CCR5

CCl11

Eotaxin

CCR3

CCl13

MCP-4

CCR1, CCR2, CCR3

CCl14

HCC-1

CCR1

CCl15

HCC-1/lKN1/MIP-1y

CCR1, CCR3

CCl16

HCC-4/lEC/lCC-1

CCR1, CCR2, CCR5, HRH4

CCl17

TARC

CCR4

CCl18

DC-CK1/PARC/AMAC-1

Unknown

CCl19

MIP3~/ElC/exodus-3

CCR7

CCl20

MIP3a/LARC/exodus-1

CCR6

CCl21

SlC/6Ckine/exodus-2

CCR7

CCl22

MDC/STCP-1

CCR4

CCl23

MPIF/CK~8/CK~8-1

CCR1

CCl24

Eotaxin-2/MPI F-2

CCR3

CCl25

TECK

CCR9

CCl26

Eotaxin-3

CCR3

CCl27

CTACKlllC

CCR10

CCl28

MEC

CCR3, CCR10

Chemokine
CC Chemokine
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autocrine growth factor in melanoma [91]. In addition, decoy chemokine
receptors bind ligands with high affinity but negligible activity, in order to control
the availability of chemokine for receptor and fine tune directionality of chemical
gradients [88, 89, 92].

GPCR signal transduction is based on movement of transmembrane
helixes
The theory of G-protein function is largely based on the opsin model,
wherein interaction between ligand and receptor disrupts an ionic lock between
TM3 and TM6. This in turn disrupts several stabilizing interactions between the
TM regions allowing the GPCR to shift from an inactive to an active state capable
of interacting with a G-protein [93-96]. GPCRs are also capable of forming homo
and hetero dimers and oligomers, allowing protein function to vary with
quaternary structure [83, 97-103].
The lack of insight into GPCR structure is largely due to the difficulty in
expressing, purifying, and solubilizing the large amounts of protein required for

x-

ray crystallography. The original mammalian crystal structure, bovine rhodopsin
[104] was generated by micelle suspension of rhodopsin, which required
harvesting the GPCR from a large volume of bovine retinas, a process which
benefitted from the relatively undynamic structure of rhodopsin when compared
to other GPCRs [104-107]. Similar large volume purification protocols were used
in the crystallization of opsin [95].
Developing the capability of producing massive volumes of functional
receptor from baculovirus infected insect cells, coupled with antibody-mediated
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stabilization methods to stabilize the third intracellular loop (ICL3) region of the
GPCR allowed initial crystallization of the f32-adrenergic receptor [108]. Higher
resolution structures of the f32-adrenergic receptor were generated by
replacement of the ICL3 region with T 4 Lysozyme (T4L) a soluble and stable
protein [109, 110] which exchanges a mobile and flexible unit for a solid and
immobile element which is a desirable characteristic in the development of wellordered three dimensional crystals. Utilization of the T 4L replacement technique
along with replacement of the C-terminal tail with a histidine purification epitope
allowed successful crystallization of the a2A adenosine receptor [111].
Comparison of the rhodopsin, f32-adrenergic receptors and the a2A
adenosine receptor structures offers some key insights into the functional
differences between the GPCRs, as depicted in Figure 5. At the extracellular
surface of the receptors, there are significant differences in the placement of
ECL2 and the N-terminus. In Rhodopsin, the ECL2 and the N-terminus the
GPCR combine to form a f3-sheet which covers the binding pocket of the protein
and prevents cis-retinal hydrolysis. ECL2 in the f32-adrenergic receptor forms an
a helix which is displaced away from the ligand binding site by two disulfide
bonds. ECL2 on the a2A adenosine receptor is characterized by formation of an
a helix restrained by disulfide binding as in the case of the f32-adrenergic
receptor however in the case of a2A adenosine, there are 2 additional disulfide
bonds on the helix, and the surface of the binding site displays significantly lower
electron density than that of the f32-adrenergic receptor.
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Figure 5: Receptor structures and ligand binding sites for GPCR crystal
structures. Structures are presented in ribbon format for A) bovine
rhodopsin/retinal (PDBID: 1F88), B)
1F88), C)

~2-adrenergic

~2-adrenergic

receptor/carazolol (PDBID:

receptor/timolol (PDBID: 1F88), and D) a2A-adrenergic

receptor/ZM241385. Bound ligands are depicted as spheres in the ribbon helix
format and as stick figures in the ligand binding site images. Modified from [112].
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Figure SA: Receptor structures for GPCR crystal structures.
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Figure 58: Receptor ligand binding sites for GPCR crystal structures.

30

On the intracellular surface of the rhodopsin crystal structure, the second
intracellular loop (ICL2) is displaced away from the central TM helixes. In the
crystal structures of 132-adrenergic receptor and a2A adenosine receptor, ICL2
interacts with the intracellular surfaces of TM2, TM3, TM5 and TM6, specifically
with the thirtieth residue of TM6, disrupting the formation of the ionic lock formed
by this glutamate residue as seen in rhodopsin. In addition, ICL2 of the a2A
adenosine receptor forms a short helical motif not seen in the other receptor
structures. In the cases of the 132-adrenergic receptor, the a2A adenosine
receptor replacement of the ICL3 region and removal of the C-terminal tail could
also explain these differences with the rhodopsin structure. (Reviewed in [93,
107,112-115])
CXCL 12 activity is governed by structure and posttranslational
modifications
The structure of CXCL 12 has been identified by crystal structure
determination. CXCL 12 is a 67 residue polypeptide with an n-terminalloop,
followed by three anti-parallel l3-strands, and a c-terminal a-helix packed against
the l3-sheet [116]. CXCL 12 exists in equilibrium between monomeric and dimeric
structures and the chemokine aggregates at nonacidic pH and in response to
multivalent anions like phosphate, sulfate, citrate, or heparin [117, 118]. CXCL 12
activity is regulated by the protein carboxypeptidase N, which cleaves CXCL 12's
C-terminal lysine, disabling the chemokine's proliferative and chemoattractant
abilities [119]. A CXCL 12 ligand lacking the C-terminal a-helix can still bind and
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induce internalization of CXCR4, but does not induce calcium mobilization, ERK
phosphorylation, or chemotaxis [120].
CXCl12 signaling occurs in a two-site / two-step reaction as depicted in
Figure 6. In this reaction, the N-terminus of CXCR4 interacts with the R-F-F-E-SH motif of the N-terminal loop of CXCl12 [121-123]. This triggers a
conformational change in the CXCR4 N-terminus bringing CXCl12 into contact
with the extracellular portions of TM2 and TM7 as well as ECl1 and ECl2 [122].
The extracellular binding interface of CXCl 12 was described by Brelot et al as
composed of residues 097 on TMII, 0187 on ECl2, and E288 on TMVII [124].
Ligand binding at these points is largely driven by hydrogen bond interactions
between the highly basic surface of CXCl12 and the acidic residues of CXCR4.
Interaction between the N-terminus of CXCl12 and extracellular surfaces of the
TM helixes produces signal transduction [121, 125, 126].

CXCR4 signal transduction is determined by CXCR4 structure.
CXCR4 is characterized structurally by seven membrane spanning helical
domains, an extracellular amino terminus, and an intracellular carboxyl terminus.
The seven TM domains are joined by three ECl and three ICl loops. The
extracellular loop region consists of 4 SUb-regions: the N-terminal strand from
residues 1 to 39, the ECl1 encompassing residues 98 to 109, the ECl2
extending from residue 176 to 202, and the ECl3 from 262 to 282. Initial studies
into the interaction of CXCR4/CXCl12 revealed that the N-terminal strand is
essential to the interaction of chemokine and receptor, while reduced binding and
signaling was seen in mutations to the extracellular portions of TM2 and TM7 as
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Figure 6: Two-site I two-step interaction between CXCL 12 and CXCR4. In
the two-site / two-step reaction, the RFFESH loop of the N-terminus of CXCL 12
binds to the N-terminus of CXCR4, and the N-terminus of CXCL 12 subsequently
interacts with the extracellular surfaces of the transmembrane helixes. Adapted
from [121].
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Figure 6: Two-site I two-step interaction between CXCL 12 and CXCR4.
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well as ECl1 and ECl2. The N-terminus was essential to receptor transport to
the cell surface [124]. N-terminal deletions of CXCR4 impair CXCl12 binding and
signaling. Specifically, acidic (Glu14 and Glu15) and tyrosine (Tyr21) residues of
the n-terminus are required for CXCl12 binding [124].
The intracellular loop region consists of 4 SUb-regions: the first intracellular
loop encompassing residues 64-76, the second intracellular loop extending from
residue 132 to 155, ECl3 from 223 to 241, and the carboxyl-terminus of the
protein extending from residue 308 to 352. This region governs signal
transduction of the receptor, and has multiple interactions to stimulate signaling
cascades. Mutational analysis of the intracellular surface has defined several
essential elements to Signal transduction, including the DRY motif of the second
intracellular loop, which will inactivate receptor signaling if disrupted [124], and
the N-terminal region of ICl3, disruption of which eliminates CXCl12 mediated
signaling [124].
The interhelical segments are also essential for CXCR4 mediated signal
transduction. Zhang et al developed a series of mutations focused on the TM3
residue Asn 119 (N119). N119 mutation to Ser (N119S) or Ala (N119A) produced
a constitutively active conformation of CXCR4, while mutation to lys (N119K)
produced a constitutively inactive conformation of the receptor [127]. The N119S
conformation produced an elevated signaling level which could be further
stimulated by CXCl12 binding, in contrast to the N119A mutation which although
constitutively signaling at a level greater than the N119S mutant, could not be
further stimulated. The constitutively active mutants also both bound G-proteins

3S

to a greater extent than the native state of the receptor. In contrast to both of
these strains, N119K signaled poorly in response to CXCL 12 binding, and did not
bind G-proteins to any extent greater than the unstimulated native receptor.
CXCR4/CXCL 12 signaling occurs by a variety of pathways

CXCR4 signaling occurs primarily via the pertussis toxin-sensitive Gi
pathway, composed of Gai,

G~

and Gy [128]. CXCL 12 interaction with CXCR4

induces dissociation of Gai from the trimeric G-proteins, and

G~y

activates

several phosphorylation pathways, including ERK1/2, JNK, MAPK, and GSK
3a/~

[129]. Activation of the

G~y

subunit also results in signaling by the

Phospholipase C pathway to enhance calcium mobilization as well as signaling
by the Phosphoinositide-3-kinase pathway to activate AKT. CXCR4 binding of
CXCL 12 also serves to augment intracellular cAMP levels [130] and activate
cAMP-dependant signaling pathways, such as PKa or CREB [131,132]. The
combined activation of these factors results in cell migration [133-135].
Activation of these signaling pathways allows CXCR4 to induce several
changes in the cell phenotype. CXCR4 enhances cell adhesion by enhancing
binding between integrin couples such as VLA-4 and VCAM-1 [136]. CXCR4
stimulation produces a phenotype with enhanced invasiveness by increasing
AKT mediated MMP9 expression. Finally, CXCR4 facilitates cytoskeletal
rearrangement by stimulating actin polymerization by formation of F-actin [137].
CXCR4 expression in cancer cells can be enhanced by several factors including
demethylation [138], or increased expression of hypoxia inducible factor (HIF) 1a
[139]. CXCR4 activity can also be down-regulated in several fashions, such as
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internalization on lipid rafts and inactivation by

~-arrestin

binding due to excess

CXCL 12 [139] or repression of CXCR4 DNA by G-CSF [140].
CXCR4 internalization is in fact essential to CXCR4 function. Interactions
between

~-arrestin

and the C-terminus of CXCR4 govern receptor internalization

[141], but coexpression of CXCR4 with overexpression of

~-arrestin

has been

demonstrated to produce a 3-6 fold increase in CXCL 12-induced ERK
phosphorylation [142], as well as increased sensitivity to CXCL 12 to induce
chemotaxis [143], effects that could be blocked by knockdown of
expression [143]. In addition, once

~-arrestin

~-arrestin

has internalized CXCR4 it serves to

prevent degradation of the receptor [144] and modulates endosomal sorting to
recycle inactivated receptors back to the cell surface [145].
This produces a signaling model of CXCR4 based on receptor recycling.
Interactions between CXCR4 and CXCL 12 produce an active receptor, which
initiates multiple G-protein mediated signaling cascades. The active receptor
then interacts with

~-arrestin,

which silences CXCR4 by internalization.

Internalized receptors are then protected from degradation, inactivated and
recycled to the cell surface. The necessary balance between activation and
inactivation of CXCR4 is reflected in the activity of the WHIM variant of CXCR4.
In the CXCR4-WHIM variant, absence of several C-terminus residues impairs

~

arrestin-2 recruitment and binding, which produces a delay in internalization of
the receptor. Cells expressing the CXCR4-WHIM variant also displayed delayed
phosphorylation of Erk 1/2 [146]. This suggests that rapid cycling of CXCR4
augments the ability of the receptor to detect changes over time in the availability
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of ligand, producing a mechanism to fine tune the directionality of chemotaxis.
This explains the poor immune response of WHIM syndrome immune cells, in
spite of enhanced CXCL 12 mediated chemotaxis in WHIM patient leukocytes
[147] and lymphocytes [148].
There are multiple assays available to assess CXCR4-mediated signaling.
Some of the most common methods include assessment of CXCL 12-induced
calcium mobilization [149-151], phosphorylation of secondary Signaling
molecules such as ERK1/2, JNK, MAPK, and GSK
internalization assays to assess the activity of

3a/~

~-arrestin

[151-153], and
[142-144]. Assessment

of CXCL 12-induced calcium mobilization involves pretreating cells with Fura-2 or
Indo-I, fluorescent dyes which alter the ratio of their emissions in response to
exposure to calcium. Treatment with Triton X-100 releases mitochondrial calcium
stores providing a consistent measure by which assay results can be normalized,
thus this method provides a rapid, real time, consistent measure of CXCL 12induced signaling which is very amenable to usage in high-throughput processes.
Western blot analysis can be used to determine the quantity of
phosphorylated ERK1/2 and PI3K1AKT in a given sample. However, assessment
of protein phosphorylation requires lysis and purification of the protein samples,
preventing any assessment of signaling in real time. In addition, variability in
protein expression and signaling makes translation of this measurement to a
high-throughput process difficult.
Internalization assays to assess the activity of

~-arrestin

can be performed

utilizing fluorescently tagged receptor proteins, allowing cell surface expression
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of the receptor to be detected by fluorescent microscopy. Although receptor
internalization would be a very qualitative measurement of

~-arrestin

activity, the

results would be difficult to quantify, making comparisons between samples
different, and making it difficult to translate this method to high throughput
protocols.

GPCRs are common targets for pharmaceuticals
GPCRs account for the majority of the top selling pharmaceuticals and
roughly 40% of all licensed pharmaceuticals, a partial listing of which is
presented in Table 4. The serotonin receptor serves as the target for several
medications such as Resperdal, Zyprexa, Imitrex, Buspar, Prozac, Paxil, Zoloft,
and Effexor. The histamine receptors serve as targets for many pharmaceuticals
as well, including Claratin, Allegra, Zantac, Pepcid, and Gaster. Cardura, Flomax,
Hytrin, and Wellbutrin all function through inhibition of the alpha-adrenergic
receptor. Tenormin, Ventolin, Toprol-XL, and Serevent all inhibit the betaadrenergic receptor. Diovan, Vasotec, and Cozaar all inhibit the angiotensin"
receptor and the angiotensin-converting enzyme. Several other GPCR receptors
serve as targets for pharmaceuticals including the GABA (Diprivan), GNRH
(Lupron), histone deacetylase (Depakote), Leukotriene (Singulair), LHRH
(Zoladex), Muscarinic acetylcholine (Atrovent), and the prostanoid selective FP
receptor (Xalatan).

Several anti-CXCR4 compounds have been developed
Despite significant research, there is currently only one FDA-approved
CXCR4 inhibitor on the market, AMD3100, and that compound is designated
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Table 4: GPCR structures serve as targets for numerous pharmaceuticals.
Anti-GPCR compounds serve as targets for more than 40% of all licensed
pharmaceuticals for a wide variety of indications ranging from hypertension,
gastric esophageal reflux disease, allergy, to psychosis.
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Table 4: GPCR structures serve as targets for numerous pharmaceuticals.
Pharmaceutical

Receptor target

Indication

Cardura

a adrenergic

Prostatic Hypertrophy

Flomax

a adrenergic

Prostatic Hypertrophy

Hytrin

a adrenergic

Hypertension

Wellbutrin

a adrenergic

Depression

Diovan

Angiotensin"

Hypertension

Vasotec

Angiotensin Converting Enzyme

Hypertension

Cozaar

Angiotensin Converting Enzyme

Hypertension

Tenormin

Angina

Serevent

13 adrenergic
13 adrenergic
13 adrenergic
13 adrenergic

Diprivan

GABA

Anesthesia

Lupron

GnRH

Prostate cancer

Claratin

Histamine

Allergy

Allegra

Histamine

Allergy

Zantac

Histamine

GERD

Pepcid

Histamine

GERD

Gaster

Histamine

GERD

Depakote

Histone Deacetylase

Epilepsy

Singulair

Leukotriene

Asthma

Zoladex

LHRH

Prostate cancer

Atrovent

Muscarinic Acetylcholine

Bronchospasm

Xalatan

Prostanoid Selective FP

Glaucoma

Risperdal

Serotonin

Psychosis

Zyprexa

Serotonin

Psychosis

Imitrex

Serotonin

Migraine

BuSpar

Serotonin

Anxiety

Prozac

Serotonin

Depression

Paxil

Serotonin

Depression

Zoloft

Serotonin

Depression

Effexor

Serotonin

Depression

Ventolin
Toprol-XL
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Bronchospasm
Hypertension
Asthma

solely for stem-cell mobilization and not as adjuvant chemotherapy for cancer or
HIV-1 infection. AM03100, as depicted in Figure 7, is a bicyclam used as a
mobilization agent for hematopoietic stem cells [80]. AM03100 exhibited
antagonistic activity to proliferation and chemotaxis of acute lymphoblastic
leukemia [154], acute myelogenous leukemia [155], ovarian cancer [156],
primary brain tumors [157], anaplastic thyroid carcinoma [158], and colo recta I
cancer [159). However, cardiotoxic side effects limit its utility as a
chemotherapeutic agent [160).
There is a long history of bicyclic amine compounds being used to
modulate the activity of GPCRs, several of which are depicted in Figure 8.
Zimelidine was one of the earliest selective serotonin antagonists (SSRI)
prescribed as anti-depressants [161] although it has been withdrawn from the
market for inducing Guillain-Barre syndrome, a form of peripheral neuropathy
[162]. Zimelidine, along with citalopram [163-165], represents some of the
earliest use of bicyclic amines as chemotherapy, and they continued to play an
important role in the pharmacotherapy of depression through the development of
subsequent bicyclic SSRls such as venlafaxine [166-168).
There has been limited success with bicyclam derivatives such as AMO070 (Figure 7), which recently completed Phase I clinical trials as anti-HIV-1
chemotherapy [169). There has also been successful development of in vitro
CXCR4 inhibitors in the benzimidazole [170] and imidazopiperazine [171]
analogs of the AMO bicyclams, but these compounds are heavily protein bound
and suffer from severe protein shift in antiviral assays [170). These bicyclam
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Figure 7: Anti-CXCR4 compounds. Several compounds have been
demonstrated to selectively inhibit CXCR4, targeting the extracellular surface of
the receptor and the interaction between CXCR4 and either its ligand CXCL 12,
or the interaction between CXCR4, gp120, and the V3 loop of HIV-1.
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Figure 7: Anti-CXCR4 compounds.
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These compounds function by inhibiting serotonin receptors.
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Figure 8: Bicyclic aromatic compounds inhibit GPCR activity.
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derivatives strongly interact with two residues, Asp171 and Asp262, located on
the extracellular side of TM4 and TM6, on either end of the CXCL 12 binding
pocket [172].
Other small molecule derivatives, such as the KRH series, depicted in
Figure 7, can inhibit CXCR4 mediated chemotaxis and intracellular calcium
mobilization [173], but none of these compounds have entered clinical trials.
These compounds share a binding site with the AMD bicyclams, targeting the
aspartate residues in the CXCL 12 binding pocket [174].
Peptide compounds represent another family of CXCR4 inhibitors with
polyphemusin derivatives, such as T140 [175], (outlined below) and CXCL 12
peptidomimetics such as CTCE-990B (Figure 7) [176] which generate significant
anti-CXCR4 activity. CTCE-990B is a 17-amino acid palindromic dimer of the Nterminal region of CXCL 12, which has been demonstrated to function as a
CXCR4 antagonist and to decrease metastasis of breast cancer cells [177, 17B],
osteosarcoma cells [176] and melanoma cells [176]. CTCE-990B has also been
found to induce mitotic catastrophe in ovarian cancer cells [179], and induce
apoptosis and inhibit tumor proliferation in prostate tumor cells [1BO]. CTCE-990B
entered phase Iblll clinical testing and showed efficacy with stable disease in six
of twenty patients and no serious adverse effects associated with the drug,
however Chemokine Therapeutics Corp, the parent corporation of CTCE-990B
filed for bankruptcy in 200B, leaving any further development in limbo. All of
these compounds have been designed targeting the extracellular surface of
CXCR4 and their primary objective has been inhibition of interaction with HIV-1.
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There are no FDA approved chemotherapeutic or anti-metastatic antiCXCR4 agents
AMD3100 is the only anti-CXCR4 agent that has been FDA approved,
however it is not approved for HIV-1 or cancer chemotherapy, but as a
mobilization agent for hematopoietic stem cells. There are currently forty clinical
trials involving CXCR4: seventeen of these are studies observing CXCR4
expression in a variety of clinical scenarios, such as rheumatoid arthritis or acute
myocardial infarction. CXCR4 expression in response to pharmaceuticals such
as atorvastatin or an anti-herpes simplex gel was also assessed. Another ten of
these studies are exploring the role of anti-CXCR4 compounds AMD31 00 and
TG-0054 in stem cell mobilization. Two of the studies involve anti-CXCR4
compound AMD070 and its role as an anti-HIV-1 agent. Two other studies are
preliminary safety studies of anti-CXCR4 compounds MSX-122 and ALX-0651.
The remaining nine studies concern CXCR4 and anti-CXCR4 compounds
AMD3100, BKT140, and BMS-936564 as chemotherapy or as neoadjuvant
therapy for leukemia, lymphoma, myelodysplasia, or multiple myeloma. All of the
anti-CXCR4 compounds currently in clinical trials target the extracellular surface
of the receptor.
Structure based drug design is an effective technique for identifying new
pharmaceuticals.
Structure based drug design (SBDD) has had substantial success in the
field of drug discovery, with over 50 novel compounds entering clinical trials and
multiple FDA approvals [181]. SBDD is an empirical method based on developing
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lead compounds either targeting specific structures of a target molecule,
mimicking structural features or ligands, or generating new structures derived
from established active compounds.
One particularly illuminating example of structure based drug design
highlights the development of T140 and its subsequent derivatives by SSOO
based on a successful lead compound. T140 structurally originates from a series
of antimicrobial 19-mer polypeptide compounds derived from Atlantic horseshoe
crab hemocytes called polyphemusins [182]. Initial SSOO work generated a
synthetic 19-mer polypeptide based on the polyphemusin sequence which
specifically prevents HIV-1 binding, T22, depicted in Figure 9 [183]. Extensive
study went into identifying the interaction of T22 with CXCR4 on the cell surface
[184-189], and structure-activity relationships of the polypeptide [190, 191]. The
N-terminal and C-terminal arginine residues as well as the disulfide rings were
identified as essential elements of anti-HIV-1 activity. Aromatic substitution of
Trp3 was found to maintain activity of the compound, while the positive charge of
the beta turn side chain was found to be essential to strong anti-HIV-1 activity.
Through quantitative structure activity relationship (QSAR) analysis,
pharmacophores or regions and properties of the T22 molecular structure which
were essential to its interaction with CXCR4 were identified and investigated
through a series of analog peptide structures [192-194], allowing eventual
downsizing of the original 19-mer polypeptide to a smaller 14-mer peptide, T140
[195]. Subsequent structure-activity relationship analysis of T140 [127, 175, 196200], allowed additional pharmacophore development based on this structure
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Figure 9: Polyphemusin derivative structures. Polyphemusins act as specific
inhibitors of CXCR4. Structure based drug design was used to refine the
structure of the compounds from a 19-mer peptide compound to a 14 residue
peptide. Further refinement of the T140 structure produced size reductions in the
form of cyclic pentapeptide compounds, and finally small molecule inhibitors of
CXCR4.
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Figure 9: Polyphemusin derivative structures.
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[30, 201-204]. Basic amino acid residues of T140 were found to produce nonspecific binding and cytotoxicity, and replacement of these residues with Glu and
L-citrulline was found to produce selective anti-CXCR4 activity with low
cytotoxicity and high anti-HIV-1 activity [201]. Pharmacophore analysis of T140
illustrated that four of the fourteen residues (Arg2, Na13, Tyr5, and Arg14) were
essential to CXCR4 function [196], allowing the 14-mer T140 peptide to be
reduced to a cyclic pentapeptide with strong anti-CXCR4 activity. A series of
analogs based on this cyclic pentapeptide, TE14011, identified a 4-F-benzoyl
derivative with enhanced anti-HIV-1 activity, identifying this group as a novel
pharmacophore for CXCR4 antagonism [202]. Further size reduction of the T140
pharmacophore was produced by replacing the Nal-Gly subunit of the cyclic
pentapeptide with a v-amino acid or pseudopeptides cyclized by disulfide and
olefin bridges to develop novel cyclic tetrapeptide derivatives of T140 [205].
Subsequent QSAR analysis of the cyclic penta peptide derivatives of T140 [206],
in conjunction with the identification of an enhanced pharmacophore in
conjunction with identification of an electro-deficient N-terminal aromatic moiety
helped to develop small-molecule inhibitor based on the cyclic pentapeptide
derivatives of T140 [204].
Lipid bilayer simulations suggest that T140 binding to CXCR4 is mediated
by interaction with a series of residues, Asp171 on TM4, Arg188 and Tyr190 on
ECL2, Gly207 on TM5, and Asp262 on ECL3 [200]. Photolabeling studies of
radiolabeled T140 identified TM4 as the most important segment of CXCR4
involved in binding [207].
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Those of us not fortunate enough to have unlimited access to Atlantic
horseshoe crabs need to develop our own lead compounds, and rational
methods for identifying new lead compounds and drug development scaffolds are
another extension of SBDD. In silico screening methodologies such as virtual
screening are some of the most promising of these new rational methods for lead
compound identification. Virtual screening prescreens vast databases, such as
the Zinc compound library a compound virtual database [208], the 2010 version
of which contains the refined three dimensional structures of thirteen million
commercially available compounds. This prescreening is accomplished by
targeting a three dimensional structure to determine those compound which best
fit, or dock, into a chosen allosteric binding site or ligand binding site. The theory
is that by prescreening and identifying compounds with structurally favorable
features, the total volume of compounds needed to identify a new lead inhibitor
can be reduced by several orders of magnitude. This database enrichment would
allow reduced in vitro or in vivo screening of compounds.
Virtual screening has been successful in determining new lead
compounds for many different targets such as: carbonic anhydrase II [209],
Ptp1 b [210], estrogen receptor [211], thrombin [211], factor Xa [211], thymidylate
synthase [212], retinoic acid receptor [213], farnesyl transferase [214], kinesin
[215], hypoxanthine-guanine-xanthine phosphoribosyl transferase [216], DNA
gyrase [217], H IV-1 RNA transactivation response element [218], aldose
reductase [219], rac GTPase [220], checkpoint kinase-1 [221], alpha amylase
[222], BCR-ABL tyrosine kinase [223], protein kinase CK2 [224], and alpha-
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reductase [225]. In one documented case virtual screening targeting DNA gyrase
identified lead compounds where experimental high throughput screening of
libraries was unsuccessful [181, 217].
Docking of compounds into the target structure can occur using a prepositioned, or rigid, chemical conformation for the screened compounds or by
docking compound fragments and constructing the full compound based of
energetically favorable positions of the initial fragment placements. Docked
compound conformations are then evaluated based on the electrostatic and
hydrophobic interactions they would form between the compounds and the target
site, which in combination with any identified steric conflicts formed can be used
to derive a ranking of the interaction between the compound and the target, or
score. There are numerous docking methods employed in virtual screening, the
most well reviewed of which include DOCK [226], Autodock [227], GOLD [228],
eHiTS [229], Glide [230, 231], Cdocker [232], MCDock [233] and Surflex [234],
and while these docking methods employ their own scoring methodologies,
several outside scoring programs such as PLP1 [235,236], PLP2 [237], Ludi
[238], PMF [239], FlexX [240], SCORE [226], and Ligandfit [241] also exist.
Unfortunately, no docking or scoring algorithm has been determined to be
superior than others, so common practice has been to determine consensus
scoring for docked ligands using two or more docking programs to identify bound
molecules identified by one than one scoring methodology [181,242,243]. The
DOCK [226], Autodock [227], and Surflex [234], have the advantage of being
designed for performance with large database virtual screening, allowing efficient
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flexible docking and evaluation of docked conformations at high volumes. One
important facet of this process is the basis of the virtual screening target itself:
the target of the virtual screening protocol. In our experience with virtual
screening we have found that the strongest determinant of identification of active
compounds instead of false positives has been a well defined target structure,
and strong experimental and in vivo evidence governing the development of the
targeted site for the docking.
Our prior experience with the Surflex-Dock [234, 244] docking program
has demonstrated that this program is highly amenable to high-throughput virtual
screening. In unpublished research, benchmarking Surflex-Dock [234, 244] with
three other common molecular docking programs, MolDock [245], DOCK [226],
and Autodock [227], we found that Surflex-Dock consistently reproduced
predicted compound binding modes as illustrated by compound/receptor crystal
structures to a greater degree than the other docking programs. The SurflexDock [234, 244] method is centered on development of a protomol, a pseudomolecule used to virtually define the binding site targeted on the protein
structure. This proto mol can be generated based on available ligands, inhibitors
or partner proteins or development can be designed based on a defined series of
target residues composing an active site. Once the protomol is developed,
Surflex-Dock conducts flexible docking by fragmenting the compounds into
components and docking the fragments into the defined site, constructing the
compound in the active site based on favorable positions for each of the
compound fragments. Multiple poses of each compound are returned to the user
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and assigned a score based on binding affinity, degree of inappropriate
penetration into the protein, and internal structural conflicts.
Receptor inhibition can be in the form of agonists, antagonists, and inverse
agonists.
Compounds targeting a receptor can alter signaling in four primary
patterns: agonism, partial agonism, antagonism, and inverse agonism. In
contrast to agonists and superagonists, which bind and activate an inhibitor
producing equivalent or greater signaling responses, partial agonists bind the
receptor and result in signaling, but the amplitude of the response is much less
than that of the full agonist. Effectively, partial agonists cause the receptor to shift
into a partially active conformation, incapable of full signal transduction, but also
not in fully inactive states. The degree of signaling can vary with the partial
agonist, and very weak partial agonists, such as AMD3100 [127], can almost
completely abolish receptor signal transduction by inducing alterations of the
intracellular TM regions and the intracellular loops [200]. In contrast to partial
agonists, inverse agonists do not induce the active conformation of the receptor
or result in signal transduction. These compounds interact with receptors with
some basal level of activity, and upon binding, reduce the constitutive signaling
of a receptor. These compounds, such as T140 [127], preferentially stabilize the
inactive, or native in the case of CXCR4, conformation of the receptor [200].
CXCR4 as a Virtual Screening Target.
CXCR4 represents an interesting potential target for virtual screening.
From our prior descriptions of CXCR4 signaling there are five potential
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mechanisms for inhibiting signal transduction. The natural ligand could be
intercepted or manipulated in such a manner that it does not interact with the
extracellular surface of CXCR4 as illustrated by Target 1 in Figure 10.
Conversely, the extracellular surface where CXCL 12 is bound could be
manipulated to prevent ligand binding as illustrated by Target 2 as per Figure 10.
This has been the approach of prior attempts at developing anti-CXCR4 agents,
and has been the binding site of AMD3100 and T140. Next, the TM helix could
be restrained preventing movement necessary to transmit the signal from the
extracellular surface to the intracellular surface as illustrated by Target 3 in
Figure 10. The intracellular surface itself could be manipulated to either restrain
the protein's intracellular surface in an inactive conformation, or prevent Gproteins from interacting with the surface as illustrated by Target 4 in Figure 10.
Finally, the G-protein heterotrimer could be manipulated in such a manner that it
does not interact with the intracellular surface of CXCR4 as illustrated byTarget
5 in Figure 10. Although the majority of anti-CXCR4 inhibition efforts have been
directed at just the extracellular surface of the receptor, there is a precedent for
targeting the intracellular components of the signaling process. YM-254890
(Figure 11) is a specific Gaq/11 inhibitor designed to prevent acute thrombosis
and neointima formation by preventing signal transduction at the G-protein level
rather than at the GPCR level like the P2Y12 receptor antagonists ticlopidine and
clopidogrel [246-251]. M119 (Figure 11) is a

G~V

inhibitor which modulates the 1-1-

opiod receptor to act as an anti-nociceptive.[252-254] This compound has also
been found to inhibit metastasis of MDA-MB-231 cells [255]. Covalent

57

Figure 10: There are 5 potential structural targets for inhibiting CXCR4
signaling: 1) Targeting the ligand CXCL 12 to prevent ligand/receptor interaction,
2) Targeting the Extracellular ligand binding site as in AMD3100 and T140, 3)
Stabilizing the transmembrane helixes to prevent ligand induced conformation
changes, 4) Targeting the Intracellular region of CXCR4 at the G-Protein
interface, 5) Targeting the G-protein to prevent GPCR-G-protein interaction.
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Figure 10: There are 5 potential structural targets for inhibiting CXCR4
signaling
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Figure 11: Structures for G-protein inhibitors. Specific inhibitors of G-proteins

have been designed. YM-254S9 is an anti-thrombotic agent that targets the
Gaq/11 subunit. M 119 is an anti-nociceptive agent targeting the
Covalent modification of G~y inhibits

G~y
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modification of the GJ3v subunit by selenocystamine (Figure 11) has also been
found to selectively inhibit GJ3v function [256].
A novel crystal structure for CXCR4.
Five novel crystal structures for CXCR4 were released on November 19,
2010 [257]. These structures were developed in a manner similar to the crystal
structures for the J32-adrenergic receptor and the a2A adenosine receptor, with
replacement of ICL3 with T4L, as well as a stabilizing L 125W mutation, and a C
terminal tail truncation. Testing of the crystallization protein demonstrated that
the modified CXCR4 was capable of binding a bis (imidazolylmethyl) amine
(SIMA) ligand, although at a lower binding affinity than wild-type CXCR4.
Calcium flux assays using the crystallization protein were ineffective, which the
authors suggested was due to ineffective G-protein binding due to C-terminal
truncation and replacement of ICL3. Structures were generated as co-crystals
with either IT1 t, an isothiourea derivative which has been demonstrated to inhibit
interaction between CXCR4 and HIV-1 [258], or CVX15, a 16-mer peptide
derivative of T140 with demonstrated anti-metastatic activity by CXCR4 inhibition
[30]. Three constructs of CXCR4, CXCR4-1, CXCR4-2, and CXCR4-3, were
cocrystallized with IT1t with additional cocrystals of the CXCR4-2/IT1t complex
and CXCR4-2/CVX15.
The primary description of the structure was for the highest accuracy (2.5
angstrom, monomer, and bound to IT1t) structure, with the other four
conformations being described in relation to it. Significant differences between
the primary CXCR4 structure and other GPCRs involved significant structural
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deviations by TM1 and TM4 from their expected positions in the

~2-adrenergic

receptor and the a2A adenosine receptor. A tighter helical turn at Pro 92
produced an additional 120 degree rotation in TM2, which produces a different
series of residues facing the binding pocket. TM6 is characterized by a sharp
kink at residue 254, producing a deviation of the extracellular end of the helix.
Characterization of the extracellular region links the base of the N-terminal
segment to the cytoplasmic side of TM7 by a disulfide bond and an additional
disulfide linkage between TM3 and ECL2. The ligand binding pocket is larger,
more open, and more superficial than in comparable GPCRs. Characterization of
the intracellular surface indicates that positioning of the intracellular side of the
TM helixes is conserved between the CXCR4,

~2-adrenergic

receptor, a2A

adenosine receptor, and rhodopsin structures, while TM7 was one turn shorter
than expected.
Differences were noted between the five crystal structures. Construct
CXCR4-3 contained a T240P mutation which abolished signal transduction
capability, which was structurally characterized to contain a disruption of the
intracellular side of TM6 corresponding to a region between Gly231 and Pro240.
Constructs bound to inhibitors were found to have a larger, more open and more
shallow cavity on the extracellular surface compared to other GPCRs, and
constructs were found to have alteration of the position of TM5 by 0.5 angstroms
from the center of the receptor, TM6 1.5 angstroms towards the center of the
receptor and TM7 by 1.5 tangential to the receptor.
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Subsequent investigation of these crystal structures by Indira Chaudhuri, a
post doctoral fellow in the Trent laboratory, has identified several interesting
factors concerning the conformation of the receptors and their utility for virtual
screening. Comparison of the crystal structure to the lipid bilayer structure of
CXCR4 in Figure 12 reveals that there is a significant truncation of the Nand C
terminal regions, as well as disruption of ICL3 in the crystal structure of CXCR4.
In addition, an extreme kink in TM6 corresponding to residue 254 producing a
sharp deviation of TM6 and TM7. Further, unlike in the homology model and in
the other available GPCR structures, ECL2 is displaced upwards and outwards,
extending between TM1 and TM2. Differences are also noted in the N119S
structures, in that the N terminal region, rather than being more compact in the
N119S structure seems to be almost completely disordered in the homology
model based on the crystal structure.
Several features of the CXCR4 crystal structure represent causes for
concern if it is to be used as a basis for SBDD and virtual screening in these
studies. The structure was released on November 19, 2010 [257], well after the
experiments involved in this structure were completed. Truncations of the Cterminal segment and replacement of ICL3 with T 4L mean that essential
intracellular features of the receptor would be absent, precluding investigation of
the intracellular surface of the protein. Further, the absence of these structures
could artificially influence movement or rigidity of the TM helix regions especially
TM5, TM6 and TM7. Truncation of the C-terminal tail could cause the remaining
portion of the sequence to adopt an unfavorable position, such as the novel kink
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Figure 12: Comparison of the CXCR4 x-ray crystal determined structure of
CXCR4 and the CXCR4 homology model. A) On the left, the CXCR4 crystal
structure, (POS 10: 30EO) is presented in blue ribbon. ICL3 is replaced with T4L
protein on the cytoplasmic surface of the receptor. Homology model of CXCR4
illustrated on right in green ribbon presentation. S) CXCR4 crystal structure,
(POS 10: 30EO) is presented in yellow ribbon for comparison with the homology
model of CXCR4 on the right in green ribbon. Truncation of the Nand C termini
as well as loss of the ICL3 loop region are visible in the CXCR4 crystal structure.
Also, note the displacement of TM6, TM7 and the altered conformation of the
ECL2100p.
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Figure 12A: Comparison of the CXCR4 x-ray crystal determined structure of
CXCR4 and the CXCR4 homolo model.
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Figure 128: Comparison of the CXCR4 x-ray crystal determined structure of
CXCR4 and the CXCR4 homol
model.
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at residue 254, by failure to effectively anchor TM7 on the intracellular side of the
membrane. This could allow TM7 to unnaturally shift towards the extracellular
side of the membrane distorting ECl3 and TM6. In addition, the author's own
testing indicated that there were ligand binding deficiencies by the crystallization
protein, suggesting irregularities in the structure of the ligand binding pocket and
by extension the extracellular loop structure. Thus, perhaps rhodopsin based
homology modeling of this receptor would be a more effective in virtual screening
until more representative crystal structures are completed.
Dissertation Overview
This dissertation investigates several potential inhibitors of CXCR4
identified by virtual screening targeting the ECl and ICl regions of this receptor.
We hypothesize that we will be able to effectively inhibit CXCR4 mediated
metastasis by targeting multiple sites of CXCR4. Compounds targeting the
extracellular portion of CXCR4 will be investigated in the second chapter. Based
on research by Dr. Kelby Napier, we evaluate compounds targeting the T140
binding site of CXCR4 for their capacity to inhibit CXCl12-induced chemotaxis.
We successfully identify one compound, EClVS14, which inhibits chemotaxis
with an IC50 value of 5 !-1M, and is highly selective for CXCR4 without Significant
cytotoxicity. Subsequent QSAR analysis of the structure of this inhibitor reveals
the importance of the 1-[bis (phenylmethyl) amino] methyl moiety and the fact
that electronegative modifications of the terminal benzene enhance activity.
Subsequent Molecular dynamics simulations of the compound in complex with
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CXCR4 reveal that the compound induces significant modifications of the
receptor structure.
The third chapter of this dissertation will investigate novel compounds
targeting the intracellular region of CXCR4 responsible for interaction with Gai.
Based on in silica studies by Dr. Kelby Napier, we will utilize virtual screening to
identify compounds which will selectively inhibit CXCR4. Our screens will identify
thirty-seven compounds, twenty four of which will inhibit CXCL 12-mediated
chemotaxis at 50 jJ, for an exceptionally high initial hit rate of 65%. Ten of these
compounds will inhibit chemotaxis at IC50 values of 10 jJM or less and will be
highly selective for CXCR4. These compounds displayed relatively no
cytotoxicity, and 3 of the compounds significantly inhibited tumor cell
proliferation. Molecular dynamics revealed that the compounds acted by a variety
of mechanisms with some compounds restricting the receptor to the native
conformation, while others induced an intermediary configuration, and still others
were incapable of interacting with the native conformation of the receptor.
The fourth chapter of this dissertation involves validation work for the
compounds identified in the previous two chapters. We will use in silica docking
methods to predict the binding mode of the compounds with the receptor. Based
on these docking simulations, we will conduct additional molecular dynamics
simulations to examine the effect of mutating these residues on receptor
structure. Mutagenic analysis will also investigate the effect of mutation on
receptor function. Finally, three of the most active compounds from the previous
chapters will be selected and tested in an in vivo anti-metastatic an animal
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model, successfully demonstrating the anti-metastatic potential of these
compounds.
In total this work demonstrates that structure based drug design utilizing in

silico analysis in combination with in vitro and in vivo testing can be utilized to
develop novel lead compounds which can function as anti-metastatics.
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CHAPTER II
STRUCTURE BASED DRUG DESIGN OF EXTRACELLULAR LOOP
TARGETED COMPOUNDS BY QUANTITATIVE STRUCTURE ACTIVITY
RELATIONSHIP ANALYSIS AND MECHANISTIC STUDIES.
Introduction

CXCR4 has been extensively linked to cancer metastasis (see recent
reviews [259-263]). CXCR4 expression by the tumor cell allows for tumor cell
migration, and homing of neoplastic cells to sites of where non-malignant stromal
cells express CXCL 12 [37]. This implies that tumor cell metastasis is not a
random event, but directed by the expression of chemokine receptors and
adhesion molecules on the neoplastic cells, and their respective ligands in the
target organs [9, 16]. Elevated CXCR4 expression is also associated with
increased circulating tumor cells in non-small cell lung cancer [264], as well as
poor outcomes in advanced cases of this disease [265].
It is also important to note that while CXCR4 expression has been
correlated with increased metastasis of neoplastic cells [9], reductions in CXCR4
expression, or knockdown, can produce the opposite effect. Knockdown of
CXCR4 expression has been demonstrated to reduce proliferation and invasion
of ovarian cancer cells [266], and metastasis in breast cancer cells [267] and
prostate cancer cells [268]. AMD3100, an anti-CXCR4 inhibitor, has consistently
inhibited CXCR4 signaling and migration in in vivo experiments in a variety of cell
71

lines [269-271]. It has also exhibited antagonistic activity to proliferation and
chemotaxis of acute lymphoblastic leukemia [154], acute myelogenous leukemia
[155], ovarian cancer [156], primary brain tumors [157] , Anaplastic thyroid
carcinoma [158] , and colo recta I cancer [159].
AMD3100 is a bicyclam compound as depicted in Figure 13. Originally
identified as an impurity on a series of anti-HIV-1 compounds, AMD3100 was
found to selectively antagonize viral entry [272] by T-tropic strains of the HIV-1
virus through inhibition of CXCR4 [273-275]. Although AMD31 00 , successfully
completed initial phase I clinical trials [276], poor in vivo Anti-HIV-1 activity and
cardiotoxic side effects halted phase II trials and limit AMD31 ~O ' s utility as an
anti-HIV-1 therapy [160].
In spite of its cardiotoxic side effects, AMD3100 is currently the only FDAapproved CXCR4 inhibitor on the market, and is only indicated for use in stemcell mobilization and not as adjuvant chemotherapy for cancer or as therapy for
HIV-1 infection. There has been limited success in the development of bicyclam
derivatives such as AMD-070 (Figure 13), which recently completed Phase I
clinical trials as anti-HIV-1 chemotherapy [169] . There has also been successful
development of in vitro CXCR4 inhibitors in the benzimidazole (Figure 13) [170]
and imidazopiperazine [171] analogs of the AMD bicyclams as anti-HIV-1 agents,
but these compounds are heavily protein bound and suffer from severe protein
shift in antiviral assays [170] suggesting that the drug concentration available in
the systemic circulation would be greatly reduced by circulating albumin proteins.
These bicyclam derivatives strongly interact with two residues , Asp171 and
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Figure 13: Anti-CXCR4 compounds. Illustrated compounds specifically
interfere with CXCR4 activity and are targeted at the extracellular surface of the
CXCR4 receptor.
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Figure 13: Anti-CXCR4 compound
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Pro

Asp262, located on the extracellular side of transmembrane helix 4 and 6, on
either end of the CXCL 12 binding pocket [172] . In reference to the potential
mechanisms of inhibiting CXCR4 depicted in Figure 10, these compounds target
Target 2, the extracellular interface of the receptor.
Other small molecule derivatives, such as the KRH compounds (Figure
13) KRH-1636 and KRH-3955 are selective CXCR4 inhibitors. KRH-1636 was
extensively investigated as an anti-HIV-1 entry inhibitor, and was identified as
selectively binding CXCR4 [277], but development was halted due to poor oral
bioavailability. KRH-3955 produced greater oral bioavailability, while inhibiting
HIV-1 entry as well as CXCL 12 binding and intracellular calcium mobilization
[173]. The compound was found to bind in the extracellular region of the receptor
and interact with all three extracellular loops [278], sharing a binding site with the
AMD bicyclams, targeti",g the aspartate residues in the CXCL 12 binding pocket
[174]. Like the bicyclam derivatives, these compounds also target the
extracellular surface of the receptor, Target 2 in Figure 10. None of the KRH
compounds have entered clinical trials.
Peptide compounds such as polyphemusin derivatives T140 (Figure 13)
[175] and CXCL 12 peptidomimetics such as CTCE-9908 (Figure 13) [176]
generate significant anti-CXCR4 activity. CTCE-9908 has been demonstrated to
function as a CXCR4 antagonist and decrease metastasis of breast cancer cells
[177, 178], osteosarcoma cells [176] and melanoma cells [176] in vitro and in tail
vein injection studies of mouse lung metastasis. CTCE-9908 presents an
especially compelling proof of principle for anti-CXCR4 agents in that it
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demonstrates that inhibition of CXCR4 can effect a reduction in tumor cell
metastasis.
The peptide CXCR4 inhibitors have been designed targeting the
extracellular surface of CXCR4. CTCE-9908 mimics the ligand binding
mechanism of CXCL 12, primarily interacting with the N-terminus of CXCR4. Lipid
bilayer simulations suggest that T140 bind ing to CXCR4 is mediated by
interaction with a series of residues, Asp171 on transmembrane helix 4, Arg188
and Tyr190 on extracellular loop 2, Gly207 on transmembrane helix 5, and
Asp262 on extracellular loop 3 [200]. Photolabeling studies of radiolabeled T140
identified transmembrane helix 4 as the most important segment of CXCR4
involved in binding [207].
SBDD is an empirical method of drug design based on developing lead
compounds either targeting specific structures of a target molecule, mimicking
structural features or ligands, or generating new structures derived from
established active compounds. One of the earliest examples of utilization of this
method for targeting CXCR4 activity utilized synthetic peptides based on the
transmembrane domains of CXCR4 [279]. Peptides correlating to TM2 were
capable of completely abolishing CXCL 12-induced calcium mobilization at
0.2IJM . Elimination of the acidic apex and basal amino acids was demonstrated
to improve potency 1O-fold, while replacement with positively charged lysine
residues improved potency 100-fold.
As seen in the description of the evolution of the polyphemusin
compounds in Chapter 1, drug discovery and development is an iterative,
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cyclical, and evolutionary process, illustrated in Figure 14. In the first step of this
process, initial lead compounds are identified through a screening assay.
Compounds which demonstrate activity in the screening assay are then further
characterized through in vitro biological assays to identify their impact on cell
signal transduction, homeostasis, cytotoxicity, and possible identification of their
molecular mechanism. Active compounds are then subsequently modeled, and
derivatives are generated to test a hypothesis of interaction based on the model.
The activity of initial derivatives in in vitro assays is used to perform quantitative
structure activity relationship analysis and determine the essential elements of
the active compound and methods by which activity could be increased.
Compounds are then tested in animal models for toxicity and efficacy, and
subsequent generations of derivatives are generated to test hypotheses of
interaction.
We will be applying this model of SBDD to designing inhibitors targeting
the extracellular surface of CXCR4. The initial step of identifying a lead
compound was carried out in previous research by Dr. Napier. His work used a
N119S structure of XCR4 derived from homology modeling and developed
through solvated lipid bilayer molecular dynamics, as a target for identifying antiCXCR4 compounds targeting the extracellular surface of the receptor, at the
binding site for T140 [200]. N119S was chosen as the original virtual screening
target because the inverse agonist T140 was one of the docking targets, and this
inverse agonist could not bind to the inactive native conformation of the receptor.
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Figure 14: Structure-based drug design is an iterative and cyclical process.
After initial identification of a structural basis for pathology and identification of an
active site , initial compounds are screened for toxicity and functionality. The
activity of functional compounds is then rationalized by in silico methods.
Compounds will then be tested in in vivo models. Successful lead compounds
will then be subjected to QSAR analysis and derivation and testing of derivatives
in functional screens will identify active pharmacophores for further testing
rationalization and derivation.
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Figure 14: Structure-based drug design is an iterative and cyclical process.
Id entifica t ion of Pathology

Identification of active

Metastatic tumor
are CXCR4+ and migrate
in towards CXCL12
Met ast asis

QSAR of active inh ibitors

Derivations of

lung metastasis
Intraventricular injection
model of bone metastasis

Virtual re-docking
Moleculardynamics
simulations

In vivo analysis

In silico rationa Iization

79

An initial rigid docking protocol, DOCK [226], was used to prescreen the
Zinc library database, and the FlexX (Tripos) program was used to flexibly dock
the top 2100 compounds from the rigid body analysis, with the top 100
compounds from the FlexX analysis scored and ranked by energy (DOCK) and
Cscore (FlexX). Dr. Napier was then able to use chemotaxis experiments to
identify 10 compounds which inhibited CXCR4-mediated chemotaxis. One of
these compounds, designated compound 14, selectively inhibited CXCR4mediated chemotaxis, but not CCR5-mediated chemotaxis. Because of the
selective anti-CXCR4 activity of compound 14, it was chosen as the lead
compound to be used as a scaffold for development of subsequent derivatives.
In this chapter, we will describe the continuation of the SBDD process by
further characterizing the anti-CXCR4 activity of compound 14 as well as the
other identified CXCR4 inhibitors. We will further characterize the nature of
compound 14's activity on CXCR4 by designing a series of inhibitors to
investigate important regions of the compound 14 structure. Finally, the
interaction between compounds with anti-CXCR4 activity will be investigated
through molecular dynamiCS simulations to analyze the interaction between
identified inhibitors and CXCR4.
This chapter will highlight the following results: Compound 14 (renamed
EClVS14) selectively inhibits CXCR4-mediated chemotaxis, but not intracellular
calcium flux without significant cytotoxicity. QSAR will be used to identify terminal
benzene modifications in conjunction with acetamide derivation of the EClVS 14
structure as a potential mechanism for increasing anti-CXCR4 activity. Molecular
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dynamics simulations demonstrated that ECl VS 14 induces a more closed
extracellular position of the extracellular loops (ECl) but an intermediately open
position for the intracellular loops, suggesting that ECl VS 14 could act as a
weak-partial agonist. In total, this work will provide an extensive characterization
of EClVS14 through in vitro analysis and investigation of multiple derivative
structures, as well as dynamic simulation of compound binding, producing
significant progress in the SSOO process.
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Methods
Compound Selection
The prior virtual screening studies by Napier et al identified ten compounds as
both specific and non-specific inhibitors of CXCR4 mediated chemotaxis, which
will be referred to as EClVS compounds after "ExtraCellular hOoP Virtual
Screen". EClVS14 was the most promising identified compound with specific
inhibitory activity of CXCR4-mediated chemotaxis. The other nine EClVS
compounds also exhibited significant inhibition of CCR5-mediated chemotaxis.
Of the ten compounds displaying activity towards CXCR4, all were selected for
testing except ECl VS48 and EClVS88. As these compounds displayed
significant cytotoxicity in the original research, they were excluded from these
studies.
As ECl VS 14 displayed significant specific inhibition of CXCR4 activity, it
was selected to perform QSAR analysis in order to identify modifications that
could alter the activity of the compound in respect to CXCR4. Twenty three
ECl VS 14 derivatives were synthesized by our organic chemistry collaborators
led by G. B. Hammond, Dept. of Chemistry, University of louisville, and prepped
for analysis in human CXCR4 expressing cell lines, which will be referred to with
the prefix EVS14 and a numerical designation. These derivatives explored the
role of the bis (phenyl methyl) amino methyl moiety and effects of modification of
this group, as well as exploring the effect of lengthening the hydrazine-linked
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alkyl moiety or converting it to an acetamide and modifying the terminal benzyl
group.
Fourteen compound EVS 14-2 derivatives were also synthesized for
testing, with an EVS14-2 prefix and an alphanumeric designation. These
compounds retained ECLVS14-2's conversion of the hydrazine-linked alkyl to a
propylhydrazine and demonstrated modification or replacement of the bis
(phenylmethyl) amino methyl moiety.

Transfeetion and generation of RBL-2H3 and 300.19 stable eel/lines
expressing hCXCR4-GFP
To fully evaluate the effects of the potential inhibitors we stably transfected
overexpressing CXCR4 cell lines in collaboration with Dr. Haribabu Bodduluri.
CXCR4-GFP was generated in Dr. Bodduluri's lab by in frame cloning of the
entire coding region of CXCR4 ahead of the GFP coding regions. RBL-2H3 and
300.19 cells were obtained from our co-investigator, Dr. Haribabu Bodduluri.
RBL-2H3 cells are maintained as monolayer cultures in DMEM supplemented
with 15% FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 Ilg/ml
streptomycin. 300.19 cells are maintained as suspension cultures in RPMI
supplemented with 10% FBS, 100 U/ml penicillin and 100 Ilg/ml streptomycin,
and 55 IlM of

~-mercaptoethanol.

Transfections are performed by

electroporation. The RBL-2H3 and 300.19 stable single cell lines expressing GFP
were derived with pEGFPN2 vectors. The stable cell lines are maintained in the
presence of 1 mg/ml of G418, an aminoglycoside antibiotic which inhibits
polypeptide synthesis [280] in the absence of a resistance gene present on the
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pEGFPN2 vector. Cells are cultured in complete medium for 24 hrs after
transfection and used for microscopy. The cell surface expression of hCXCR4 is
also determined by incubating receptor or parental cells with 12G5 Ab followed
by PE labeled secondary Ab, and analyzed by FACS (BD Biosciences).
300.19 lymphocyte derived cells will be used for the majority of described
experiments. This line was selected because as a non-adherent cell line, greater
cell populations could be acquired quickly, allowing higher-throughput screening
of the investigated compounds. Also, as a lymphocyte derived cell line, these
cells retained stronger basal chemotactic capabilities than even highly metastatic
tumor derived cell lines. In a chemotaxis experiment this would make the
difference between normalizing migration to a control value of 150-300 cells per
counted field in the 300.19 cell line, or 150-300 migrated cells total.

Chemotaxis analysis
Chemotaxis analysis for suspension 300.19 cells expressing hCXCR4GFP or BLT1 was performed as previously described [151, 281]. In brief, 24 well
Transwell chambers (Corning Costar, Cambridge, MA) with pore diameter 8.0 IJm
were used. CXCL 12 (Peprotech) was added to chemotaxis buffer (RPMI media +
10% FBS + 1 mM Hepes) and added to the lower chamber. Cell variability
required that CXCL 12 concentration be optimized for each run, and results were
normalized to the CXCL 12 alone control. Inhibitor was then added to the
CXCL 12 + Chemotaxis buffer solution. 1,000,000 Cells were resuspended in
Chemotaxis buffer and added to the upper chamber. Cells were then allowed to
migrate for 3 hours at 37 DC. Migrated cells in the bottom chamber were then
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counted via hemocytometer. Each run featured positive and negative controls run
in duplicate and each compound was run in duplicate. Negative controls lacked
CXCL 12 in the bottom chamber, while positive controls included both CXCL 12
alone chambers and CXCL 12 + DMSO to account for the suspension medium of
the inhibitors.
Cell signaling analysis
Cell signaling by CXCR4 was investigated by assessment of intracellular
calcium mobilization. Intracellular calcium mobilization was performed using both
300.19 cells as described previously [149-151]. Briefly, cells were suspended in
loading buffer (1xPBS +1 % FBS) and loaded with INDO-I for 30 minutes at 37
°C. Cells were then washed with washing buffer (1 x PBS +0.1 % FBS) and
resuspended in assay buffer (1XHBSS +1%FBS). Cells were then loaded into
fluorimeter cuvettes (Sigma-Aldrich) and assessed for fluorescence by
FACScaliber (BD Biosciences). Cells were allowed to equilibrate in the chamber
for 60 seconds, after which compound was added. Cells were allowed to
equilibrate for another 60 seconds, after which response to CXCL 12 addition was
assessed. Cell variability required that CXCL 12 or other chemokine
concentration be optimized for each run, and results were normalized to the
CXCL 12 or other chemokine alone control. Positive and negative controls and
compounds were assessed in duplicate for each run. Negative controls were
assessment of untreated cells, while positive controls included CXCL 12 alone
and CXCL 12 + DMSO samples.
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Class A GPCR selectivity for non-family member BL T1
The selectivity of the compounds for CXCR4 was assessed by
investigating their effect on the Class A GPCR BLT1. Assays for chemotaxis and
intracellular calcium mobilization, as described earlier, were used to assess
compound activity in 300.19 cells expressing BLT1 [149] grown in Dr. Bodduluri's
laboratory.

Determination of nonspecific cytotoxicity
The potential cytotoxic effects of the compounds were investigated in our
own hCXCR4-GFP expressing 300.19 cells. Cytotoxicity was investigated using
a modified cytotoxicity protocol [282]. In brief: 300.19 cells are plated into a 24
well plate at 100000 cells/ml in a total volume of 600 III and exposed for 3 hours
to OMSO, inhibitor compounds or camptothecin (positive control). Cells were
then collected by centrifugation at 8000xg, washed with PBS, and resuspended
in 0.2 ml PBS + 0.1 % BSA. Cell suspension was mixed with 2 IJI 100 IJg/ml PI
(Sigma) incubated for five minutes at room temperature in the dark and then
analyzed by FACScaliber (BO Biosciences). PI emission is detected through a
600 nm long-pass filter and a 615 nm short-pass filter on FL2 channel, counting
10,000 events per sample.

Compound Screening And Dose Response Analysis
Compounds identified in the Napier virtual screens (ECLVS) and the
subsequent ECLVS14 derived compounds were tested in vitro using the above
assays. CXCR4 response to the compounds was initially evaluated at a
screening concentration of 50 IlM. 50 IlM is a high initial screening concentration
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for a drug discovery effort when concentrations of 10 to 20 ).lM are typically used
[173, 283]. However, for a conventional compound screening protocol, the
compounds are usually derived from structurally similar lead compounds, for
which there is established EC50 data. Screening of compounds exhibiting activity
at 50 ).lM or derivatives at 10 ).lM underwent dose-response assays to eliminate
any potential false-positives produced by the elevated screening concentration.
Molecular dynamics modeling of CXCR4 and ECL VS complexes

Complexes of active ECl VS compounds and CXCR4 were investigated
by molecular dynamics. The highest scoring conformations of the EClVS
compounds were utilized as a guide to initial placement of the inhibitor. As the
initial virtual screens for the active compounds were targeted at the N119S
conformation of CXCR4 and the interface surface of Gai , the compounds were
re-docked into the native structure using Surflex-Dock [234, 244] . A novel
protomol was generated for the native CXCR4 structure using the residues
identified in Table 5, which adequately provided docking coverage to the Nterminus and extracellular loops two and three. Surflex-Dock [234, 244] was used
to dock EClVS compounds with anti-CXCR4 activity at 10 IJM or less into the
defined extracellular surface of the native structure of CXCR4. All compounds
were successfully docked into the structure. The top scoring conformation for
each compound was utilized in generating the CXCR4 compound complexes.
Fully solvated lipid bilayer molecular dynamics simulations of native
CXCR4 bound with active ECl VS compounds were performed using the AMBER
suite of programs using the parm99 force field [284]. Restraints were initially
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Table 5: Protomol generated for docking of ECLVS and EVS14 compounds
into native structure of CXCR4. Surflex-Dock [234, 244] will be used to
generate a novel residue based protomol, based on the amino acids within 8
angstroms of the T140 binding site residues, Asp171 on TM4, Arg188 and
Tyr190 on ECL2, Gly207 on TM5, and Asp262 on ECL3 identified in lipid bilayer
simulations [200].
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Table 5: Protomol generated for docking of ECLVS and EVS14 compounds
into native structure of CXCR4.
Amino Acid

Residue

Asn

176

Val

177

Ser

178

Glu

179

Ala

180

Cys

186

Asp

187

Arg

188

Phe

189

Tyr

190

Pro

191

Asn

192

Leu

194
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used to guide conformation of the receptors as previously described in [285]. In
brief, an initial 5000 step steepest decent minimization was conducted with
Protein and compound restrained (100 kcal mor 1 A-1), followed by another 5000
step steepest decent minimization with no protein or compound restraints. This
was followed by a 25 ps MD (T=100 K) holding protein fixed (100 kcal mor 1 A- 1 ),
and another unrestrained 5000 step steepest decent minimization without
restraints. The temperature of the system was then increased from an initial point
of 1OOK to 300K while maintaining 100 kcal mor 1 A-1 restraints. An additional
three 25 ps steps of minimization were then conducted to gradually decrease the
restraints from 100 kcal mor 1 A-1 to 10 kcal mor 1 A-1 and finally to 1 kcal mor 1

A- 1. Ten production runs of 500

ps were then conducted free of restraints for a 5

ns total production run.
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Results
ECLVS compounds significantly inhibit CXCR4 mediated chemotaxis.
Our goal was to assess the identified EClVS compounds targeting the
extracellular surface of CXCR4 in order to discover novel small molecules which
could selectively inhibit receptor function and be used as scaffolds for
development of clinically active anti-metastatic compounds. The EClVs
compounds are depicted in Figure 15, and listed in Table 6. We sought to
evaluate the compounds by chemotaxis assays which quantitatively examined
the capability of cells to migrate towards a ligand gradient. Initial screening of the
eight EClVS compounds at 50 !-1M identified two compounds which significantly
inhibited chemotaxis as depicted in Figure 16. Results were normalized to the
CXCl12 alone control. In contrast to treatment with CXCl12 alone treatment
with DMSO , the vehicle used to suspend the compounds, induced no
chemotaxis. At the initial screening concentration of 50 !-1M, EClVS14 reduced
CXCl12-induced chemotaxis by 79% while ECl VS58 reduced CXCl12-induced
chemotaxis by 94%. Dose response analysis was used to determine the
concentration of the active compounds EClVS 14 and EClVS58 where
chemotaxis was inhibited by 50% in reference to the CXCl12 alone control
(IC50). Results of the dose response analysis are depicted in Figure 17.
EClVS14 inhibited chemotaxis with an IC50 value of 5 !-1M , while EClVS58 had
an IC50 value of 20 !-1M.
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Figure 15: ECLVS compounds. Compounds identified by virtual screening
using Ludi [238] molecular docking software targeting the T140 binding site of the
extracellular surface of CXCR4.
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Figure 15: ECLVS compounds.
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Table 6: ECLVS compounds. Compounds from the ECLVS series are listed
below with chemical name, supplier, and molecular weight.
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Table 6: ECLVS compounds.
Compound
ECLVS14
ECLVS43
ECLVS44
ECLVS55
ECLVS58
ECLVS59

ECLVS72

ECLVS82

NAME
(Z)-2-( ((E)-benzylideneamino )oxy)-N'-( 1(( dibenzylamino )methyl)-2-oxoindolin-3ylidene )acetohydrazide
methyl 4-(2,3-di(pyridin-2-yl)quinoxaline6-carboxamido )benzoate
N-( (3-( oxazolo[4,5-b ]pyridin-2yl)phenyl)carbamothioyl)cinnamamide
N-( 4-( 2, 5-d ioxo-3-( (pyrid in-3ylmethyl)amino )pyrrolidin-1yl)phenyl)acetamide
(3E,5E)-1-methyl-3,5-bis(pyridin-3ylmethylene)piperidin-4-one
(E)-3-amino-N'-cyano-4-(4methoxyphenyl)-6-phenylbenzo
[b ]thiophene-2-carboximidamide
4-((5,7-bis(trifluoromethyl)-1,8naphthyridin-2-yl)oxy)-N-(pyridin-3ylmethyl)benzenesulfonamide
N,N'-(1,10-phenanthroline-2,9diyl)dibenzamide
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Supplier

MW

TimTec
Stock Library

531.6

ChemBridge:

461.47

ChemBridge:

40.45

ChemBridge:

339.36

ChemBridge:

291.35

ChemBridge:

398.48

Bionet
Research

528.43

Specs

418.45

Figure 16: ECLVS Compounds Inhibit CXCR4 Mediated Chemotaxis.
Compounds ECLVS14 and ECLVS58 Significantly inhibit CXCR4-mediated
chemotaxis in response to CXCL 12. DMSO alone did not significantly induce
chemotaxis in hCXCR4-GFP expressing 300.19 cells.
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Figure 16: ECLVS Compounds Inhibit of CXCR4 Mediated Chemotaxis.
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Figure 17: IC50 of Active Inhibitors of CXCR4 Mediated Chemotaxis.

Concentrations which inhibited 50% of chemotaxis in relation to CXCl12 alone
signaling (IC50) were determined for active EClVS compounds. Vertical axis is
presented in terms of IC50 of chemotaxis in jJM. Of the original EClVS
compounds, only EClVS14 had an IC50 value less than 10 jJM.
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Fi ure 17: IC50 of Active Inhibitors of CXCR4 Mediated Chemotaxis.
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We then sought to determine the specificity of the EClVS compounds for
CXCl12-induced chemotaxis. To do this, chemotaxis assays were carried out
using 300.19 cells expressing the class A GPCR Bl T1 which mediates
chemotaxis in response to the chemokine l TB4. Initial screening of EClVS14
and EClVS58 revealed that both compounds significantly inhibited l TB4mediated chemotaxis in cells expressing Bl T1 at 50

~M.

However, as can be

seen in Figure 18, dose response analysis of the ECl VS compounds revealed
that while EClVS58 inhibited BlT1 chemotaxis to a greater degree than CXCR4
mediated chemotaxis (IC50 of 20

~M

vs. 5

~M) ,

EClVS14 produced significantly

greater anti-CXCR4 activity at 5 !-1M tha n anti-Bl T1 at 25 !-1M. This suggests that
the inhibitory effects produced by EClVS14 are somewhat specific for CXCR4.
Division of ECLVS compounds into inhibitors and non-inhibitors of CXCL 12
induced calcium mobilization

Intracellular calcium mobilization is a common method for assessing
GPCR receptor activation and signaling. Thus, we investigated the impact of
ECl VS compounds on CXCl12-induced calcium mobilization. CXCl12-induced
signaling was assessed by the change in amplitude of the calcium signal and
deviation from baseline produced by CXCl12 administration, and results were
normalized to the CXCl12-alone control. Initial screening of the eight EClVS
targeted compounds at 50 !-1M for inhibition of calcium mobilization identified five
EClVS compounds which produced significant reductions in calcium release , as
depicted in Figure 19. Interestingly, the two compounds which produced
significant reduction in CXCR4 mediated chemotaxis had no effect on calcium
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Figure 18: ECLVS14 selectively inhibits CXCR4 Mediated Chemotaxis.
Specificity screening of active EClVS com pounds in BlT1 expressing cells
revealed that both compounds inhibited chemotaxis in both systems. EClVS58
inhibited BlT1 chemotaxis to a greater degree than CXCR4 mediated
chemotaxis. EClVS14 produced significantly greater anti-CXCR4 activity at 5 !-1M
than anti-BlT1 at 25 !-1M.
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Figure 18: ECLVS14 selectively inhibits CXCR4 Mediated Chemotaxis.
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Figure 19: ECLVS compounds inhibit CXCR4 mediated Intracellular
Calcium Mobilization. Calcium Mobilization assays performed with ECl VS
compounds at a concentration of 50 IJM. Vertical axis is presented in terms of
normalized calcium signal, wherein the amplitude of the calcium response to the
CXCl 12-alone control co rresponds to 1. Decreased signal amplitude correlates
with inhibition of calcium mobilization. Five of eight tested ECl VS compounds
significantly inhibited calcium mobilization.
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Figure 19: ECLVS compounds inhibit CXCR4 mediated Intracellular
Calcium Mobilization.
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mobilization. The final compound EClVS72 significantly enhanced calcium
release (data not shown). Subsequent dose response analysis conducted to
determine the IC50 of the active compounds revealed that two of the five active
compounds, EClVS59 (5 IJM) and EClVS82 (2 .5 IJM) had calcium mobilization
IC50 values of 10 IJM or less as seen in Figure 20.
We then sought to determine the specificity of the EClVS compounds for
CXCl12-induced intracellular calcium mobilization. To do th is, calcium
mobilization assays were carried out using 300.19 cells expressing BlT1 and
signaling was assessed in response to l TB4. Initial screening of the five EClVS
compounds which inhibited CXCl12-induced calcium mobilization revealed that
all five compounds significantly inhibited l TB4-induced intracellular calcium
mobilization. Subsequent dose response analysis, depicted in Figure 21 ,
revealed that the IC50 of four of the five ECl VS compounds were comparable
between CXCR4 and BlT1 mediated calcium mobilization: EClVS43 (42 IJM vs.
50 IJM) , EClVS44 (47 .5 IJM vs. 50 IJM), EC l VS55 (47 .5 IJM vs. 50 IJM) and
EClVS82 (2 .5 IJM vs. 3.5 IJM). In contrast EClVS59 produced very specific
inhibition of CXCR4 mediated calcium mobilization , with anti-CXCR4 activity of 5
IJM compared to 40 IJM for inhibition of BlT1-mediated calcium mobilization,
suggesting that anti-calcium mobilization activity in EClVS59 is selective for
CXCR4.
As inhibition of chemotaxis and calcium mobilization by the EClVS
compounds could be due to nonspecific toxic side effects, the EClVS
compounds were screened for cytotoxicity. Mimicking the conditions in the
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Figure 20: ICSO of ECLVS compound mediated inhibition of calcium
mobilization. Concentrations which inhibited 50% of calcium mobilization in

relation to CXCl 12 alone signaling (IC50) were determined for active ECl VS
compounds. Vertical axis is presented in terms of IC50 of calcium mobilization in
IJM. Two of the five active compounds exhibited significant inhibition of calcium
mobilization at 10 IJM or less.
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Figure 20 : ICSO of ECLVS compound mediated inhibition of calcium
mobilization.
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Figure 21: ECLV559 selectively inhibits CXCR4 Mediated Calcium
Mobilization. The five EClVS compounds which inhibited CXCl12-induced
calcium mobilization were tested for specificity in BlT1 expressing cells,
revealing that all five compounds inhibited calcium mobilization in both systems
at a 50 !-1M screening concentration. Four of the five compounds produced BlT1
mediated calcium mobilization equivalent to CXCR4 mediated calcium
mobilization. EClVS59 was selective for CXCR4 mediated calcium mobilization.
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Figure 21: ECLVS59 selectively inhibits CXCR4 Mediated Calcium
Mobilization
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chemotaxis assay, 300.19 cells were cu ltured in the presence of EClVS
compounds at the initial screening concentration of 50 IJM and cytotoxicity was
assessed using propidium iodide (PI) based flow cytometry. PI is unable to
penetrate the cell membrane in viable cells, so cells staining positive for PI do not
have intact membranes. Cytotoxicity values are presented as percentage of cells
staining positive for PI in Figure 22 . Of the nine ECl VS compounds only two
produced displayed elevated cytotoxicity when compared to untreated cells or
cells treated with DMSO only control. Compounds EClVS44 (88 .3%) and
EClVS59 (99.8%) displayed significant increases in cytotoxicity above that of
untreated (3.5%) and DMSO-treated (3.7%) controls.
Three of the EClVS compounds possess anti-CXCR4 activity at less than
10 IJM, EClVS14 with a chemotaxis IC50 of 5 IJM , and EClVS59 and EClVS82
with calcium mobilization IC50s of 5 IJM and 2.5 IJM respectively. Both EClVS14
and EClVS59 were demonstrated to selectively inhibit CXCR4, while ECl VS82
was non-selective. In addition, while EClVS14 produced relatively little
cytotoxicity, EClVS59 produced almost 100% cytotoxicity after 3 hours. Thus,
because EClVS14 selectively inhibited CXCR4-mediated chemotaxis and
produced no non-specific cytotoxicity, this compound was chosen as a parent
compound for subsequent derivation and fo r the development of QSAR analysis.

Development of ECLVS14 derivatives for QSAR analysis.
EClVS14 derivatives were developed targeting specific modifications of the
compound structure as depicted in Figure 23. Modifications of the central chain
could introduce greater flexibility between the terminal benzylidenemethanamine
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Figure 22: ECLVS compounds produce relatively little non-specific
cytotoxicity. Vertical axis is expressed in terms of cells staining positive for PI,
a marker for membrane disruption and non-viable cells. Only two of the eight

Eel VS compounds with exhibited significant cytotoxicity. These compounds
produced greater than 80% cytotoxicity at 50 IJM.
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Figure 22: ECLVS compounds produce relatively little non-specific
cytotoxicity.
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Figure 23: Modifications of ECLVS14 for QSAR analysis. ECLVS14
derivatives will be designed with several modifications in mind. Acetamide
derivatives will be developed. The central chain will be lengthened. The
benzylidenemethanamine moiety will also be modified to include additional
electronegative or polar substituents. The necessity of the 1[bis(phenylmethyl)amino]methyl (1-BPMAM) moiety will be assessed in
compounds lacking this moiety. The phenylmethanamine moiety will also be
assessed by addition of electronegative or polar substituents or replacement with
a less aromatic substituent.
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Figure 23: Modifications of ECLVS14 for QSAR analysis.
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moiety and the imidazole, thus the effect of increasing chain length on this group
will be assessed. Loss of the acetamide moiety could result in loss of hydrogen
bonding between the compound and the receptor thus derivatives based on this
moiety will be developed. Increasingly electronegative or polar substituents
targeting the benzylidenemethanamine moiety could facilitate increasing ionic or
hydrogen bonding interactions between compound and receptor, while the
addition of aliphatic elements or decreasing the aromatic characteristics of the
group could modulate binding as well. Mod ifications of the 1[bis(phenylmethyl)amino]methyl (1-BPMAM) moiety could facilitate compound
binding in a manner similar to that of modifications of the
benzylidenemethanamine moiety, while removal of the entire group could
facilitate greater and deeper binding of the compound in the binding site .
EVS14 compounds significantly inhibit CXCR4 mediated chemotaxis.
Twenty-three ECLVS14 derivatives assigned the deSignation EVS14
(illustrated in Figure 24 and listed in Table 7) were synthesized by our organic
chemist collaborators led by G. B. Hammond, Dept. of Chemistry, University of
Louisville and prepped fo r analysis in human CXCR4 expressing cell lines by
suspending the compounds in DMSO to a concentration of 20 mM. These
derivatives explored the role of the bis (phenyl methyl) amino-methyl moiety and
effects of modification of this group, as well as exploring the effect of lengthening
the hydrazine-linked alkyl moiety or converting it to an acetamide and modifying
the terminal benzyl group.
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Figure 24: EVS14 compounds. Derivatives of ECLVS14 were generated
focusing on conversion of the hydrazine alkyl linker moiety to an acetamide alkyl
linker moiety, as well as investigating the effects of lengthening the hydrazine
alkyl linker, and assessing the effect of presence or absence of the 1-BPMAM
moiety.
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Figure 24: EVS14 compounds
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Table 7: EV514 compounds. Compounds from the EVS14 series are listed
below with chemical name, supplier, and molecular weight.
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Compound
EVS14-1

EVS14-2

EVS14-3
EVS14-4
EVS14-5
EVS14-6
EVS14-7
EVS14-8
EVS14-9
EVS14-10
EVS14-11

Table 7: EVS14 compounds.
NAME
(Z)-3-(((E)-benzylideneamino )oxy)-N'-(1(( dibenzylamino )methyl)-2-oxoindolin-3ylidene )propanehydrazide
(Z)-4-(((E)-benzylideneamino )oxy)-N'-(1(( dibenzylamino )methyl)-2-oxoindolin-3ylidene )butanehydrazide
(Z)-5-(((E)-benzylideneamino )oxy)-N'-( 1(( dibenzylamino )methyl)-2-oxoindolin-3ylidene)pentanehydrazide
(Z)-2-( ((E)-( 4-fluorobenzylidene )amino )oxy)-N-(2oxoindolin-3-ylidene )acetamide
(Z)-2-( ((E)-( 4-chlorobenzylidene )amino )oxy)-N-(2oxoindolin-3-ylidene )acetamide
(Z)-N-(2-oxoindolin-3-ylidene )-2-( ((E)-( 4(trifluoromethyl)benzylidene )amino )oxy)acetamide
(Z)-2-( (cyclohexylideneamino )oxy)-N-(2-oxoindolin3-ylidene )acetamide
(Z)-2-( ((E)-( 4-methoxybenzylidene )amino )oxy)-N(2-oxoindolin-3-ylidene )acetamide
(Z)-2-( ((E)-( 4-methylbenzylidene )amino )oxy)-N-(2oxoindolin-3-ylidene )acetamide
(Z)-2-( ((E)-( 4-nitrobenzylidene )amino )oxy)-N-(2oxoindolin-3-ylidene )acetamide
(Z)-2-( ((E)-(2,4-dimethoxybenzylidene )amino )oxy)N-(2-oxoindolin-3..ylidene )acetamide
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MW
545.63

559.66

573.68
325.29
341.75
375.3
299.32
337.33
321.33
352.3
367.36

Compound
EVS14-12

EVS14-13

EVS14-14

EVS14-15

EVS14-16

EVS14-17

EVS14-18
EVS14-19
EVS14-20
EVS14-21
EVS14-22
EVS14-23

Table 7, continued: ECLVS Compounds
NAME
(Z)-N'-( 1-((dibenzylamino )methyl)-2- oxoindolin-3ylidene )-2-( ((E)-( 4-(trifluoromethyl)
benzylidene )amino )oxy) acetohydrazide
(Z)-N'-( 1-((dibenzylamino )methyl)-2-oxoindolin-3ylidene )-2-( ((E)-( 4-methylbenzylidene)
amino )oxy)acetohydrazide
(Z)-N'-( 1-( (dibenzylamino )methyl)-2-oxoindolin-3ylidene )-2-(((E)-( 4fluorobenzylidene )amino )oxy)acetohydrazide
(Z)-2-(((E)-( 4-chlorobenzylidene)amino )oxy)-N'-(1(( dibenzylamino )methyl)-2-oxoindolin-3ylidene )acetohydrazide
(Z)-2-(( cyclohexylideneamino )oxy)-N'-(1(( dibenzylamino )methyl)-2-oxoindolin-3ylidene )acetohydrazide
(Z)-N'-( 1-((dibenzylamino )methyl)-2-oxoindolin-3ylidene )-2-( ((E)-(2,4-dimethoxybenzylidene)
amino )oxy)acetohydrazide
(Z)-N'-( 1-( (dibenzylamino )methyl)-2-oxoindolin-3ylidene )-2-( ((E)-( 4-nitrobenzylidene)
amino )oxy)acetohydrazide
(Z)-N'-(2-oxoindolin-3-ylidene )-4-( ((E)-( 4(trifluoromethyl)benzylidene )amino )oxy)butanehydrazide
(Z)-2-( ((E)-benzylideneamino )oxy)-N'-(2-oxoindolin-3ylidene )acetohydrazide
(Z)-N'-(2-oxoindolin-3-ylidene )-2-( (( E)-(2(trifluoromethyl)benzylidene )amino )oxy)acetohyd razide
(Z)-N'-(2-oxoindolin-3·-ylidene )-2-( ((E )-(3(trifluoromethyl)benzylidene )amino )oxy)acetohydrazide
(Z)-N'-( 1-((dibenzylamino )methyl)-2-oxoindolin-3ylidene )-4-( ((E)-( 4-(trifluoromethyl)benzylidene)
amino)oxy) butanehydrazide
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MW
599.6

545.63

549.59

566.05

523.63

591.66

576.6
418.37
322.32
390.32
390.32
627.66

Chemotaxis analysis was pursued using the EVS14 compounds to identify
structural elements which could enhance anti-CXCR4 activity. The chemotaxis
values of ECLVS14 and the EVS14 compounds are presented in Table 8. Of the
twenty-three EVS14 compounds tested, ten significantly inhibited CXCR4
mediated chemotaxis. Initial screening chemotaxis at SO IJM is depicted in Figure
2S. Dose response analysis depicted in Figure 26, was pursued to identify the
ICSO values of the nine EVS 14 compounds which inhibited chemotaxis. Two of
the EVS14 compounds produced ICSO values of less than 10 IJM; EVS14-21 and
EVS14-22 exhibited ICSO values of S IJM and 7.S IJM respectively.
Specificity screening of active EVS compounds in BLT1 expressing cells
revealed that eight of the ten compounds inhibited chemotaxis in both systems.
Dose response analysis revealed that of the eight compounds with anti-BLT1
activity, only EVS14-4 and EVS14-S produced inhibition of chemotaxis at greater
than the screening concentrations for BL T1, as depicted in Figure 27. All of the
compounds other than EVS14-S produced significantly greater anti-CXCR4
activity than anti-BLT1activity. EVS14-S produced significantly greater reduction
in BLT1 mediated chemotaxis than CXCR4-mediated chemotaxis.
EVS 14 compounds were further evaluated for their capability of inhibiting CXCR4
mediated intracellular calcium mobilization. The EVS14 compounds frequently
precipitated at higher concentrations during the intracellular calcium mobilization
experiments. As such, screening of these compounds was carried out at 10 IJM.
At this concentration precipitation of the compound was not noted in the
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Table 8: Table of ECLVS14 and EVS14 compound chemotaxis activity.
Chemical characteristics of parent compound ECLVS14 and the EVS14
derivatives are listed below along with chemotaxis index listings and the ICSO of
active compounds.
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Table 8: Table of ECLVS14 and EVS14 compound Chemotaxis activity.

EVS14-4
EVS14-5

Linker
length
1
2
3
4
acetamide
acetamide

EVS14-6

acetamide

EVS14-7

acetamide

EVS14-8

acetamide

EVS14-9
EVS14-10

acetamide
acetamide

EVS14-11

acetamide

EVS14-12

1

EVS14-13
EVS14-14
EVS14-15

1
1
1

EVS14-16

1

EVS14-17

1

EVS14-18

1

EVS14-19

3

EVS14-20

1

EVS14-21

1

EVS14-22

1

EVS14-23

1

Compound
ECLVS14
EVS14-1
EVS14-2
EVS14-3

Terminal Phenyl
phenyl
phenyl
phenyl
phenyl
4-fluorophenyl
4-chlorophenyl
4- trifluroro
methyl phenyl
Cyclohexylidene
amino
4-methoxy
phenyl
4-methylphenyl
4-nitrophenyl
2,4-dimethoxy
phenyl
4-trifluroro
methylphenyl
4-methylphenyl
4-fluorophenyl
4-chlorophenyl
Cyclohexylidene
amino
2,4-dimethoxy
phenyl
4-nitrophenyl
4-trifluroro
methyl phenyl
phenyl
2-trifluroro
methylphen~

3-trifluroro
methyiphenJli
4-trifluroro
methyl phenyl
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1-BPMAM
Moeity
1-BPMAM
1-BPMAM
1-BPMAM
1-BPMAM

Compound
ICSO
5IJM
40 IJM
Not Active
Not Active

H
H

Chemotaxis
index
0.21 ± 0.16
0.24 ± 0.11
0.46 ± 0.23
0.39 ± 0.20
0.10±0.12
0.18 ± 0.24

H

0.15±0.24

15 IJM

H

0.53 ± 0.26

Not Active

H

0.38 ± 0.21

Not Active

H
H

0.23 ± 0.22
0.64 ± 0.08

35IJM
Not Active

H

0.72±0.14

Not Active

1-BPMAM

0.39 ± 0.24

Not Active

1-BPMAM
1-BPMAM
1-BPMAM

0.73 ± 0.16
0.73 ± 0.24
0.59 ± 0.24

Not Active
Not Active
Not Active

1-BPMAM

0.82 ± 0.03

Not Active

1-BPMAM

0.53 ± 0.13

Not Active

1-BPMAM

0.57±0.19

Not Active

H

0.28 ± 0.11

25IJM

H

0.09 ± 0.07

25IJM

H

0.28 ± 0.10

5IJM

H

0.02 ± 0.02

7.5 IJM

1-BPMAM

0.21 ± 0.08

27.5 IJM

15IJM
20 IJM

Figure 25: ECLVS14 Derivative Compounds Inhibit CXCR4 Mediated
Chemotaxis. Ten of the twenty three (43.5%) ECLVS14 derived compounds
significantly inhibited CXCR4-mediated chemotaxis. Chemotaxis assays
performed at a concentration of 50 !-1M.
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Figure 25: ECLVS14 Derivative Compounds Inhibit CXCR4 Mediated
Chemotaxis.
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Figure 26: IC50 of Active Inhibitors of CXCR4 Mediated Chemotaxis.
Concentrations which inhibited 50% of chemotaxis in relation to CXCL 12 alone
signaling (IC50) were determined for active EVS14 compounds. Vertical axis is
presented in terms of IC50 of chemotaxis in !-1M. Of the EVS compounds, EVS1421 and EVS14-22 had IC50 values less than 10 !-1M.
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Figure 26: ICSO of Active Inhibitors of CXCR4 Mediated Chemotaxis.
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Figure 27: EVS14 compounds selectively inhibit CXCR4 Mediated
Chemotaxis. Specificity screening of active EVS compounds in BLT1 expressing
cells revealed that eight of the ten compounds inhibited chemotaxis in both
systems. Only EVS14-4 and EVS14-5 produced inhibition of chemotaxis at
greater than the screening concentrations for BLT1 . All of the compounds other
than EVS 14-5 produced significantly greater anti-CXCR4 activity than antiBLT1 activity. EVS14-5 produced significantly greater reduction in BLT1 mediated
chemotaxis than CXCR4-mediated chemotaxis.
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Figure 27: EVS14 compounds selectively inhibit CXCR4 Mediated
Chemotaxis.
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spectrophotometer cuvette. None of the compounds significantly inhibited
CXCR4 mediated intracellular calcium mobilization, as can be seen in Figure 28 .
In all, the EVS14 compounds maintain the characteristics of their parent
compound EClVS14. Several of the derivatives selectively inhibit CXCR4mediated chemotaxis, while maintaining EClVS14's inability to modulate
CXCR4-mediated calcium mobilization.
aSAR analysis reveals essential pharmacophores of ECLVS14
Specific analysis of the EVS 14 compounds reveals several specific factors
of EClVS14 involved in its anti-CXCR4 activity. One of the most obvious
modifications of the parent compound involved extension of the hydrazine-linked
alkyl moiety. Modifications of the hydrazine-linked alkyl moiety to ethyl (EVS141), propyl (EVS 14-2), and butyl (EVS14-3) derivatives revealed that as the
hydrazine-linked alkyl group was lengthened, activity decreased, as can be seen
in Figure 29. When the hydrazine-linked alkyl moiety is the only modification from
ECl VS 14, neither the propyl or butyl derivatives significantly inhibited
chemotaxis. The ethyl derivative significantly inhibited chemotaxis, but the IC50
was much lower than the hydrazine-linked alkyl parent compound (40 IJM vs. 5
IJM).
Several of the EClVS14-derived compounds are comparable, in that they
were modified in the same manner at the terminal benzene as depicted in Figure
30. These compounds differ in that some retain the 1-BPMAM moiety and the
hydrazine-linked alkyl of the parent compound, while their counterparts lack this
moiety and have converted the hydrazine-linked alkyl into an acetamide. When
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Figure 28: EV514 compounds do not inhibit CXCR4 mediated calcium
mobilization. Calcium Mobilization assays performed with EVS14 compounds at
a concentration of 10 !-1M. Vertical axis is presented in terms of normalized
calcium signal, wherein the amplitude of the calcium response to the CXCL 12alone control corresponds to 1. Decreased signal amplitude correlates with
inhibition of calcium mobilization. None of the tested EVS14 compounds
significantly inhibited calcium mobilization.
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Figure 29: Increasing length of the hydrazine-linked alkyl moiety decreases
activity. Sequential modifications of the hyd razine-linked alkyl moiety of
ECl VS 14, depicted as X in the figure , increased the length from the hydrazine
(EClVS14) to ethyl (EVS14-1), propyl (EVS14-2) and butyl (EVS14-3)
derivatives, with decreasing chemotaxis activity with increasing chain length.
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Figure 29: Increasing length of the hydrazine-linked alkyl moiety decreases
activity.
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Figure 30: Effect of terminal benzene modifications on anti-CXCR4 activity.
Acetamide derivatives lacking the 1-BPMAM moiety with terminal benzene
modifications with greater electro negativity have greater anti-chemotaxis activity
than their hydrazine-linked alkyl counterparts which retain the 1-BPMAM moiety.
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Figure 30: Effect of terminal benzene modifications on anti-CXCR4 activity.
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EVS14-11
(2 ,4-dimethoxybenzyl idene)methanamine
Not Active

comparing these two groups, we find that the absence of the 1-BPMAM moiety
and the conversion to an acetamide confers a significant increase in chemotaxis
index. None of the compounds which retained the 1-BPMAM moiety
accompanied by terminal benzene modifications significantly inhibited
chemotaxis.
Identifying which alteration was responsible for this change is difficult to
tease out with the available compounds. The structure of compound EVS14-20
mimics parent compound ECLVS14 except that it lacks the 1-BPMAM moiety as
can be seen in Figure 31 . Although both compounds significantly inhibit
chemotaxis, the ICSO of the parent compound retaining the group is significantly
less than the derivative lacking the group (S !-1M vs. 2S !-1M). Compounds EVS146, EVS14-12, EVS14-21 , EVS14-22 , all are modified at the terminal benzene
with a trifluoromethyl group, but are variably altered at the hydrazine-linked alkyl
and 1-BPMAM moiety. All three compounds lacking the 1-BPMAM moiety
significantly inhibited chemotaxis while the compound retaining the moiety did
not. However, among the compounds lacking the moiety, the two compounds
which retained the hydrazine-linked alkyl group both had ICSO values which were
less than the compound with the acetamide group (S !-1M and 7.S !-1M vs. 1S !-1M).
This comparison must be qualified in that the three position of the trifluoromethyl
substituent differs in ortho/meta/para position in all three compounds.
Unfortunately there was no compound which was modified solely in terms of the
hydrazine-linked alkyl group , so a direct comparison of this modification to the
parent compound is not available from this data.
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Figure 31: Absence of the 1-BPMAM moiety alone decreases antichemotaxis activity. A comparison of ECLVS14 which retains the 1-BPMAM
moiety and EVS 14-20 which lacks it reveals that the presence of this moiety
confers greater anti-chemotaxis inhibitory activity.
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Figure 31: Absence of the 1-BPMAM moiety alone decreases antichemotaxis activity.
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Further modification of the compounds lacking the 1-BPMAM moiety and
converting to the acetamide group reveals that activity of the compounds is
related to the electro negativity of the terminal benzyl group modifications. A
parabolic relationship governs chemotaxis activity. There was no significant
inhibition in the least electronegative methoxy and dimethoxy derivatives, and the
most electronegative nitro derivatives. However, as electro negativity increased
from the methyl derivatives to the chloro , trifluoromethyl and fluoro derivatives,
the ICSO of the compounds decreased , suggesting that electronegativity of the
terminal group modifications significantly influences the inhibition of chemotaxis.
The influence of terminal benzene electro negativity can be seen in the
relationship between compounds EVS14-2, EVS14-19 , and EVS14-23. All three
of these compounds retain the propylhydrazine modification , however, where the
terminal benzene on EVS14-2 is unmodified, that of EVS14-19 and EVS14-23 is
modified to a trifluoromethyl derivative, as illustrated in Figure 32 . Whereas
EVS14-2 did not significantly inhibit chemotaxis, both EVS14-19 and EVS14-23
did significantly inhibit this activity. And while the ICSO values of the compounds
are very similar, (2S !-1M and 27.S !-1M respectively) they have a significant
structural difference in that EVS14-19 lacks the 1-BPMAM moiety. This suggests
that terminal benzene electro negativity confers a greater influence over activity
than the presence or absence of the 1-BPMAM moiety.
Development of EVS14-2 derivatives for QSAR analysis
Based on preliminary chemotaxis results and a desire to further evaluate
the effects of extension of the hydrazine-linked alkyl moiety, Dr. Hammond
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Figure 32: Terminal benzene electronegativity confers greater influence
over anti-chemotaxis activity than the presence or absence of the 1BPMAM moiety. Comparison of EVS14-9 with EVS14-23 reveals that both

compounds with modification of the terminal benzene have roughly equivalent
inhibition of chemotaxis despite differing in the presence or absence of the 1BPMAM moiety.
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Figure 32:Terminal benzene electronegativity confers greater influence
over anti-chemotaxis activity than the presence or absence of the 1BPMAM moiety.
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27.5 ~M

developed an additional series of ECLVS14 derivatives based on the
propylhydrazine derivative EVS14-2. Fourteen compound EVS14-2 derivatives
were synthesized for testing. These compounds, illustrated in Figure 33 and
listed in Table 9, retained EVS14-2's conversion of the hydrazine-linked alkyl to a
propylhydrazine and demonstrated modification or replacement of the 1-BPMAM
moiety.
Chemotaxis analysis was pursued using the EVS 14-2 derivative
compounds to identify structural elements which could enhance anti-CXCR4
activity. The chemotaxis values of the EVS 14-2 derivatives are presented in
Table 10. Of the fifteen compounds tested , ten significantly inhibited CXCR4
mediated chemotaxis. Initial screening chemotaxis at 50 IJM is depicted in Figure
34. Dose response analysis depicted in Figure 35, was pursued to identify the
IC50 values of the five EVS 14-2 derivative compounds which inhibited
chemotaxis. Compound EVS14-2-AB was the sole compound to exhibit an IC50
less than 10 IJM
Specificity screening of active EVS1 4-2 derivatives, depicted in Figure 36 ,
in BLT1 expressing cells revealed that five of the seven compounds inhibited
chemotaxis in both systems. All of the com pounds produced significantly greater
anti-CXCR4 activity than anti-BL T1 activity.
EVS 14-2 derivatives were further evaluated for their capacity for inhibiting
CXCR4 mediated intracellular calcium mobilization. Much like their parent
compound , the EVS14-2 derivatives frequently precipitated at higher
concentrations during the intracellular calci um mobilization experiments and
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Figure 33: EV514 -2 derivative compounds. Derivatives of EVS14-2 were
generated focusing on modification of the benzene groups of the 1-BPMAM
moiety while maintaining the propylhydrazine modifications of EVS14-2.
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Figure 33: EVS14-2 derivative compounds
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Table 9: EVS14-2 derivative compounds. Derivatives of EVS14-2 were
generated focusing on modification of the benzene groups of the 1-BPMAM
moiety while maintaining the propylhydrazine modifications of EVS14-2. The
following table lists compound name and molecular weight.
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Table 9: EVS14-2 derivative compounds
Compound
EVS14-2-B

EVS14-2-C

EVS14-2-D

EVS14-2-E

EVS14-2-J

EVS14-2-K

EVS14-2-L

EVS14-2-N

EVS14-2-P

EVS14-2-T
EVS14-2-AA
EVS14-2-AB
EVS14-2-AD
EVS14-2-AE

NAME
(Z)-N'-( 1-((benzyl( 4-methylbenzyl)amino )methyl)-2oxoindolin-3-ylidene )-4-( ((E)benzylideneamino )oxy)butanehydrazide
(Z)-N'-( 1-((benzyl(3-methoxybenzyl)amino )methyl)-2oxoindolin-3-ylidene )-4-(((E)benzylideneamino )oxy)butanehydrazide
(Z)-N'-( 1-((benzyl( 4-methoxybenzyl)amino )methyl)-2oxoindolin-3-ylidene )-4-(((E)benzylideneamino )oxy)butanehydrazide
(Z)-N'-( 1-( (benzyl(2,4-dimethoxybenzyl)amino )methyl)-2oxoindolin-3-ylidene )-4-(((E)benzylideneamino )oxy)butanehydrazide
(Z)-N'-( 1-((benzyl( 4-chlorobenzyl)amino )methyl)-2oxoindolin-3-ylidene )-4-( ((E)benzylideneamino )oxy)butanehydrazide
(Z)-N'-( 1-((benzyl(2-fluorobenzyl)amino )methyl)-2oxoindolin-3-ylidene )-4-( ((E)benzylideneamino )oxy)butanehydrazide
(Z)-N'-( 1-((benzyl( 4-fluorobenzyl)amino )methyl)-2oxoindolin-3-ylidene )-4-( ((E)benzylideneamino )oxy)butanehydrazide
(Z)-N'-( 1-((benzyl( 4-(trifluoromethyl)benzyl)amino )methyl)2-oxoindolin-3-ylidene )-4-( ((E)benzylideneamino )oxy)butanehydrazide
(Z)-N'-(1-((benzyl( 4-nitrobenzyl)amino )methyl)-2oxoindolin-3-ylidene )-4-(((E)benzylideneamino )oxy)butanehydrazide
(Z)-N'-( 1-( (benzyl(pyridin-4-ylmethyl)amino )methyl)-2oxoindolin-3-ylidene )-4-(((E)benzylideneamino )oxy)butanehydrazide
(Z)-N'-( 1-((benzyl(ethyl)amino )methyl)-2-oxoindolin-3ylidene )-4-( ((E)-benzylideneamino )oxy)butanehydrazide
(Z)-N'-( 1-((benzyl(vinyl)amino )methyl)-2-oxoindolin-3ylidene )-4-( ((E)-benzylideneamino )oxy)butanehydrazide
(Z)-4-( ((E)-benzylideneamino )oxy)-N'-(2-oxo-1-(piperidin1-ylmethyl)indolin-3-ylidene )butanehydrazide
(Z)-4-(( (E)-benzylideneamino )oxy)-N'-( 1(morpholinomethyl)-2-oxoindolin-3~Iidene )butanehydrazide
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MW
573.7

589.7

589.7

619.7

594.1

577.7

577.7

627.7

604.7

560.7
497.6
495.6
447.5
449.5

Table 10: Table of EVS14-2 compound Chemotaxis activity Chemical
characteristics of the EVS 14-2 derivatives are listed below along with chemotaxis
index listings and the ICSO of active compounds.
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Table 10: Table of EVS14-2 and EVS14-2-AD compound Chemotaxis activity
Compound

Terminal
Phenyl

1-BPMAM Moeity

Chemotaxis
index

Compound
IC50

EVS14-2-B

phenyl

N-benzyl-N-( 4methylbenzyl)ethanamine

1.59 ± 0.30

Not Active

EVS14-2-C

phenyl

N-benzyl-N-(3methoxybenzyl)ethanamine

1.09 ± 0.29

Not Active

EVS14-2-D

phenyl

N-benzyl-N-( 4methoxybenzyl)ethanamine

0.20 ± 0.05

17.5 IJM

EVS14-2-E

phenyl

N-benzyl-N-(2,4dimethoxybenzyl)ethanamine

1.34 ± 0.37

Not Active

EVS14-2-J

phenyl

N-benzyl-N-( 4chlorobenzyl)ethanamine

0.44 ± 0.13

Not Active

EVS14-2-K

phenyl

N-benzyl-N-(2fluorobenzyl)ethanamine

1.43 ± 0.18

Not Active

EVS14-2-L

phenyl

N-benzyl-N-( 4fluorobenzyl)ethanamine

0.23 ± 0.05

22.5 IJM

EVS14-2-N

phenyl

N-benzyl-N-( 4(trifluoromethyl)
benzyl)ethanamine

1.45 ± 0.19

Not Active

EVS14-2-P

phenyl

N-benzyl-N-( 4nitrobenzyl)ethanamine

0.66 ± 0.20

Not Active

EVS14-2-T

phenyl

N-benzyl-N-(pyridin-4ylmethyl)ethanamine

0.17 ± 0.01

40 IJM

EVS14-2-AA

phenyl

N-benzyl-N-ethylethanamine

0.22 ± 0.09

20 IJM

EVS14-2-AB

phenyl

N-benzyl-N-ethylethenamine

0.36 ± 0.22

Not Active

EVS14-2-AD

phenyl

1-ethylpiperidine

0.03 ± 0.01

Not Active

EVS14-2-AE

phenyl

4-ethylmorpholine

0.21 ± 0.07

22.51JM
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Figure 34: EVS14-2 derivative compounds Inhibit CXCR4 Mediated
Chemotaxis. Seven of the fifteen EVS 14-2 derived compounds significantly
inhibited CXCR4-mediated chemotaxis. Chemotaxis assays performed at a
concentration of 50 !-1M.
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Figure 34. EVS14-2 derivative Compounds Inhibit CXCR4 Mediated
Chemotaxis
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Figure 35: IC50 of Active Inhibitors of CXCR4 Mediated Chemotaxis.
Concentrations which inhibited 50% of chemotaxis in relation to CXCL 12 alone
signaling (IC50) were determined for active EVS14-2 derivatives. Vertical axis is
presented in terms of IC50 of chemotaxis in I-IM. Of the EVS14-2 compounds,
EVS14-2-AB had an IC50 value of less than 10 I-IM.
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Figure 35: IC50 of Active Inhibitors of CXCR4 Mediated Chemotaxis.
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Figure 36: EVS14-2 derivatives selectively inhibit CXCR4 Mediated
Chemotaxis. Specificity screening of active EVS14-2 derivatives in BLT1
expressing cells revealed that five of the seven compounds inhibited chemotaxis
in both systems. All of the compounds other than EVS 14-5 produced greater
anti-CXCR4 activity than anti-BLT1 activity.
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Figure 36 : EVS14-2 derivatives selectively inhibit CXCR4 Mediated
Chemotaxis.
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EVS14-2-AE

screening was carried out at 10 IJM. At this concentration precipitation of the
compound was not noted in the spectrophotometer cuvette. None of the
compounds significantly inhibited CXCR4 med iated intracellular calcium
mobilization, as can be seen in Figure 37.
In all, some of the EVS14-2 derivatives improve on their predecessor.
Several of the derivatives selectively inhibit CXCR4-mediated chemotaxis, while
maintaining ECLVS14's inability to modulate CXCR4-mediated calcium
mobilization.
QSAR analysis of EVS14-2 derivatives illustrates the effects of alteration of
the 1-BPMAM moiety.
The majority of the EVS 14-2 derived compounds deal with replacement or
modification of the 1-BPMAM moiety, as illustrated in Figure 38. It is difficult to
identify relationships between different modifications of the benzene elements of
the 1-BPMAM moiety. Only two of the modifications significantly inhibited
chemotaxis, the methoxy and fluoro derivatives. Replacement of the 1-BPMAM
moiety seemed to offer greater alteration of chemotaxis and seemed to correlate
with size. Replacement of one benzene substituent with a pyridine significantly
inhibited chemotaxis, and inhibition increased as the substituents shrank in size,
from pyridine to ethyl to ethenyl (40 IJM vs. 20 IJM vs. 5 IJM). Wholesale
replacement of the 1-BPMAM moiety with a piperidine or morpholine substituent
conferred a similar enhancement of inhibition compared to the EVS14-2 parent
compound (20 IJM and 22 .5 IJM).
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Figure 37: EVS14-2 derivatives do not inhibit CXCR4 mediated calcium
mobilization. Calcium Mobilization assays performed with EVS14-2 derivatives
at a concentration of 10 I-IM. Vertical axis is presented in terms of normalized
calcium signal, wherein the amplitude of the calcium response to the CXCL 12alone control corresponds to 1. Decreased signal amplitude correlates with
inhibition of calcium mobilization. None of the tested EVS14-2 derivatives
significantly inhibited calcium mobilization.
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Figure 37. EVS14-2 derivatives do not inhibit CXCR4 mediated calcium
mobilization.
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Figure 38: EVS14-2 derivatives modify or replace the 1-BPMAM moiety. The
EVS 14-2 derived compounds deal with replacement or modification of the 1BPMAM moiety. Seven of the fourteen modifications significantly inhibited
chemotaxis. Replacement of one benzene substituent with a pyridine significantly
inhibited chemotaxis, and inhibition increased as the substituents shrank in size,
from pyridine to ethyl to ethenyl (40 !-1M vs. 20 !-1M vs. 5 !-1M). Wholesale
replacement of the 1-BPMAM moiety with a piperidine or morpholine substituent
conferred a similar enhancement of inhibition compared to the EVS14-2 parent
compound (20 !-1M and 22.5 !-1M).
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Figure 38: EVS14-2 derivatives modify or replace the 1-BPMAM moiety.
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Substitution

ICSO

EVS14-2-D

N-benzyl-1-(4methoxyphenyl)-Nmethylmethanamine

17.5 IJM

EVS14-2-L

EVS14-2-T

EVS14-2-AA

N-benzyl-Nmethylethanamine

\

\

EVS14-2-AB

\
40 IJM

5IJM

1-methylpiperidine

20 IJM

F

N
cr \
\

\

20 IJM

0--

N

(}~
!J

\

crN~
\

EVS14-2-AD

N

OJ
\

N-benzyl-Nmethylethenamine

N

C)~

N-benzyl-1-(4-fluorophenyl)22.51JM
N-methylmethanamine

N-benzyl-N-methyl-1(pyridin-4-yl)methanamine

X

!J

"0
"Nl

EVS14-2-AE

4-methylmorpholine

22.5 IJM
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Acetamide derivatives of ECLVS14 are associated with elevated levels of
non-specific cytotoxicity.
As inhibition of chemotaxis by the EClVS14 derivative compounds could
be due to nonspecific toxic side effects, the EClVS compounds were screened
for cytotoxicity. Mimicking the conditions in the chemotaxis assay, 300.19 cells
were cultured in the presence of IClGa compounds at the initial screening
concentration of 50 IJM and cytotoxicity was assessed using propidium iodide
(PI) based flow cytometry. PI is unable to penetrate the cell membrane in viable
cells, so cells staining positive for PI do not have intact membranes. Cytotoxicity
values are presented as percentage of cells staining positive for PI in Figure 39.
Of the thirty seven EVS 14 and EVS 14-2 compounds only six produced elevated
cytotoxicity when compared to untreated cells or cells treated with DMSO only
control. Interestingly, four of the eight acetamide derivatives of EClVS 14
displayed elevated cytotoxicity, suggesting that modification of this group
adversely affects the capability of CXCR4 to exhibit specific anti-CXCR4 activity.
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Figure 39: Acetamide ECLVS14 derivatives produce elevated non-specific
cytotoxicity. Vertical axis is expressed in terms of cells staining positive for PI,
a marker for membrane disruption and non-viable cells. Four of the eight
acetamide derivatives of EelVS 14 exhibited significant cytotoxicity.
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Figure 39: Acetamide ECLVS14 derivatives produce elevated non-specific
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Analysis of anti-CXCR4 compound mechanism through molecular
dynamics simulations
To test the hypothesis that compound binding will result in structural
changes associated with inactivation of CXCR4, the conformational differences
between native CXCR4, the constitutively active N119S mutant [286, 287], and
bound CXCR4 inhibitors were investigated .
The initial native CXCR4 and N119S mutant structures were developed by
Dr. Kelby Napier via homology modeling utilizing the high resolution rhodopsin
crystal structure [288]. When this work was conducted , the x-ray crystal structure
for CXCR4 had not yet been released , so th is structure was not a viable option
for these studies. Also, the rhodopsin structure was chosen rather than the new
131-adrenergic, 132-adrenergic, or a2a-adrenergic receptors , because these
structures were generated with significant modifications of the intracellular loop 3
and the C-terminal region. Homologies developed based on these structures
would have required rhodopsin based modeling of intracellular loop 3 and the Cterminal region , making this method redundant.
Molecular modeling of CXCR4
Fully solvated lipid bilayer molecular dynamics simulations of native
CXCR4 bound with active EClVS compounds were performed using the AMBER
suite of programs using the parm99 fo rce field [284]. Anti-CXCR4 compounds
were docked into the T140 binding site [200 , 207] of CXCR4 using Surflex-Dock
[234]. Restraints were initially used to guide conformation of the receptors as
previously described in [285]. In brief, an initial 5000 step steepest decent
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minimization was conducted with protein and compound restrained (100 kcal
mor 1 A- 1), followed by another 5000 step steepest decent minimization with no
protein or compound restraints. This was followed by a 25 ps MD (T=100 K)
holding protein fixed (100 kcal mor 1 A- 1) , and another unrestrained 5000 step
steepest decent minimization without restraints. The temperature of the system
will be increased from an initial point of 1OOK to 300K while maintaining 100 kcal
mor 1 A-1 restraints. An additional three 25 ps steps of minimization will be
conducted gradually decreasing the restraints from 100 kcal mol- 1 A-1 to 10 kcal
mor 1 A-1 and finally to 1 kcal mol- 1 A- 1. Ten production runs of 500 ps were then
conducted . The impact of the ECl VS and EVS 14 compounds on CXCR4
structure has not yet been determined .
Some of the ECLVS and EVS14 compounds do not bind the native
conformation of CXCR4 in molecular dynamics simulations.
The final averaged structures of native CXCR4 in complex with each of
the anti-CXCR4 compounds from the 5 ns molecular dynamics simulation are
shown in Figure 40. Of the seven docked compounds, stable CXCR4: compound
complexes were generated for compounds EClVS14, EClVS58, EClVS59,
EClVS82 and EVS14-2-AB. Compounds EVS14-21 and EVS14-22 did not form
stable complexes with the native conformation of CXCR4. Neither of these
compounds possessed the 1-BPMAM moiety, suggesting that this element is
essential for interacting with the extracellular surface of the receptor.
The molecular dynamics simulation maintained equilibrium throughout the
production run , as can be seen in Figure 41 . All energy values were noted to be
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Figure 40: Final averaged structure of Native CXCR4 dynamically bound to
compounds. Average structure of CXCR4 presented in ribbon format.
Compounds are bound to dynamically determined binding position. Interacting
residues are highlighted in stick confo rmations.
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Figure 40: Final averaged structure of Native CXCR4 dynamically bound to
compounds.
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Figure 41: Energy plot of ECLVS compounds bound to native CXCR4
versus time. Energy values across the trajectory for total energy (blue), kinetic
energy (red) and potential energy (green) are presented. CXCR4 was found to
be energetically stable and maintained equilibrium across the production run. A)
ECLVS14, B) EVS14-2-AB, C) ECLVS58, D) ECLVS59, E) ECLVS82
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Figure 41: Energy plot of compounds bound to native CXCR4 versus time.
A) EClVS14, B) EVS14-2-AB, C) EClVS58, D) EClVS59, E) EClVS82
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5

stable, indicating that the simulation was well equilibrated prior to production
analysis. Conformational stability of the CXCR4-compound complexes was
investigated using root RMSD analysis, presented in Figures 42 . RMSD values
remained stable for the majority of the production runs , with the final average
structure representative of the trajectory after approximately 1.5 ns. The helical
domains were highly stable throughout the production run , while the majority of
the structural variation was seen in the loop regions. The RMSD of the EClVS14
complex from the native conformation of CXCR4 was 3.1 , compared to RMSD
values of 3.0 angstroms for EVS14-2-AB , 3.8 angstroms for EClVS58 , 3.7
angstroms for EClVS59 and 3.6 angstroms for EClVS82 .
The dynamic binding site of EClVS1 4, shown in Figure 43 consists of the
N-terminus and ECl2 posterior to the compound . One of the benzene
substituents of the 1-BPMAM moiety of ECl VS 14 interacts with the aliphatic lIe6
side chain as well as the backbone of the Ser5, Tyr7, and Thr8 residues. The
terminal benzene of the compound interacts with Val197 and Va1198. The
indolin-2-one moiety interacts with the side chain of Trp195 throug h TT-TT stacking
interactions as well as with the leu194 side chain.
The dynamic binding site of EVS14-2-AB , shown in Figure 44 consists
anteriorly of the C-terminus and ICl2, and superiorly and posteriorly of ICl2. The
side chain of Ser144 interacts with the ethenamine moiety of the compound,
while the indoleine moeity interacts with the guanidine of Arg148 by TT-TT
stacking. The hydrazine linker region interacts with the backbone of Pro147, as
well as the side chain of Asn143. The terminal benzene is bound anterior and
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Figure 42: RMSD values of CXCR4 bound to ECLVS compounds across 5
ns of the production trajectory. Total RMSD calculated at the Co position
presented in green. Helical domains are presented in blue, and loop regions are
presented in red. The CXCR4 structure was noted to be stable, and the average
structure was noted to represent the conformation present in the trajectory after
0.5 ns of simulation time. A) ECLVS14, B) EVS14-2-AB, C) ECLVS58 , D)
ECLVS59 , E)ECLVS82
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Figure 42: RMSO values of CXCR4 bound to ECLVS14 across 5 ns of the
production trajectory. A) ECLVS14, B) EVS14-2-AB, C) ECLVS58, D)
ECLVS59,E)ECLVS82
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Figure 43: Dynamic binding site of ECLVS14 to native CXCR4. Critical
residues for ECLVS14 binding to CXCR4 are highlighted. ECLVS14 is depicted
in red ball-stick representation, while CXCR4 residues within 3 angstroms of the
compound are presented in stick representation and superstructure of CXCR4 is
presented as cyan ribbon. ECLVS14 interacts with the N-terminus and ECL2
regions of the extracellular surface.
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Figure 43: Dynamic binding site of ECLVS14 to native CXCR4.
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Figure 44: Dynamic binding site of EVS14-2-AB to native CXCR4. Critical
residues for EVS14-2-AB binding to CXCR4 are highlighted. EVS14-2-AB is
depicted in red ball-stick representation , while CXCR4 residues within 3
angstroms of the compound are presented in stick representation and
superstructure of CXCR4 is presented as magenta ribbon. EVS 14-2-AB interacts
with the C-terminus and ICL2 regions of the Intracellular surface.
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Figure 44: Dynamic binding site of EVS14·2·AB to native CXCR4.
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posterior by side chain of Ser352 to the anterior surface of the aromatic ring, and
by the guanidine of Arg146 by TT-TT stacking posterior to the compound. As the
original docked conformation placement of EVS 14-2-AB was on the extracellular
surface of the receptor, the fact that the compound stably and dynamically bound
to the intracellular surface of the receptor came as a surprise . However, the
compound structure of EVS14-2-AB was sufficiently different from the parent
compound to suggest that it may bind in a separate conformation than EClVS14.
The dynamic binding site of EClVS58, shown in Figure 45 consists of the
N-terminus posterior to the compound , ECl2 inferior to the compounds and
ECl3 anterior to the anterior of the compound. The methyl end of the methyl
piperidin-1-one moiety is stabilized by interaction with the aliphatic elements of
the side chain of Glu32 and the backbone of Glu31 . One of the pyridine moieties
interacts with the aliphatic portion of Tyr12 as well as with anterior and posterior
cysteine residues 274 and 28. The carboxyl end of the methyl piperidin-1-one
moiety interacts with the guanidine elements of the Arg183 side chain. The other
pyridine moiety interacts with the aliphatic elements of the Arg183 side chain as
well as the side chain of his 281.
The dynamic binding site of EClVS59, shown in Figure 46 consists of
ECl3 posterior to the compound , ECl2 inferior to the compound and the Nterminus anterior to the compound. The methoxybenzene moiety is stabilized by
interaction with the aliphatic elements of the phe276 and Val280 side chains. The
cyanoacetimidamide is stabilized by multiple hydrogen bonds, between the
backbones of Cys274, Thr279 and His281 as well as the guanidine of Arg 183.
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Figure 45: Dynamic binding site of ECLVS58 to native CXCR4. Critical

residues for EClVS58 binding to CXCR4 are highlighted. EClVS58 is depicted
in red ball-stick representation, while CXCR4 residues within 3 angstroms of the
compound are presented in stick representation and superstructure of CXCR4 is
presented as yellow ribbon. EClVS58 interacts with the N-terminus, ECl2 and
ECl3 regions of the extracellular surface.
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Figure 45: Dynamic binding site of ECLVS58 to native CXCR4.
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Figure 46: Dynamic binding site of ECLVS59 to native CXCR4. Critical
residues for ECLVS59 binding to CXCR4 are highlighted. ECLVSS9 is depicted
in red ball-stick representation, while CXCR4 residues within 3 angstroms of the
compound are presented in stick representation and superstructure of CXCR4 is
presented as orange ribbon. ECLVS59 interacts with the N-terminus and ECL2
regions of the extracellular surface.
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Figure 46: Dynamic binding site of ECLVS59 to native CXCR4.
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The dynamic binding site of EClVS82, shown in Figure 47 consists of
ECl3 and the proximal portion of the N-terminus lateral to the compound, and
the distal portion of the N-terminus posterior to the compound. One of the
benzamide elements is stabilized by interaction with the aliphatic elements of the
Phe276 side chain, as well as the backbones of the Glu275 and Cys274 residues
inferior to the compound, and the backbones of the Glu31 and Glu32 residues .
The phenanthroline element of the compound interacts with the side chain of
Glu32 to the anterior of the compound, and with aliphatic elements of the Met6
and Thr13 side chains posterior to the compound, and the Asn11 and Tyr12 side
chains lateral to the compound.
These dynamics determined structures shed light on the potential
mechanism of the activity of the ECl VS compounds. The compounds primarily
interacted with the N-terminal and the second extracellular loop regions .
Stabilization of these regions could allosterically disrupt the conformation of the
CXCl12 binding site, or prevent movement of TM7 necessary for effective signal
transduction. Interaction between the compounds and ECl2 could also directly
interfere with CXCl12 ligand binding. Interaction with the intracellular surface of
the receptor could produce effects similar to those seen with the IClVS
compounds (described in Chapter III). Interaction by the compounds with the Cterminal region could potentially stabilize TM7, or interfere with the interface
between the C-terminus and Gai. Interposition of the compound between the Cterminus and ICl2 could prevent effective formation of the cleft which would be
occupied by bound Gai.
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Figure 47: Dynamic binding site of ECLVS82 to native CXCR4. Critical
residues for ECLVS82 binding to CXCR4 are highlighted. ECLVS82 is depicted
in red ball-stick representation, while CXCR4 residues within 3 angstroms of the
compound are presented in stick representation and superstructure of CXCR4 is
presented as orange ribbon. ECLVS82 interacts with the N-terminus and ECL3
regions of the extracellular surface.
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Figure 47: Dynamic binding site of ECLV582 to native CXCR4.
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ECLVS compound binding alters the conformation of the extracellular and
intracellular surfaces of CXCR4.

Given the interactions of the EClVS compounds with the extracellular
surface of CXCR4, we sought to investigate what effect inhibitor binding could
have on overall receptor conformation. To do this, we sought to compare the
structure of the ECl VS complexed conformations of CXCR4 to the inactive
native conformation and the constitutively active N119S conformations of the
protein.
The comparison between the structures of the EClVS14-bound, native
CXCR4, and the N119S conformation is characterized by differences in loop
positioning. Although the structure of the loops is conserved between the three
conformations, there are several differences in positioning. In the N-terminal
region, the anti-parallel

~-sheet

is more compact and the distance between ECl1

and the N-terminal region is decreased, mimicking the N119S conformation by
movement of ECL. The entire region N-terminal is displaced away from the
extracellular surface of the TM regions and towards ECl3. ECl3 is outwardly
displaced from the center of the receptor. At the intracellular surface of CXCR4,
ICl1 and the C-terminus of the protein retain the native conformation and
position, while ICl2 is shifted opposite that of the N119S conformation and
towards the center of the molecule and ICl1. ICl3 adopts the shape of the native
conformation, while the apex of the loop is shifted towards the C-terminus.
The comparison between the structures of the EVS14-2-AB, native CXCR4, and
the N119S conformation is characterized by differences in loop positioning.
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Although the structure of the loops is conserved between the three
conformations, there are several differences in positioning. In the N-terminal
region, the anti-parallel

~-sheet

is preserved, but more linear than in either the

native or N119S conformations. The region is also shifted away from ECl2 and
towards the ECl3. ECl1 and ECl largely adopt the native conformation, while
ECl3 is outwardly displaced from the center of the receptor. At the intracellular
surface of CXCR4, ICl1, ICl2 and the C-terminus essentially adopt the native
conformation of the receptor. The conformation of ICl3 is shifted such that the
apex of the loop is shifted towards the C-terminus and the center of the receptor.
The comparison between the structures of the ECl VS58, native CXCR4, and the
N119S conformation is characterized by differences in loop positioning. In the Nterminal region, the anti-parallel

~-sheet

is more compact and the distance

between ECl1 and the proximal portion of the N-terminal region is decreased,
mimicking the N119S conformation by movement of ECl 1. The anti-parallel

~

sheet is also shifted away from ECl2, resulting in a conformation significantly
different from either the native or N119S conformations. At the intracellular
surface of CXCR4, ICl1 retains the native conformation and position, while ICl2
is shifted opposite that of the N119S conformation and towards the center of the
molecule and ICl1. ICl3 adopts the shape of the native conformation, but a mild
flexion of TM6 shifts the region towards the center of the molecule and ICl3.
More significant differences characterize the comparison of the structures
of the EClVS59, native CXCR4, and the N119S conformation. In the N-terminal
region, the anti-parallel

~-sheet

is preserved, but more compact than the native
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conformation. In addition, the proximal portion of the region is much more
disordered adopting a more extended loop structure than in either the native or
N119S conformations. ECL 1 is shifted towards the N-terminal region, and the
ECL2 region is shifted away from the extracellular surface of the TM helices. The
apex of the ECL3 loop is shifted away from the N-terminus. At the intracellular
surface of CXCR4, ICL 1 and the C-terminus essentially adopt the native
conformation of the receptor. ICL2 is shifted opposite that of the N119S
conformation and towards the center of the molecule and ICL 1 while the
conformation of ICL3 is shifted such that the apex of the loop is shifted towards
the C-terminus and the center of the receptor.
The comparison between the structures of the ECLVS82, native CXCR4,
and the N119S conformation is characterized by conservation of the native
CXCR4 structure. In the N-terminal region, each of the ECL loops and the Nterminal region adopt the native conformation of the receptor. At the intracellular
surface of CXCR4, ICL 1 is shifted slightly downward away from the surface of
the TM regions, while ICL2 is shifted opposite that of the N119S conformation
and towards the center of the molecule and ICL 1. The apex of ICL3 is displaced
away from that of the native conformation and away from the C-terminus and the
TM surface. The C-terminus is displaced slightly downward from the
conformation, while the distal portion of the loop is more extended and
disordered than in the native structure.
These compound:CXCR4 complex conformations suggest that the
receptors adopt intermediary conformations of the native and N119S
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conformation, characterized by movement of the N-terminal regions and
movement of the ICl loops towards the center of the receptor.
ECLVS compound binding alters the conformation of the transmembrane
helixes of CXCR4.
Given the alterations of the ECl VS compounds of the surface of CXCR4,
we sought to investigate what effect inhibitor binding could have on the structure
of the transmembrane helixes. We compared the reduced representations of the
transmembrane helices for each of the ECl VS complexed conformations of
CXCR4 to the inactive native conformation and the constitutively active N119S
conformation of the protein. Multiple receptor conformations were compared
using the helixanal program developed by Dr. Trent.
The structure of the ECl VS 14 transmembrane helixes is presented in
Figure 48a. TM1, TM2 and TM3 structure and positioning is conserved between
the complexed conformation and the native form. The TM4 kink at Pro170 and
flexion at lIe173 aligned with the native conformation of the receptor, although
the helix is shifted towards TM5 . The TM5 bulge present in the native structure
between Met205 and lIe213 is present in the complexed structure. TM6 helix is
more compact in conformation than native, and the apical turn of the helix is
displaced towards the plasma membrane. The apex of TM7 is less flexed at
Glu288 than in the native conformation , displacing the apex of the helix towards
an intermed iate position between N119S and native.
The structure of the EVS 14-2-AB transmembrane helixes is presented in
Figure 48b. TM1 adopts the conformation of the native helix other than a flexion
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Figure 48: Transmembrane regions of the ECLVS compounds complexed
with CXCR4 adopt a similar conformation to native CXCR4. Reduced
representations of receptor transmembrane helices are presented : native CXCR4
in green , N119S in red , EClVS14 conformation in teal , EVS14-2-AB
conformation in violet, ECl VSS8 conformation in yellow, EClVSS9 conformation
in orange, ECl VS82 conformation in blue.
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Figure 48: Transmembrane regions of ECLVS compounds complexed with
CXCR4 adopt a similar conformation to native CXCR4.
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of lIe44 displacing the apex of the helix towards TM2. TM2, TM3, TM4, TM5 and
TM6 structure and positioning is conserved between the complexed conformation
and the native form. Angularity at the apex of TM7 align with native structure,
while the base of the helix is more linear than in the native conformation, lacking
the kink at leu301 , which results in an outward displacement of the base of the
helix.
The structure of the ECl VS58 transmembrane helixes is presented in
Figure 48c. TM1 is more linear in conformation than native and lacks a kink at
Val54 present in the N119S conformation. TM2, TM3 and TM4 adopt the
structure and positioning of the native conformation of the receptor. The although
the apical position of the TM5 helix matches the native conformation, the apical
portion of the bulge more closely resembles the more extended structure of the
N119S mutant. Torsion of the helix shifts the apex of the bulge outward from the
center of the receptor, while a decreased flexion at the base of the bulge shifts
the base of the helix away from the center of the receptor. TM6 helix is more
linear than native, without bowing of N119S , apical turn is intact. TM7 apical
flexions align with native structure, whi le the base of the helix is more linear than
in the native conformation, lacking the kink at leu301 , which resu lts in an
outward displacement of the base of the helix.
The structure of the EClVS59 transmembrane helixes is presented in
Figure 48d . TM1 is more linear in conformation than native and lacks a kink at
Val54 present in the N119S conformation , producing an outward displacement of
the apex of the receptor. TM2 , TM3, TM4 and TM6 structure and positioning is
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conserved between the complexed conformation and the native form. The TMS
bulge present in the native structure between Met20S and lIe213 is present in the
complexed structure, but the bulge is more extended than in the native structure.
Angularity at the apex of TM7 aligns with native structure, while the base of the
helix is more linear than in the native confo rmation, lacking the ki nk at leu301 ,
which results in an outward displacement of the base of the helix.
The structure of the ECl VS82 transmembrane helixes is presented in
Figure 48e. TM1 is more linear in conformation than native and lacks a kink at
ValS4 present in the N119S conformation, resulting in displacement of the apex
and base of the helix. The remaining helices adopt the structure and positioning
of the native conformation.
Further examination of the transmembrane helixes involved assessment
of the distances between the intracellular and extracellular termini of the
interhelical segments. At the extracellular surface , as seen in Table 11 , the
compounds adopted several specific conformations. EClVS14 produced similar
interhelical distances to the native confo rmation of the receptor aside from the
TM1-2 , TM2-3, TM1-6 , and TM2-6 distances, which were all increased compared
to the native conformation for the receptor. EVS 14-2-AB produced increases in
the TM1-7 and TM1-6 interhelical distances when compared to the native
conformation , while the TM-1S distance was comparable to the N119S distance.
EClVSS8 produced increased interhelical distances between TM1-2 and TM1-7,
while the interhelical distance between TM2-3 was decreased , and the TMS-6
distance was intermediate between native and N119S . EClVSS9 produced
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Table 11: ECLVS compounds modulate the distance between the
extracellular termini of the transmembrane helixes of CXCR4. Interhelical
distances measured at extracellular termini of transmembrane domains of native
CXCR4, constitutively active N119s, and compound docked structures.
Distances measured at the extracellular termini of reduced representations of the
averaged structures. Illustrated interhelical distances demonstrate 1.5 angstrom
or greater deviation from either the Native or N 119S structure.
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Table 11: ECLVS compounds modulate the distance between the
extracellular termini of the transmembrane helixes of CXCR4.
ECLVS
TMA TMB

Native

N119S
14

EVS14- ECLVS
2-AB
58

ECLVS

ECLVS

59

82

1

2

6.5

7.6

7.3

7.0

7.9

9.4

5.9

5

6

11.2

13.1

11.3

11.1

12.3

10.5

11.2

6

7

12.1

13.1

12.4

12.2

12.0

13.2

11.5

1

7

15.8

14.6

16.2

16.9

16.7

18.2

11.5

2

3

18.3

18.6

19.4

18.2

17.3

18.1

17.5

2

7

19.1

19.3

19.9

19.5

20.5

19.4

18.8

1

3

20.9

22.2

21.9

21.6

20.5

22.9

19.6

1

4

21.9

23.3

22.4

22.9

21.2

24.9

20.9

1

6

26.0

25.4

27.0

27.8

26.3

27.8

23.3

2

6

28.7

28.0

30.3

29.6

29.2

29.5

27.1

1

5

33.6

34.8

34.3

35.3

33.6

35.2

27.9
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increases in the interhelical distances ofTM1-2, TM1-4, and TM1-6, while
decreasing the interhelical distance between TM5-6. TM6-7 and 1-5 adopted an
interhelical distance comparable to the N119S conformation. Finally, EClVS82
decreased the interhelical distances between TM1-2, TM1-7, TM1-6, Tm 1-5 and
TM2-6.
At the intracellular surface, as seen in Table 12, the compounds adopted
several specific conformations. EClVS14 produced an increased distance
between TM6-7 when compared to native, while the distances between TM2-6,
TM3-4, and TM4-6 were intermediate between the native and N119S
conformations. EVS14-2-AB produced an increased distance between TM2-7,
Tm3-7 and TM6-7 when compared to native, while the distances between TM3-4
and TM5-7 were intermediate between the native and N119S conformations.
ECl VS58 produced an increased distance between TM3-6 when compared to
native, while the distances between TM2-6 were intermediate between the native
and N119S conformations. The interhelical distances between TM1-3, TM1-5,
TM2-5, and TM2-7 were decreased when compared to the native conformation.
EClVS59 produced an increased distance between TM2-7, TM3-7, TM4-5, Tm47 and TM6-7 when compared to native, while the distances between TM2-5,
TM3-4, TM-3-5 and TM5-7 were intermediate between the native and N119S
conformations. The interhelical distances between TM1-3 were decreased when
compared to the native conformation. ECl VS82 produced an increased distance
between TM6-7 when compared to native, while the distance between TM3-4
was intermediate between the native and N119S conformations.
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Table 12: ECLVS compounds modulate the distance between the
intracellular termini of the transmembrane helixes of CXCR4. Interhelical
distances measured at intracellular termini of transmembrane domains of native
CXCR4, constitutively active N119S, and compound docked structures.
Distances measured at the intracellular termini of reduced representations of the
averaged structures. Illustrated interhelical distances demonstrate 1.5 angstrom
or greater deviation from either the Native or N119S structure.
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Table 12: ECLVS compounds modulate the distance between the
intracellular termini of the transmembrane helixes of CXCR4.

TMA TMB

ECLVS

EVS14

ECLVS

ECLVS

ECLVS

14

-2-AB

58

59

82

Native N119S

2

6

10.7

12.9

11.1

10.8

10.3

11.1

10.6

3

5

11.5

16.5

10.9

11.3

11.9

13.2

11.6

2

7

11.7

12.3

11.9

14.4

11.0

13.7

11.7

3

6

12.0

13.4

11.5

11.5

12.5

11.2

11.0

6

7

12.3

11.8

13.4

16.5

11.5

15.5

13.9

3

4

16.0

12.6

15.6

15.2

15.6

15.5

16.4

4

6

19.5

17.6

18.8

18.7

19.1

19.5

19.0

3

7

21.5

22.2

21.9

25.4

21.0

23.8

22.0

4

7

22.3

21.0

22.2

24.9

21.6

24.2

22.1

2

5

22.5

25.3

22.6

22.3

21.6

23.7

22.6

1

3

24.6

25.7

24.3

24.6

24.6

22.9

24.1

5

7

24.8

23.7

25.3

27.8

21.8

27.7

25.4

4

5

26.6

26.8

25.5

25.7

26.3

28.0

27.1

1

5

32.2

33.9

31.7

31.5

29.8

32.2

31.6
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The overall representation of these interhelical distance measurements
and the reduced representation analysis speaks to a difference in activity
between the anti-CXCR4 compounds. EClVS14 binding seemed to alter the
interhelical distances by modulating TM2 and TM6 position at the extracellular
surface producing a more open conformation of the receptor on this surface, and
seemed to modulate the interaction between TM6 and the other helices at the
intracellular surface to produce a similarly open conformation at this surface. This
suggests that EClVS14 may drive the receptor towards an intermediate
conformation, more open than the native, but not as open as the constitutively
active N119S conformation.
EVS14-2-AB binding alters TM1 interaction with the other helices at the
extracellular surface, and TM? at the intracellular surface, primarily through its
interactions with the C-terminus. ECl VS58 and ECl VS59 primarily increased
intrahelical distances at the extracellular surface and decreased intrahelical
distances at the intracellular surface, suggesting that binding of these
compounds could drive the intracellular surface of the receptor towards a more
closed conformation which would be less receptive to G-protein binding.
EClVS82 on the other hand, decreased intrahelical distances at the extracellular
surface, suggesting that it was driving the receptor to a more closed
conformation at this surface, which could stabilize the receptor in an inactive
conformation.

202

Discussion
There is been a dearth of successful compounds which are capable of
acting as neoadjuvant chemotherapies for anti-metastasis. We have utilized
SBDD to target CXCR4 with homology modeling and virtual screening to develop
novel inhibitors of CXCR4. In this work, non-peptide CXCR4 antagonists were
structurally characterized through QSAR analysis of structural derivatives.
These compounds represent an investigation into the structural
determinants of activity and the role that the subgroups of EClVS14 play in
determining its anti-CXCR4 activity. Retesting of the original ECl VS compounds
identified EClVS 14 as a selective inhibitor of CXCR4-mediated chemotaxis and
EClVS58 as a non-selective inhibitor of CXCR4-mediated chemotaxis, neither of
which inhibited CXCR4-mediated intracellular calcium flux. This is an important
distinction to make, as there are multiple signaling pathways that could
potentially influence CXCR4-mediated chemotaxis. Cell migration due to CXCR4
activation is the result of activation of multiple signaling pathways[133-135],
including the ERK1/2, JNK, MAPK, and GSK

3a/~

phosphorylation systems,

[129] activation of phospholipase C to enhance calcium mobilization [130],
activation of the phosphoinositide-3-kinase pathway to activate AKT [130], and
activation of PKa or CREB [131, 132]. Thus anti-chemotaxis activity of EClVS 14
and EClVS58 could be due to inactivation of multiple signaling pathways outside
of calcium mobilization.
Derivatives of the parent EClVS 14 structure revealed several important
structural-activity relationships governing ECl VS 14 activity, seen in Figure 49.
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Figure 49: Structural modifications of ECLVS14 and their effects on
activity. Data from chemotaxis and cytotoxicity assays were analyzed to
correlate the chemical structure of available analogs to inhibitory activity.

204

Figure 49: Structural modifications of ECLVS14 and their effects on activity
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Analysis of the 1-[bis (phenyl methyl) amino] methyl moiety revealed that absence
of this group diminished anti-CXCR4 activity as confirmed by EVS14-20.
However, comparison between compounds EVS14-19 and EVS14-2-1 which
differed solely in the presence or absence of the 1-BPMAM moiety revealed no
significant difference in anti-CXCR4 activity.
Modifications of the hydrazine-alkyllinker moiety to ethyl, propyl, and butyl
derivatives revealed that as the hydrazine-alkyllinker is lengthened, activity
decreases, as seen with compounds EVS14-1, EVS14-2, and EVS14-3. There
was no direct comparison available between the parent compound with a
hydrazine-alkyl linker moiety and one which was altered to the shortened
acetamide moiety. However, several compounds had modified 1-BPMAM
moieties and acetamide along with comparable terminal benzene modifications.
In each case the compound with the modified 1-BPMAM moiety and acetamide
demonstrated increased anti-CXCR4 activity. And as the absence of the 1BPMAM moiety has been shown to have either a negligible or negative effect on
anti-CXCR4 activity it would stand to reason that shortening the hydrazine-alkyl
linker moiety of the parent compound to an acetamide would increase antiCXCR4 activity. The benefits of this alteration would have to be balanced by the
increased potential for cytotoxic side effects of conversion of the compound to an
acetamide.
Modification of the terminal benzene by halogenation, methylation,
nitroxylation or conversion to a cyclhexylideneamine disrupted the activity of the
parent compound, as seen in compounds EVS14-12, EVS14-13, EVS14-14,
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EVS14-15, EVS14-16, EVS14-17, and EVS14-18. However, increases in antiCXCR4 activity were seen in compounds with increasing electronegativity as well
as acetamide replacement and removal of the 1-BPMAM moiety.
It is important to note that EClVS 14 did not significantly impair intracellular
calcium mobilization. In fact, the vast majority of the EClVS14 derivatives were
incapable of inhibiting this signal transduction mechanism. The relative
insensitivity of calcium mobilization to compound EelVS 14 suggests that this
compound may allow selective inhibition of CXCR4-mediated chemotaxis without
modification of calcium signaling. EClVS14 is very unique in its inability to
modify calcium signaling, a characteristic that is not shared by any other CXCR4
inhibitors [289-291], including T140 [195] and AMD3100 [275].
Our 5 ns molecular dynamics simulations have allowed us to gain a finer
mechanistic understanding of the interaction between CXCR4 and EClVS14. We
have found that ECl VS 14 drives CXCR4 into a unique conformation. It seems to
be a more open extracellular surface than seen in the native conformation, but
less open than seen in the N119S conformation.
This work represents a significant examination of the activity and
development of an anti-CXCR4 lead compound with direct application to the
inhibition of cancer metastasis as a neoadjuvant chemotherapeutic agent.
Investigation of multiple generations of EClVS14 derivatives as well as extensive
molecular dynamics simulations have allowed us to carry forward the structure
based drug design program and gain greater insight into the function of CXCR4
and its interaction with a potent inhibitor.
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CHAPTER III
DISCOVERY OF INTRACELLULAR LOOP TARGETED COMPOUNDS BY
VIRTUAL SCREENING
Introduction
As depicted in Figure 50 , there are 5 sites where signal transduction by
CXCR4 can be disrupted . One could attempt to bind or sequester CXCL 12 to
prevent CXCR4 from interacting with its cognate ligand. One could attempt to
inhibit the interaction of CXCL 12 and the extracellular surface of the receptor by
blocking the interaction pOints between CXCL 12 and CXCR4 on the extracellular
surface of the receptor. One could attempt to stabilize the transmembrane
helices in an effort to prevent extracellular to intracellular signal transduction .
One could attempt to prevent the interaction of G-proteins with the intracellular
surface of CXCR4 by attempting to block the interaction points between CXCR4
and the G proteins. Finally, one could attempt to bind and sequester the G
protein in such a manner that it will not interact with CXCR4.
Although CXCL 12 knockdown has been demonstrated to inhibit tumor cell
proliferation and migration [292, 293], these genetic therapies are not yet
applicable to the clinical setting. In addition , in the face of rising concentrations of
CXCL 12, as would be expected in favorable microenvironments by CXCR4
expressing neoplastic cells [34-36], inhibition by binding and sequestering
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Figure 50: There are 5 potential structural targets for inhibiting CXCR4
signaling: 1) Targeting the ligand CXCL 12 to prevent ligand/receptor interaction ,
2) Targeting the Extracellular ligand binding site as in AMD3100 and T140 ,
3)Stabilizing the transmembrane helixes to prevent ligand induced conformation
changes, 4)Targeting the Intracellular region of CXCR4 at the G-Protein
interface, 5) Targeting the G-protein to prevent GPCR-G-protein interaction.
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Figure 50: There are 5 potential structural targets for inhibiting CXCR4
signaling

Target 1

210

Chalcones

CXCL 12 would become increasingly difficult. In spite of this, as series of
compounds has been designed which selectively bind CXCL 12. These
compounds, chalcones (Figure 51 ), inhibit intracellular calcium mobilization,
ligand binding and chemotaxis mediated by CXCL 12 at an IC50 of 100 nM [294].
The majority of anti-CXCR4 drug discovery efforts have been targeted at
the extracellular surface of the receptor, or Target 2 in Figure 50. CTCE-9908 is
a palindromic 17-amino acid cyclic peptide analog of CXCL 12 as depicted in
Figure 52 , which features dual 8 amino acid repeats which mimic the 8 amino
acid N-terminus of CXCL 12 [176]. Binding of CTCE-9908 is purported to mimic
the CXCL 12 binding model, primarily interacting with the N-terminal region of
CXCR4. Identified initially as anti-HIV agents, many other anti-CXCR4
compounds act at the extracellular surface of CXCR4 including AMD31 00 and
T140 which are depicted in Figure 52 . AMD3100 strongly interacts with residues
Asp171, Asp262 and Glu288, located on the extracellular side of TM4, TM6 and
TM7 [295-297]. T140 utilizes a similar binding mechanism interacting with
residues Asp171 , Arg188 , Tyr190, Gly207 and Asp262 [200]. The net effect of
these interactions is that although some of the specific residues may be different,
both AMD3100 and T140 interact at the CXCL 12 binding site, and inhibit signal
transduction, CXCL 12 -CXCR4 interactions, and stabilizing the conformation of
the native receptor or driving the confo rmation into an intermediate position
which does not effectively transmit signal [200].
Direct ta rgeting of the TM region of CXCR4 would be a difficult task.
Unlike many GPCRs, CXCR4 lacks a central channel leading to an

211

Figure 51: Chalcones inhibit CXCR4 signaling by selectively binding
CXCL 12. Chalcones are small molecules which neutralize CXCL 12. These
compounds effectively and selectively inhibit CXCL 12 mediated CXCR4
internalization, chemotaxis, and calcium mobilization in addition to
CXCR4:CXCL 12 ligand binding.
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Figure 51: Chalcones inhibit CXCR4 signaling by selectively binding
CXCL12.
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Figure 52: Anti-GPCR compounds. Two different classes of compounds are
illustrated in Figure 69. Those in Column A interact with CXCR4 at the
extracellular surface of the GPCR. Those in Column B interact with GPCRs at
the G-protein level, inhibiting Ga and Gj3V.
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Figure 52: Anti-GPCR compounds
Column A
CTCE-9908
val
/
Lys-Gly

/

Lys-NH 2
\

/
Lys-Gly

Leu

""'/"'"
""'/"'"
Ser

val

Ser

Leu

Ser

/Tyr

"'"

Arg

/Tyr
Ser

"'"

Arg

BIM-46174

AMD3100

(J

(" "')

(J

('" "')

~ 1 ~NJ-O
~ j

HS"

U~U

~

'N

~

j

NH2

Selenocytamine
~se,~NH2

T140

H2N

Se

M119K
~

o

HO
OH

215

OH

intramembranous rhodopsin-like binding pocket, rather the pocket is larger, more
open and located more superficially in the extracellular surface of the receptor
than in other GPCRs [257]. Structural studies of CXCR4 have also suggested
that movement of TM7 compared to the rhodopsin structure reduces the size of
the intramembrane region which would correspond to a retinal binding site [200].

Drug development targeting G-proteins
The intracellular surface of CXCR4 is largely undiscovered country for
drug development, in that there have been no prior attempts to inhibit CXCR4
function by targeting the intracellular surface of the receptor, and only a handful
of attempts to target G-proteins as a method for inhibiting GPCRs. G-proteins
transmit GPCR mediated signals through a series of reactions. G-proteins are
heterotrimers composed of Ga, GJ3 and Gy. Upon interaction with an activated
GPCR, GOP bound to Ga will be exchanged for GTP, facilitating a separation of
the heterotrimer into Ga and GJ3y subunits. These subunits in turn activate
downstream signaling pathways until intrinsic GTP-ases in Ga convert GTP to
GOP, facilitating the reformation of the G-protein heterotrimer.
Antagonism of the interaction between Ga and GPCRs has been
demonstrated to

modul~te

receptor function. Peptides based on the C-terminal

residues of Gai and Ga01 have been found to inhibit agonist binding and signal
transduction in A 1 adenosine receptors [298]. YM-254890 depicted in Figure 52
is a specific Gaq/11 inhibitor [299] designed to prevent acute thrombosis and
neointima formation. YM-254890 was purified from Chromobacterium sp.
OS36666 [251], and inhibits Gaq/11 function by preventing GOP/GTP exchange
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by the Ga subunit [300]. YM-254890 mediated effects on thrombosis and
response to vascular injury were compared to other antithrombotic
compounds:P2Y12 receptor antagonists ticlopidine and clopidogrel [246-251]
and was found to have greater inhibitory potency than the anti-GPCR
compounds. This makes for an interesting proof of principle in that it
demonstrates that inhibition of GPCR function can be as effective at the Gprotein level as it is at the GPCR level.
More substantial efforts have targeted

G~y

as a method of inhibiting

GPCR signal transduction. BIM-46174 (Figure 52) has been developed as an
inhibitor of the heterotrimeric G-protein complex, and effectively inhibits GPCR
signaling in these cells while inhibiting the growth and proliferation of several
cancer cell lines, although this activity also extended to non-tumor cell lines such
as HEK-293 [301]. The

G~y

subunit has been successfully targeted by virtual

screening for the development of anti-G~y compounds, which actively inhibit Gprotein mediated signaling including calcium mobilization [253]. Covalent
modification of the

G~y

subunit by selenocystamine (Figure 52) has also been

found to selectively inhibit

G~y

function [256]. Unfortunately, non-specific

modulation of G~y function would produce widespread failures in GPCR function ,
with potentially devastating outcomes in the immune compartment such as
myelosuppresion.
However, a selective

G~y

inhibitor could potentially have great therapeutic

utility. M119K, depicted in Figure 52, is one such compound which inhibits

G~y

and acts as an anti-pain medication by modulating the I..l-opiod receptor [252-
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254]. Additional use of this compound has expanded its scope to potentially
include treatment of metastatic disease. M119K was found to inhibit migration
and invasion of MDA-MB-231 and MDA-MB-436 cells, but perhaps most
importantly, M119K was found to selectively inhibit CXCR4 mediated migration
and chemotaxis by selectively inhibiting

G~y

functions, while Gai functions

remained intact [255]. This compound demonstrates that CXCR4 function can be
successfully inhibited by targeting the intracellular portion of the signaling
apparatus.
Development efforts targeting the interface between GPCRs and Gproteins has been especially sparse, with the only efforts tied to development of
small molecule inhibitors of the interaction between rhodopsin and its G-protein
transducin [302, 303]. The first of these studies utilized a reduced intracellular
loop representation of the rhodopsin crystal structure to identify a series of
compounds which inhibited transducin binding to rhodopsin [303]. In the second
study, a portion of the transducin a subunit was used as a pharmacophore model
to identify compounds which stabilized the active state of Rhodopsin [302].
Heterotrimeric G-proteins only interact with active CXCR4 in metastatic
breast cancer cell lines.
One of the origins of this work was in a finding by Dr. Kelby Napier. Dr.
Napier had generated a series of molecular dynamics structures featuring
mutants of the TM3 residue asparagine 119 (N119). This series of mutants was
based on findings by Zhang et al which found that N119 mutation to Ser (N119S)
or Ala (N119A) produced a constitutively active conformation of CXCR4, while

218

mutation to Lys (N119K) produced a constitutively inactive conformation of the
receptor [127]. One of Dr. Napier's objectives was to attempt to recreate the
interaction between CXCR4 and a heterotrimeric G-Protein, but he found that he
was unable to generate a structure with a viable interaction between the native
CXCR4 conformation and the heterotrimeric G-Proteins. While he was also
unable to produce a viable interaction structure using the N119K conformation of
CXCR4, CXCR4 did interact with the G-protein when the N119S and N119A
structures were used. This suggested that the heterotrimeric G-proteins only
interacted with activated CXCR4 conformations. This finding is supported by
clinical data. Holland et al demonstrated that although the Ga and

G~y

subunits

could interact individually with CXCR4 in both metastatic and non-metastatic
breast cancer cell lines, the heterotrimer

Ga~y

only interacted with CXCR4 in the

meta static cell lines [137]. This data in combination with the proof of principle
studies demonstrating that the

G~y

inhibitor M119 can inhibit migration and

invasion of MDA-MB-231 and MDA-MB-436 breast cancer cells [255], suggests
that inhibition of CXCR4 targeting the intracellular surface of the receptor is a
viable target to inhibit CXCR4 mediated metastasis.
Virtual screening as a method for drug discovery
Identification of new small molecule inhibitors begins with identification of
novel lead compounds. Virtual screening presents the capability to prescreen
vast databases, such as the Zinc compound library, a 13 million compound
virtual database [208], by targeting a three dimensional structure to determine
those compound which best fit, or dock, into a chosen allosteric or ligand binding

219

site. This method has proven successful in the identification of a wide variety of
targets [209-225].
This method is dependent on the development of an accurate threedimensional structure. GPCR crystal structures other than bovine rhodopsin [104]
have only recently become available so the majority of virtual screening targeting
GPCRs has been accomplished using homology modeling, in spite of the fact
that there is often low sequence similarity between rhodopsin and the target
GPCR. Although new high resolution crystal structures of the 132-adrenergic
receptor [108] and the a2A adenosine receptor [111] have been released, in
each of these structures intracellular loop 3 has been replaced with T 4 lysozyme
and the C-terminus has been truncated and replaced with a histidine purification
epitope. Thus, use of these structures would have required homology modeling
based on rhodopsin to generate structures for these two regions. Novel crystal
structures for CXCR4 were released on November 19, 2010 [257], too late to be
used in any of these studies. These structures carried the same T4 Lysozyme
and C-terminal substitutions as seen in the 132-adrenergic and a2A adenosine
receptors. Thus modeling of CXCR4 focusing on the intracellular surface of the
receptor based on these crystal structures would require extensive homology
modeling to develop a workable model. Further, such drastic modifications of
ICL3 and the C-terminus could have dramatic implications on the positioning and
structure of their attached transmembrane helixes, TM5, TM6 and TM7.
One method of performing virtual screening is Surflex-Dock [234, 244].
This docking program utilizes protomols, or pseudo-molecules, to virtually define
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binding sites targeting the protein structure. Protomol development can be based
on ligands, inhibitors or partner proteins acting at the targeted site, or residues of
the protein itself which comprise or surround an active site can be used to define
the protomol. The target protein can be screened by attempting to dock
compounds into the defined protomol site. Surflex-Dock conducts flexible docking
by fragmenting the compounds into components and docking the fragments into
the defined site, constructing the compound in the active site based on favorable
positions for each of the compound fragments. Multiple poses of each compound
are returned to the user and assigned a score based on binding affinity, degree
of inappropriate penetration into the protein, and internal structural conflicts.
In this chapter, we have used SBDD to identify inhibitors of the CXCR4 by
targeting the intracellular surface of the receptor. As illustrated in Figure 53, we
have used Surflex-Dock to virtually screen the interface between constitutively
active N119S CXCR4 and the heterotrimeric G-protein. We identified compounds
which interacted with either the CXCR4 or the Ga side of the interface, and
several of these compounds significantly inhibited chemotaxis for an
exceptionally high initial hit rate of sixty-two percent. Two of these compounds,
ICLGa28 and ICLGa36, produced IC50 values of 1 IJM. Two other compounds,
ICLGa9 and ICLGa25, specifically inhibited CXCL 12-induced calcium
mobilization with an IC50 value of 1 IJM. These compounds exhibited almost no
cytotoxicity, and several were also capable of inhibiting tumor cell proliferation.
These compounds represent the first successful attempt to target the intracellular
interface of a non-rhodopsin GPCR for drug development and drug discovery.
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Figure 53: SBOO of inhibitors of the intracellular surface of CXCR4. SurflexDock was used to virtually screen the interface between constitutively active
N119S CXCR4 and the heterotrimeric G-protein. We identified thirty-seven
compounds which displayed interacted with either the CXCR4 or the Go side of
the interface, and eleven of these compounds significantly and specifically
inhibited CXCR4 with an IC50 value of 10

~M

in either chemotaxis or calcium

mobilization. The interaction between the compounds and CXCR4 was further
rationalized by molecular dynamics.
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Figure 53: SBOO of inhibitors of the intracellular surface of CXCR4.
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Methods

Virtual Screening
The lipid-bilayer simulation of the CXCR4 N119S mutant docked with the
G-protein heterotrimer was used to identify residues on the interaction surfaces
of both proteins. The interface between two proteins occurred primarily between
CXCR4 and the Gai subunit of the heterotrimer. Specific structural considerations
came into play in designing the protomol files. CXCR4 residues within 8 A of Gai
and vice-versa were identified using a distance assessment PERL script, and
these residues (Table 13) were used to produce residue based protomol files
targeting both proteins . In addition, an a-helix of Gai came into close contact with
the intracellular surface of CXCR4. This structure was used to develop a ligandbased proto mol targeting CXCR4. A portion of the third intracellular loop of
CXCR4 composed of residues 234-239 came into close contact with the surface
of Gai. This structure was used to define a ligand-based protomol targeting Gai.
In evaluating the protomols targeting CXCR4, the ligand-based protomol
best defined the interface surface on intracellular loops 1-3 and the c-terminus
without positioning itself toward the transmembrane helices and away from Gai,
as was seen with the residue based protomol. The ligand and residue based
protomols targeting Gai both identified portions of the interaction surface with
CXCR4, but neither completely covered the interface. As there was relatively little
overlap between the protomols, they were combined into a single file and this
combined proto mol provided excellent coverage of the entire interface surface.
The virtual screen was set up using the ZINC compound library, which in 2006
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Table 13: Residues of CXCR4 and Gai used in Protomol development in
Surflex. Residues on CXCR4 within 8 A of Gai and residues on Gai within 8 Aof
CXCR4 were identified using a distance assessment PERL script to evaluate the
interaction structure of CXCR4 and Gai. These residues were used to produce
residue based protomol files targeting both proteins.

225

Table 13: Residues of CXCR4 and Gai used in Protomol development in
Surflex.

CXCR4

Gai

Residue

AA

Residue

AA

71

Ser

670

Glu

72

Met

671

lie

140

His

691

Val

141

Ala

693

Asp

143

Asn

694

Val

144

Ser

696

lie

234

Lys

697

Lys

235

Arg

698

asn

236

Lys

700

Leu

237

Ala

701

Lys

238

Leu

706

Phe

239

Lys

240

Thr

305

Leu

306

Gly

307

Ala

308

Lys

309

Phe
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comprised a data set of 2.5 million compound structures. These were individually
docked, scored and ranked by Surflex-Dock using the Dataseam GRID
distributed computing system (Dataseam [304]). The top 500 compounds were
re-run as a separate subset using higher accuracy parameters (including
randomized conformations in multiple starting positions) in Surflex-Dock.

Transfection and generation of RBL-2H3 and 300.19 stable cell lines
expressing hCXCR4 and hCXCR4-GFP
To fully evaluate the effects of the potential inhibitors we have stably
transfected overexpressing CXCR4 cell lines in collaboration with Dr. Haribabu
Bodduluri, as described in chapter 2.

Chemotaxis analysis
Chemotaxis analysis for suspension 300.19 cells expressing hCXCR4GFP or BLT1 was performed as previously described in Chapter 2 [151, 281] .

Cell signaling analysis
Cell signaling by CXCR4 was investigated by assessment of intracellular
calcium mobilization as described in Chapter 2.

Class A GPCR selectivity for non-family member BL T1
The selectivity of the compounds for CXCR4 was assessed by
investigating their effect on the Class A GPCR BLT1 as described in chapter 2.

Determination of nonspecific cytotoxicity
The potential cytotoxic effects of the compounds were investigated in our
own hCXCR4-GFP expressing 300.19 cells as described in chapter 2.

Cell proliferation MTT assay
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Anti-proliferative effects of the potential inhibitors were investigated using
tissue derived cell lines. Control non-neoplastic human skin fibroblast (HS27)
cells as well as lung (A549) and breast (MDA-MB-231 and MCF7) carcinoma cell
lines were used in a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide
(MTT) assay [305] with our protocols [306-309]. In brief, 102 cell per well were
plated in 96 well plates, allowed to grow for one day prior to the addition of small
molecules. Concentrations of the small molecules at 100IlM, 10IlM, 1IlM, and
1OOnM were screened for activity. Four days after treatment, 125 IJg MTT
(Sigma) was added to each well and incubated for 4 h at 37 C. Cells were then
lysed with 100 IJllysis buffer (20% sodium dodecyl sulfate, 50% N,Ndimethylformamide, and 0.8% acetic acid, pH 4.7) incubated for another 22 hand
finally absorbance at 490 nm was determined. Samples were run in triplicate with
untreated and DMSO-alone controls. Samples involving ICL compounds were
normalized to average absorbance of the untreated samples [310-312].
Molecular modeling of CXCR4 and ICLGa complexes
Complexes of active ICLGa compounds and CXCR4 were investigated by
molecular dynamics as described in chapter 2.
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Results
Virtual screening identifies thirty-seven commercially available compounds
targeting the CXCR4:Gai interface
Virtual screening targeting the CXCR4:Gai interaction site was conducted
utilizing structures of CXCR4 and Gai initially developed by Dr. Napier. These
structures were derived from molecular dynamics simulations of CXCR4 in a fully
solvated lipid bilayer. As constitutively active mutants of CXCR4 were the only
configurations of this receptor that were capable of interacting with the G-protein
heterotrimer and interaction between the heterotrimer and CXCR4 primarily
occurred at the Gai subunit, the dynamically-refined models of the N119S-mutant
CXCR4 and Gai were used in virtual screening to identify small molecule
antagonists targeting the CXCR4:Gai interface. Use of an active conformation of
a receptor for virtual screening has been demonstrated to be beneficial for drug
development, with active conformation of the 132-adrenergic receptor enriching
screening studies by 38% when compared to similar studies using an inactive
conformation of the receptor [313].
Surflex-Dock [234, 244] was conducted in a two stage process. First, the
ZINC compound library [208] was individually docked, scored and ranked by
Surflex-Dock using GRID (Dataseam [304]). The top 5000 compounds were rerun as a separate subset using five starting positions and ten randomized initial
compound conformations. The top 37 commercially-available compounds, (Table
14 and Figure 54) were assayed using human CXCR4 expressing cell lines. This
is the first virtual screen to target the intracellular surface of CXCR4.

229

Table 14: Virtual screening identifies thirty-seven commercially available
compounds targeting the interface of CXCR4 and Gai. In one of the first
virtual screens to target the GPCR:G-protein interface, 37 commercially available
compounds sere selected based on virtual screening scores and assessment by
"Upinski's rule of five" for drug-like characteristics.
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Table 14: Virtual screening identifies thirty-seven commercially available
compounds targeting the interface of CXCR4 and Gai.

Target
ICLGA1

CXCR4

ICLGA2

Gai

ICLGA3

CXCR4

ICLGA4

Gai

ICLGA5

Gai

ICLGA6

Gai

ICLGA7

CXCR4

ICLGA8

CXCR4

ICLGA9

CXCR4

ICLGA10

Gai

ICLGA11

Gai

ICLGA12

CXCR4

ICLGA13 CXCR4

NAME
N-(benzo[d][1,3]dioxol-5-ylmethyl)2-hydroxy-3-(4-nitrophenoxy)
propan-1-aminium
(E)-1-( naphthalen-2-yl)-5-(2(pyrrolidin-1-yl)vinyl)-1 H-tetrazole
1-(4-nitrophenyl)-2-( (5-( 4pentylphenyl)-4H-1,2,4-triazol-3yl)thio )ethanone
N-(2-( 4-ethylphenoxy)ethyl)-5-(3methylpiperazin-1-yl)-2-nitroaniline
1-(4-chlorophenoxy)-3-(2-imino-3(2-(piperidin-1-yl) ethyl) -2,3dihydro-1 H-benzo[d]imidazol-1yl)propan-2-01
N 1-(3-(dimethylamino )propyl)N3, N3-dimethyl-N1-(( 4-(prop-1-en2-yl)cyclohex-1-en-1yl)methyl)propane-1,3-diamine
4-methoxy-N-( (1-(2-( 0tolyloxy)ethyl)-1 H-benzo[d]
imidazol-2-yl)methyl)aniline
4-ethoxy-N-( (1-(2-phenoxyethyl)1H-benzo[d]imidazol-2yl)methyl)aniline
N4-(benzo[g]quinolin-4-yl)-N1-(6methoxyquinolin-8-yl)pentane-1,4diamine
N-((1-methyl-1 H-benzo[d]imidazol2-yl)methyl)-1-propyl-1 Hbenzo[d]imidazol-5-amine
1-(((4-( 4-((2,5-dioxopyrrolidin-1-yl)
(methyl)amino )benzyl)phenyl)
amino )methyl) pyrrolidine-2,5-dione
2-((3-cyano-5, 7-dimethylquinolin-2yl)amino )ethyl 2-methoxybenzoate
N-(2-((3-cyano-5,7dimethylquinolin-2yl)amino )ethyl)propionamide
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Supplier

MW

Maybridge

347.3

Maybridge

291.4

Maybridge

410.5

Chemical
Block

384.5

Chem
Bridge

429.0

Chem
Bridge

321.5

Specs

387.5

Specs

387.5

Specs

436.6

Specs

319.4

Asinex

420.5

Asinex

375.4

Asinex

296.5

Table 14, continued: Virtual screening identifies thirty-seven commercially
available compounds targeting the interface of CXCR4 and Gai.
Target

ICLGA14 CXCR4

ICLGA15 CXCR4

ICLGA16 CXCR4

ICLGA17 CXCR4

ICLGA18 CXCR4

ICLGA19 CXCR4

ICLGA20 CXCR4

ICLGA21

CXCR4

ICLGA22

Gai

ICLGA23 CXCR4

ICLGA24 CXCR4

ICLGA25 CXCR4

ICLGA26

Gai

NAME

1-(3,4,5-trimethoxybenzyl)5'H-spiro[piperidine-,4'pyrrolo[1,2-a]quinoxaline]
5-(3-( (4-ethoxyphenyl)amino )-2hydroxypropyl)
-3-methyl-1-oxo-1 ,5dihydrobenzo[4,5
]imidazo[1,2-a]pyridine-4-carbonitrile
1-(9H-carbazol-9-yl)-3-( (4ethoxyphenyl)amino )propan-2-ol
2-(3-(3-( dimethylamino )propyl)-2imino2,3-dihydro-1 H-benzo[d]imidazol-1yl)-1-phenylethanol
N-((2,3-dihydrobenzo[b][1,4]
dioxin-2-yl)methyl)-2-hydroxy-3-(4nitrophenoxy)propan-1-aminium
1-methyl-2-(piperidin-1-ylmethyl)
-N-(pyridin-2-ylmethyl)-1 H-benzo[d]
imidazol-5-amine
2-(benzo[d][1,3]dioxol-5-yl)
-9-( 4-methylbenzyl)-9H-benzo[d]
imidazo[1,2-a]imidazole
N-(1-(2,3-dihydrobenzo[b][1,4]
dioxin-2-yl)ethyl)-2-hydroxy-3-(4nitrophenoxy)propan-1-aminium
N-((1-benzyl-1 H-benzo[d]
imidazol-2-yl)methyl)-1,2-dimethyl1H-benzo[d]imidazol-5-amine
2-(([1,1'-biphenyl]-4-yloxy)methyl)
-5-( (2-morpholinoethyl)amino)
oxazole-4-carbonitrile
N-(3,4-dimethylisoxazol-5-yl)-4-((3(phenylsulfonamido )quinoxalin-2yl)amino )benzenesulfonamide
N-(3-(( 4-( dimethylamino )phenyl)
amino )quinoxalin-2-yl)4-nitrobenzenesulfonamide
1-( 1-(4-fluorophenyl)-2,5-dimethyl
-1 H-pyrrol-3-yl)-2-(furan-2yl( methyl)amino )ethanone
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Supplier

MW

Asinex

419.5

Asinex

416.5

Asinex

360.5

Asinex

338.5

Asinex

361.4

ChemDiv

335.5

IBScreen

381.4

IBScreen

375.4

IBScreen

381.5

IBScreen

404.5

Enamine

550.6

Enamine

464.5

Enamine

326.4

Table 14, continued: Virtual screening identifies thirty-seven commercially
'1 bl e compoun d s targe f mg th'
t rface 0 f CXCR4 an d Gal..
eme
avala
Target

ICLGA27

CXCR4

ICLGA28

CXCR4

ICLGA29

CXCR4

ICLGA30

CXCR4

ICLGA31

CXCR4

ICLGA32

CXCR4

ICLGA33

CXCR4

ICLGA34

CXCR4

ICLGA35

CXCR4

ICLGA36

CXCR4

ICLGA37

Gai

NAME
ethyl 2-(2-(benzo[d]thiazol-2-ylthio)
-2-phenylacetamido )-6-methyl4,5,6,7-tetrahydrobenzo[b]
thiophene-3-carboxylate
(E)-4-( ((2-(3,4-d imethylphenyl)
-1,3-dioxo-2,3-dihydroisoquinolin4( 1H)-ylidene )methyl)amino )-N-( 4hydroxyphenyl)benzenesulfonamide
2-(1-(1,5-dimethyl-3-oxo-2-phenyl2,3-dihydro-1 H-pyrazol-4-yl)
-2,5-dimethyl-1 H-pyrrol-3-yl)-2oxoethyl 2-(3,5-dimethyl-4-nitro
-1 H-pyrazol-1-yl)acetate
1-(3-(3-( (3,4dimethoxyphenethyl)amino)
-2-hydroxypropoxy)
phenyl)ethanone
N-(3,4-dimethylphenyl)-2((5-((4-methoxyphenyl)amino)1 ,3,4-thiadiazol-2-yl)thio )acetamide
2-( 4-( ethoxycarbonyl)-3,5dimethyl-1 H-pyrrol-2-yl)-2-oxoethyl
5-methyl-3-phenylisoxazole
-4-carboxylate
2-(2-chlorophenyl)-N'-( 4methylcyclohex-1-en-1-yl)
quinoline-4-carbohydrazide
1-(naphthalen-1-ylamino )-1oxopropan-2-yl 2-(3,5-dimethyl-4nitro-1 H-pyrazol-1-yl)acetate
1-(4-( methoxycarbonyl)phenyl)
-2-( methylamino )-2-oxoethyl
5-methyl-3-phenylisoxazole-4carboxylate
N-(3-( (9-ethyl-9H-carbazol-3yl)amino )quinoxalin-2-yl)-4methylbenzenesulfonamide
2-( (3,4-dimethylphenyl)amino)
-N-( 5-( 3-( trifluo romethyl )benzyl)
thiazol-2-yl)acetamide
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Supplier

MW

Enamine

522.7

Enamine

539.6

Enamine

520.54

Enamine

373.44

EnamineREAL

400.52

EnamineREAL

410.42

Enamine

391.89

EnamineREAL

396.4

Enamine

408.4

Otava

507.61

Otava

419.46

Figure 54: ICLGA Compounds. Structures of thirty-seven compounds identified
in virtual screens targeting the interface between the intracellular surface of
CXCR4 and Gai are illustrated below.
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Figure 54: ICLGA Compounds
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Compounds targeting the CXCR4:Gai interface specifically inhibit
chemotaxis
Our goal was to target the CXCR4:G-protein interface to discover novel small
molecules which could selectively inhibit receptor function and be used as
scaffolds for development of clinically active anti-metastatic com pounds. We
sought to evaluate the compounds by chemotaxis assays which quantitatively
examined the capability of cells to migrate towards a ligand grad ient. Initial
screening of the thirty-seven ICL compounds at 50 IJM identified twenty-four
compounds which significantly inhibited chemotaxis as depicted in Figure 55 .
Dose response analysis was used to determine the concentration of the active
compounds where chemotaxis was inhibited by 50% in reference to the CXCL 12
alone control (IC50). Ten of the twenty-four active compounds had chemotaxis
IC50 values of 10 IJM or less (Figure 56), for an exceptionally high initial hit rate
of 27%. Compounds ICLGa28 and ICLGa36 were two of the most promising
compounds identified , with effective inhibition of chemotaxis at 1 IJM. Other
notable compounds included ICLGa 8 with effective inhibition at 3 IJM and ICLGa
compounds 5, and 37 with effective inhibition at 5 IJM .
It is important to note that the hit rate of our virtual screening studies is
significantly higher than what is seen in similar published studies. Our initial hit
rate of 64.9% at 50 IlM fo r the initial screening of our thirty seven ICL compounds
represents a great increase over contemporary studies. For comparison , recent
investigations using virtual screening of glycogen synthase kinase-313 (GSK-313)
had an initial hit rate of 12.5% for 162 compounds [314]. A recent investigation of
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Figure 55: ICLGa compounds inhibit CXCR4 mediated Chemotaxis.
Chemotaxis assays performed with ICLGa compounds at a concentration of 50
IJM. Vertical axis is presented in terms of chemotaxis index wherein sample
chemotaxis is normalized to chemotaxis of the CXCL 12 alone control. Successful
inhibition of chemotaxis reduced chemotaxis of samples compared to CXCL 12
alone. 24 of 37 tested compounds significantly inhibited chemotaxis at the initial
screening concentration of 50 IJM.
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Figure 55: Inhibitors of CXCR4 Mediated Chemotaxis
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Figure 56: IC50 of ICLGa compound mediated chemotaxis inhibition.
Concentrations which inhibited 50% of chemotaxis in relation to CXCL 12 alone
signaling (IC50) were determined for active ICLGa compounds. Vertical axis is
presented in terms of IC50 of chemotaxis in I-lM. 10 of the 26 active compounds
exhibited significant inhibition of chemotaxis at 10 I-lM or less.
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Figure 56: IC50 of Inhibitors of CXCR4 Mediated Chemotaxis
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using virtual screening of a large compound library had an initial hit

rate of 14% for 50 compounds, with IC50 values ranging from 30 to 200 J.!M
[315]. Another study targeting bacterial NAD synthetase had an initial hit rate of
20% at 300 J.!M, but only 2 of the 40 (5%) active compounds had IC50s less than
50 J.!M [316].
We then sought to determine the specificity of the ICLGa compounds for
CXCL 12-induced chemotaxis. Chemotaxis assays were carried out using 300.19
cells expressing the class A GPCR BLT1 mediating chemotaxis in response to
LTB4. Initial screening of the twenty-four active ICLGa compounds revealed that
fifteen of the compounds also inhibited LTB4-mediated chemotaxis at 50 J.!M.
However, as can be seen in Figure 57, dose response analysis of the ICLGa
compounds with anti-BL T1 activity revealed that only four of the compounds
(ICLGa6 , ICLGa12, ICLGa14 and ICLGa16) had IC50 values that were lower for
BLT1 than for CXCR4. There was an average difference of 18.5 IJM in the IC50
values of the compounds in reference to CXCR4 versus BLT1. It is important to
note that of the ten ICLGa compounds which inhibited CXCR4-mediated
chemotaxis at 10 IJM or less, only five exhibited any anti-BLT1 activity, and none
of these possessed an anti-BLT1 IC50 of less than 25 IJM. This suggests that the
inhibitory effects produced by these compounds are specific for CXCR4.

Division of ICLGa compounds into calcium and non-calcium inhibitors of
CXCR4
Intracellular calcium mobilization is a common method for assessing
GPCR receptor activation and signaling. CXCL 12-induced calcium mobilization is
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Figure 57: ICLGa compounds selectively inhibit CXCR4 Mediated
Chemotaxis. Specificity screening of active ICLGa compounds in BL T1
expressing cells revealed that 15 compounds inhibited chemotaxis in both
systems. Only 3 of the 15 compounds with BLT1 activity inhibited BLT1
chemotaxis to a greater degree than CXCR4 mediated chemotaxis. Only 5 of the
ICLGa compo unds with anti-CXCR4 activity at 10 !-1M or less exhibited anti-BLT1
activity, and none had anti-BLT1 IC50 values of less than 25 !-1M .
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Figure 57: Selective IC50 of Inhibitors of CXCR4 Med iated Chemotaxis
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a pertussis toxin sensitive [317] process, suggesting that this process is
dependent on Ga signaling. Thus, we investigated the impact of ICLGa
compounds on CXCL 12-induced calcium mobilization. CXCL 12-induced
signaling was assessed by the change in amplitude of the calcium signal and
results were normalized to the CXCL 12-alone control. Initial screening of the
ICLGa targeted compounds at 50 !-1M identified twelve compounds which
significantly reduced calcium release , seen in Figure 58 . Dose response analysis
determined that six of the twelve active compounds, ICL9 (1 !-1M) , ICL 12 (5 !-1M) ,
ICL 13 (5 !-1M) , ICLGA25 (1 !-1M) , ICL28 (10 !-1M) and ICL36 (6 !-1M) had calcium
mobilization IC50 values of 10 !-1M or less as seen in Figure 59.
We then sought to determine the specificity of the ICLGa compounds for
CXCL 12-induced intracellular calcium mobilization . Calcium mobilization assays
were carried out using 300.19 cells expressing BL T1 and signaling was assessed
in response to LTB4. Initial screening of the twelve active ICLGa compounds
revealed that nine of the twelve significantly inhibited LTB4-induced intracellular
calcium mobilization . Subsequent dose response analysis, depicted in Figure 60 ,
revealed that six of the nine ICLGa compounds with anti-BLT 1 activity had IC50
values that were lower for BLT1 than for CXCR4. Differences in calcium
mobilization were relatively small for ICLGa2 (45 !-1M vs. 40 !-1M) , ICLGa4 (35 !-1M
vs . 27 .5 !-1M) , ICLGa12 (5 !-1M vs. 2.5 !-1M) , ICLGa13 (5 !-1M vs. 2.5 !-1M) , and
ICLGa16 (35 !-1M vs. 30 !-1M) , suggesting that inhibition of calcium signaling by
these five compounds is not selective. In contrast the IC50 of calcium
mobilization was significantly greater for CXCR4 than BLT1 for IC LGa9 (1 !-1M vs.
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Figure 58: ICLGa compounds inhibit CXCR4 mediated Intracellular Calcium
Mobilization. Calcium Mobilization assays performed with ICLGa compounds at
a concentration of 50 !-1M. Vertical axis is presented in terms of normalized
calcium signal, wherein the amplitude of the calcium response to the CXCL 12alone control corresponds to 1. Decreased signal amplitude correlates with
inhibition of ca lcium mobilization. Eleven of thirty seven tested ICLGa
compounds significantly inhibited calcium mobilization.
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Figure 58: ICLGa compounds inhibit CXCR4 mediated Intracellular Calcium
Mobilization.
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Figure 59: IC50 of ICLGa compound mediated inhibition of calcium
mobilization. Concentrations which inhibited 50% of calcium mobilization in
relation to CXCL 12 alone signaling (IC50) were determined for active ICLGa
compounds. Vertical axis is presented in terms of IC50 of calcium mobilization in
IJM. Six of the twelve active compounds exhibited significant inhibition of calcium
mobilization at 10 IJM or less.
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Figure 59: IC50 of ICLGa compound mediated inhibition of calcium
mobilization.
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Figure 60: ICLGa compounds selectively inhibit CXCR4 Mediated Calcium
Mobilization. The twelve ICLGa compounds which inhibited CXCL 12-induced
calcium mobilization were tested for specificity in BLT1 expressing cells,
revealing that nine compounds inhibited calcium mobilization is in both systems
at a 50 IJM screening concentration . Five of the nine compounds produced BLT1
mediated calcium mobilization equivalent to CXCR4 mediated ca lcium
mobilization. Three of the compounds were selective for CXCR4 mediated
calcium mobilization with IC50 values less that 10 IJM.
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Figure 60: ICLGa compounds selective ly inhibit CXCR4 Mediated Calcium
Mobilization.
50 . - - - - - - - - - - - - - - - - - -

45

-

:i:

40

-o

~

.

c::: 35

«I

.~ 30

.c
o
:i:

E

25

:::::J

U
«I

20

o
an

15

o
o

10
5

0

!;l

0

0'

"

0

0'

"

it

0

~
0t'f1

~

0'

"

0'

"

- CXCR4

~
0t'f1

0'

"

254

/:?

0t'f1

0'

"

~

~
0t'f1

0'

"
- BLT1

~

0t'f1

0'

"

0

0'

"

rti

20 IJM), ICLGa25 (1 IJM vs. 40 IJM), and ICLGa28 (10 IJM vs. 22 .5 IJM)
suggesting that anti-calcium mobilization activity in these compounds is selective
for CXCR4.
The thirteen ICLGa anti-CXCR4 compounds with activity at 10 IJM or less
are depicted in Table 15. Seven compounds exhibit CXCR4-specific and
exclusive anti-chemotaxis activity. Three compounds exhibit CXCR4-specific
anti-chemotaxis and anti-calcium mobilization activity. Two compounds exhibit
non-specific exclusive anti-calcium mobilization activity. The remaining
compound exhibits CXCR4-specific and exclusive anti-calcium mobilization
activity. Given that CXCL 12-induced calcium modulation is dependent on Ga
signaling, one would expect that compounds targeting Gai would preferentially
inhibit intracellular calcium mobilization ; however that was not the case for our
compounds. Of the nine compounds targeting the Gai side of the interface, only
three of these (ICLGa2, ICLGa4, and ICLGa5) significantly inhibited calcium
mobilization, and the IC50 values of these compounds were much greater than
for many of the CXCR4 targeted compounds which inhibited this signaling. One
explanation for this discrepancy lies in the signaling pathway. CXCL 12-induced
calcium mobilization is a pertussis toxin sensitive process [317], but also requires
activation of phospholipase

C~

[318]. Gai, the Ga subunit which interacts with

CXCR4, is incapable of activating phospholipase
which activates phospholipase
320]. The

G~y

C~,

C~ ,

and the only Ga subunit

Gaq , is insensitive to pertussis toxin [319,

subunit is also capable of activating phospholipase

C~

[321].

Thus, CXCL 12-induced calcium mobilization could be dependent on interactions
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Table 15: Classification of compounds with anti-CXCR4 activity at 10 IJM or
less. ICLGa compounds with anti-CXCR4 activity with IC5a values of less than
1a IJM in either chemotaxis or calcium mobilization are listed in the table below.
Three of the compounds ICLGa25, ICLGa28 and ICLGa36 produced inhibition of
CXCR4 below 1a IJM for both activities.
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Table 15: Classification of compounds with anti-CXCR4 activity at 10 IJM or
less.

Compound

Chemotaxis
IC50 (IJM)

Calcium IC50
(IJM)

Activity

Target

ICLGa4

10

35

Chemotaxis

Gai

ICLGa5

5

45

Chemotaxis

Gai

ICLGa8

3

--

Chemotaxis

CXCR4

ICLGa9

45

1

Calcium

CXCR4

ICLGa12

12.5

5

Calcium

CXCR4

ICLGa13

12.5

5

Calcium

CXCR4

ICLGa17

10

--

Chemotaxis

CXCR4

ICLGa22

10

--

Chemotaxis

Gai

ICLGa25

10

1

Dual

CXCR4

ICLGa28

1

10

Dual

CXCR4

ICLGa29

10

--

Chemotaxis

CXCR4

ICLGa36

1

6

Dual

CXCR4

ICLGa37

5

--

Chemotaxis

Gai
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between Gai and either Gaq or G~V. In the case of the ICLGa compounds, some
compounds could interfere with the interaction between CXCR4 and Gai,
completely preventing signal transmission through the receptor inhibiting both
chemotaxis and calcium mobilization as is the case with ICLGa25, ICLGa28 and
ICLGa36.

Compounds targeting the CXCR4:Gai interface have relatively little nonspecific cytotoxicity, but three active ICLGa compounds selectively inhibit
tumor cell proliferation.
Inhibition of chemotaxis and calcium mobilization by ICLGa compounds
could be due to nonspecific toxic side effects, the active ICLGa compounds were
screened for cytotoxicity. Mimicking the conditions in the chemotaxis assay,
300.19 cells were cultured in the presence of ICLGa compounds at the initial
screening concentration of 50 IJM and cytotoxicity was assessed using propidium
iodide (PI) based flow cytometry. PI is unable to penetrate the cell membrane in
viable cells, so cells staining positive for PI do not have intact membranes.
Cytotoxicity values are presented as percentage of cells staining positive for PI in
Figure 61. Of the twenty-six ICLGa compounds producing significant inhibition of
chemotaxis and calcium mobilization, only seven produced displayed elevated
cytotoxicity when compared to untreated cells or cells treated with DMSO only
control. To further investigate the cytotoxicity of these compounds, dose
response assays were conducted at concentrations of 10, 5, and 1

~M,

seen in

Figure 62. Compounds ICLGa9, ICLGa25, and ICLGa36 displayed no
cytotoxicity beyond the initial 50

~M

screening concentration. Compounds
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Figure 61: ICLGa compounds produce relatively little non-specific
cytotoxicity. Vertical axis is expressed in terms of cells staining positive for PI,
a marker for membrane disruption and non-viable cells. Only seven of the
twenty-six ICLGa compounds with anti-CXCR4 activity compounds exhibited
significant cytotoxicity. Only five of the compounds produced greater than 50%
cytotoxicity at 50 IJM. Two additional compounds, ICLGa25 and ICLGa36,
displayed elevated cytotoxicity compared to untreated and DMSO-alone controls,
but to a lesser extent than 50% cytotoxicity.
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Figure 61: ICLGa compounds produce relatively little non-specific
cytotoxicity
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Figure 62: Toxic concentrations of ICLGa compounds. Only one of the 7

ICLGa compounds exhibiting cytotoxicity at 50

~M

exhibited cytotoxicity at 5

~M

or less. The three compounds with significant anti-CXCR4 activity below 1a ~M
exhibited no toxic effects below 50

~M.
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Figure 62: Toxic concentrations of ICLGa compounds.
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ICLGa2, ICLGa7 and ICLGa16 all retained significant cytotoxicity at 10 )lM. Only
compound ICLGa4 maintained significant cytotoxicity at 5 )lM. There were no
structural similarities between the compounds with cytotoxicity beyond 10 )lM.
ICLGa9, ICLGa25 and ICLGa36 all selectively inhibited CXCR4 activity at
1 )lM in either chemotaxis or calcium mobilization. All three of these compounds
also displayed significant cytotoxicity at 50 )lM, but no cytotoxic effects at lower
concentrations. As BIM-46174 had been demonstrated to inhibit tumor
proliferation and induce apoptosis [301] we sought to investigate the impact of
ICLGa on tumor cell proliferation. To determine the potential for the ICLGa
compounds to impact the proliferation of tumor cells, we assessed cell growth
capacity using the 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT) assay. We investigated the effect of these compounds on four cell lines:
HS27, a "normal" fibroblast cell line; MCF7, an estrogen-dependant nonmetastatic breast cancer cell line; MDA-MB-231, an estrogen-independent
metastatic breast cancer cell line; and A549, a lung cancer cell line. Cells were
left untreated, treated with 12.5 mM DMSO, or treated with varying
concentrations of three ICLGa compounds, ICLGa9, ICLGa25 and ICLGa36,
then incubated for four days before analysis. In our analysis, the absorbance
values were normalized to untreated samples.
The three ICLGa compounds showed particularly interesting effects on
cell proliferation. In the normal cell line HS27 cells as depicted in Figure 63a,
both ICLGa25 and ICLGa36 displayed marginal proliferation inhibition at higher
concentrations, but these effects abated as concentration dropped below 20 !-1M.
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Figure 63: Inhibition of cell proliferation by ICLGa compounds. Cell
proliferation was assessed by MTT assay. Vertical axis represents MTT signal
detected in each sample normalized to the untreated control. Horizontal axis
represents concentration of ICLGa sample.
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Figure 63: Inhibition of cell proliferation by ICLGa compounds.
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ICLGa9 consistently inhibited cell proliferation even at concentrations nearing 1
!-1M. (Fig . 1119)

In MCF7 cells as depicted in Figure 63b, ICLGa9 inhibited cell proliferation
with an ICSO va lue of S !-1M. ICLGa36 also significantly inhibited cell proliferation
with an ICSO va lue of 12.S !-1M . ICLGa2S only marginally inhibited cell
proliferation of MCF7 cells at high concentrations.

In MDA-MB-231 cells as depicted in Figure 63c, ICLGa9 inhibited cell
proliferation with an ICSO value of S !-1M. ICLGa2S significantly inhibited
proliferation of MDA-MB-231 cells; with an ICSO value of 10 !-1M. ICLGa36
significantly inhibited cell proliferation of MDA-MB-231 cells, with an ICSO value
of 30 !-1M.
Finally, in AS49 cells as depicted in Figure 63d , ICLGa9 inhibited cell
proliferation with an ICSO value of 7.S !-1M. ICLGa2S significantly inhibited cell
proliferation of AS49 cells, with an ICSO value of 10 !-1M. ICLGa36 significantly
inhibited cell proliferation of AS49 cells, with an ICSO value of 22.S !-1M.
The three compounds illustrate three avenues of proliferation inhibition.
ICLGa9 is generally inhibitory, affecting both normal and cancer cells at levels
lower than the cytotoxicity levels seen in Figure 62. ICL2S inhibited the growth of
metastatic cancer cell lines AS49 and MDA-MB-231, but not HS27 cells or nonmetastatic MCF7 cells. Finally, ICL36 inhibited the growth of non-metastatic
MCF7 cells, metastatic cancer cell lines to a lesser extent, and did not inhibit
proliferation of HS27 cells. These results are intriguing as a CXCR4 inhibitor
need not be cytotoxic to function as a metastasis inhibitor.
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Analysis of anti-CXCR4 compound mechanism through molecular
dynamics simulations
As demonstrated by Holland et aI, heterotrimeric G-protein interaction with
CXCR4 occurs in metastatic breast cancer cell lines but not non-metastatic lines
[137]. We have postulated that this behavior is due to differential activation of
CXCR4 in the metastatic cell lines producing altered CXCR4 conformation, a
hypothesis that is supported by the find ings of Dr. Napier that in silico the
constitutively active N 1198 conformation of CXCR4 is capable of interacting with
the G-protein heterotrimer while the native protein conformation is not.
The initial native CXCR4 and N1198 mutant structures were developed by
Dr. Kelby Napier via homology modeling utilizing the high resolution rhodopsin
crystal structure [288]. When this work was conducted, the x-ray crystal structure
for CXCR4 had not yet been released, so th is structure was not a viable option
for these studies.
Molecular modeling of CXCR4 and ICLGa complexes
We hypothesize that the binding of ICLGa complexes with anti-CXCR4
activity induces a conformational change in the receptor, impeding signaling.
Complexes of active ICLGa compounds and CXCR4 were investigated by
molecular dynamics. The highest scoring conformations of the ICLGa
compounds were utilized as a guide to initial placement of the inhibitor. 8urflexDock [234, 244] was used to dock 12 ICLGa compounds with anti-CXCR4
activity at 10 IJM or less and without excessive cytotoxicity into the defined
intracellular surface of the native structure of CXCR4. All twelve compounds
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were successfully docked into the structure regardless of their initial status as
CXCR4-targeted or Gai targeted compounds. Fully solvated lipid bilayer
molecular dynamics simulations of native CXCR4 bound with active ICLGa
compounds were performed using the AMBER suite of programs using the
parm99 force field [284].
Some ICLGa compounds do not bind to the Native conformation of CXCR4
in molecular dynamics simulations.
The final averaged structures of native CXCR4 in complex with each of
the anti-CXCR4 compounds from the 5 ns molecular dynamics simulation are
shown in Figures 64. Of the twelve docked compounds, stable CXCR4:
compound complexes were generated fo r compounds ICLGa8, ICLGa12,
ICLGa25, ICLGa28, ICLGa29 and ICLGa37. ICLGa5, ICLGa9, ICLGa13,
ICLGa17, ICLGa22, and ICLGa36 did not form stable complexes with the native
conformation of CXCR4.
Inverse agonist, antagonist and weak partial agonist inhibitors all
potentially can bind to different structures of CXCR4. Weak partial agonists
should prefer to interact with inactive conformations of the receptor, where their
partial agonistic activity is more capable of inducing a partially active
conformation . Conversely, inverse agonists interact with constitutively active
receptors and receptors with basal activity suggesting that these inhibitors should
preferentially interact with an inactive conformation of the receptor, in order to
shift the conformation to an inactive state. The fact that these 6 active ICLGa
compounds do not bind to the native conformation of the receptor suggests that
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Figure 64: Final averaged structure of Native CXCR4 dynamically bound to
ICLGa Compounds. Average structure of CXCR4 presented in ribbon. ICLGa
compounds are in their dynamically determined binding position in red .
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Figure 64: Final averaged structure of Native CXCR4 dynamically bound to
ICLGa Compounds.
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these active anti-CXCR4 compounds may act as inverse agonists, and may be
unable to interact with the inactive conformation of the receptor.
The ICLGa compounds which did form stable complexes with native
CXCR4 were energetically stable throughout the production run as can be seen
in Figures 65 . Conformational stability of the bound CXCR4-compound
complexes was investigated using RMSD analysis, seen in Figures 66 . RMSD
values remained stable for the majority of the production runs, with the final
average structure representative of the trajectory after approximately 1.5 ns. The
helices were stable through the production run and the majority of the variation
was seen in the loops. The conformation assumed by ICLGa29 was the closest
to that of uncomplexed native CXCR4. The RMSD of the ICLGa29 complex was
3.1, compared to RMSD values of 3.2 for ICLGa28, 3.3 for ICLGa8, 3.4 for
ICLGa37, 4.0 for ICLGa25 and 4.5 for ICLGa12.
The dynamic binding site of ICLGa8, shown in Figure 67 , consists of ICL 1
superior to the compound , ICL2 to the right, and the C-terminal tail to the left and
posterior to the compound . The ethoxybenzene component of ICLGa8 is
stabilized by hydrophobic interactions with the aliphatic portions of the Lys149
and Ser71 side chains. The central imidazole component is stabilized by
interactions with the Lys 68 side cha in, as well as the backbones of Thr342 and
Glu343. The anisole group is interposed between folds of the C-terminal tail,
interacting with a hydrophobic network composed of the side chain of Va1340, the
backbone of Ser338, and the aliphatic portion of the side chains of Glu345, Ser
346 and Ser348.
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Figure 65: Energy plot of ICLGa compounds bound to native CXCR4.
Energy values across the trajectory fo r total energy (blue), kinetic energy (red)
and potential energy (green) are presented. CXCR4 was found to be
energetically stable and maintained equilibrium across the production run . A)
ICLGa8, 8) ICLGa12, C) ICLGa25 D) ICLGa28 E) ICLGa29 F) ICLGa37
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Figure 65: Energy plot of ICLGa compounds bound to native CXCR4. A)
ICLGa8, B) ICLGa12, C) ICLGa25 D) ICLGa28 E) ICLGa29 F) ICLGa37
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Figure 66: RMSD values of CXCR4 bound to ICLGa Compounds across 5 ns
of the production trajectory. Total RMSD calculated at the Co position
presented in green. Helical domains are presented in blue, and loop regions are
presented in red. The CXCR4 structure was noted to be stable, and the average
structure was noted to represent the conformation present in the trajectory after
0.5 ns of simulation time. A) ICLGa8, 8) ICLGa12, C) ICLGa25 D) ICLGa28 E)
ICLGa29 F) ICLGa37
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Figure 66: RMSD values of CXCR4 bound to ICLGa Compounds across 5 ns
of the production trajectory. A) ICLGa8, B) ICLGa12, C) ICLGa25 D)
ICLGa28 E) ICLGa29 F) ICLGa37
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Figure 67: Dynamic binding site of ICLGa8 to native CXCR4. Critical residues
for ICLGa8 binding to CXCR4 are highlighted. ICLGa is depicted in red ball-stick
representation, while CXCR4 residues withi n 3 angstroms of the compound are
presented in stick representation and superstructure of CXCR4 is presented as
teal ribbon. ICLGa8 interacts with the ICL 1, ICL2, and C-terminal regions of the
intracellular surface.
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The dynamic binding site of ICLGa12, shown in Figure 68 consists of ICL 1
superior to the compound, ICL2 to the rig ht, and the C-terminal tail to the left and
posterior to the compound. The anisole and quinolone components of ICLGa12
are oriented in a planar conformation. The quinolone portion lies between folds of
the C-terminal tail and ICL 1, in a conformation stabilized by interactions with the
aliphatic portion of the Lys68 and thr342 side chains and the backbone of Ser344
above and the backbones of Ser 348,351 and 352 below. The aromatic region of
the anisole component is stabilized by interactions with the aliphatic portion of
the Lys149 side chain and Pro147.
The dynamic binding site of ICLGa25, shown in Figure 69 consists of ICL 1
superior to the compound, ICL2 to the right, and the C-terminal tail to the left and
posterior to the compound. The nitrobenzene and dimethylaniline components of
ICLGa25 are in a stacked conformation. The nitrobenzene component is
stabilized by hydrogen bonding to the side chain of Arg334 which is further
stabilized by intramolecular hydrogen bonding between Arg334 and Glu345. The
dimethylaniline is further stabilized by hydrophobic interaction with Phe349. The
central quinoxaline component of ICLGa25 is projected between ICL 1 and ICL3
and is stabilized by hydrogen bonding to Lys68, as well as a hydrophobic
network composed of the backbone of Ser 71, the side chain of Leu150, and the
aliphatic portion of the Lys149 side cha in.
The dynamic binding site of ICLGa28, shown in Figure 70 consists of ICL 1
superior to the compound, ICL2 to the right, the C-terminus anterior to the
compound , the ICL3 posterior to the compound. The phenol group of ICLGa28 is
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Figure 68: Dynamic binding site of ICLGa12 to native CXCR4. Critical
residues for ICLGa12 binding to CXCR4 are highlighted . ICLGa12 is depicted in
red ball-stick representation , while CXCR4 residues within 3 angstroms of the
compound are presented in stick representation and superstructure of CXCR4 is
presented as magenta ribbon. ICLGa12 interacts with the ICL 1, ICL2, and Cterminal regions of the intracellular surface .
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Figure 68: Dynamic binding site of ICLGa12 to native CXCR4
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Figure 69: Dynamic binding site of ICLGa25 to native CXCR4. Critical
residues for ICLGa25 binding to CXCR4 are highlighted . ICLGa25 is depicted in
red ball-stick representation, while CXCR4 residues within 3 angstroms of the
compound are presented in stick representation and superstructure of CXCR4 is
presented as orange ribbon. ICLGa25 interacts with the ICL 1, ICL2, and Cterminal regions of the intracellular surface.
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Figure 69: Dynamic binding site of ICLGa25 to native CXCR4.
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Figure 70: Dynamic binding site of ICLGa28 to native CXCR4. Critical
residues for ICLGa28 binding to CXCR4 are highlighted. ICLGa28 is depicted in
red ball-stick representation, while CXCR4 residues within 3 angstroms of the
compound are presented in stick representation and superstructure of CXCR4 is
presented as white ribbon. ICLGa28 interacts with the ICL 1, ICL2, ICL3 and Cterminal regions of the intracellular surface.
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Figure 70: Dynamic binding site of ICLGa28 to native CXCR4.
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interposed between the C-terminus and ICL3 stabilized by interactions with
Lys236 of ICL3, and Lys308 and His337 of the C-terminus. The isoquinolone
structure extends towards ICL 1, and is stabilized by a hydrophobic network
composed of the aliphatic portions of the Lys68 and Ser71 side chains, as well
as the backbone of Arg70 and the side chain of Leu150. The dimethyl benzene
component is stabilized by a separate hydrophobic network composed of the
aliphatic portion of the Lys149 side chain , Pro147 and the backbone of Arg148.
The dynamic binding site of ICLGa29, shown in Figure 71 consists of ICL 1
superior to the compound , ICL2 to the right, and the C-terminal tail to the left and
posterior to the compound. The orientation of the compound in the binding site is
unique among the ICLGa compounds in that the compound is oriented vertically
in the binding site whereas the other compounds were oriented horizontally in the
site. The compound is stabilized by hydrogen bonding between linker chain
carboxyl groups and the side chain amines of Lys68 and Lys149. The 2,4
dimethyl-3-nitro-pyrazole projects towards ICL 1, and is stabilized by a
hydrophobic network composed of the aliphatic portion of the Lys68 , Lys149 side
chains as well as the backbone of Arg70 , Ser71 and the side chain of Leu150.
The dynamic binding site of ICLGa37, shown in Figure 72 consists of ICL 1
superior to the compound, and ICL2 and the C-terminus posterior to the
compound. The 3,4 dimethyl-benzene group is stabilized by hydrophobic
interactions with the aliphatic portions of the side chains of CXCR4 residues Lys
68 , Ser71 , Leu150 and Ser348 . The benzyl portion of the meta-trifluoromethyl
benzene component of the compound is stabilized by hydrophobic interactions
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Figure 71: Dynamic binding site of ICLGa29 to native CXCR4. Critical
residues for ICLGa29 binding to CXCR4 are highlighted. ICLGa29 is depicted in
red ball-stick representation , while CXCR4 residues within 3 angstroms of the
compound are presented in stick representation and superstructure of CXCR4 is
presented as yellow ribbon. ICLGa29 interacts with the ICL 1, ICL2 and Cterminal regions of the intracellular surface.
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Figure 71: Dynamic binding site of ICLGa29 to native CXCR4.
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Figure 72: Dynamic binding site of ICLGa37 to native CXCR4. Critical
residues for ICLGa37 binding to CXCR4 are highlighted. ICLGa37 is depicted in
red ball-stick representation , while CXCR4 residues within 3 angstroms of the
compound are presented in stick representation and superstructure of CXCR4 is
presented as blue ribbon . ICLGa37 interacts with the ICL 1, ICL2 and C-terminal
regions of the intracellular surface.
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Figure 72: Dynamic binding site of ICLGa37 to native CXCR4.
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with the aliphatic portion of the side chain of Lys149 and Leu150. In the center of
the compound, hydrogen bonds form between Lys149 and the thiazole of the
compound.
These structures shed light on the potential mechanism of the activity of
the bound ICLGa compounds. All of the compounds interacted with the aliphatic
components of the side chains and backbones of ICL 1 and ICL2, suggesting that
the compounds could act as bridging elements between these two regions,
stabilizing their position and preventing signal transduction or producing a more
closed intracellular surface potentially incapable of binding Gai. Interaction by the
compounds with the C-terminal region could potentially stabilize TM?, or interfere
with the interface between the C-terminus and Gai. This could be especially true
in the case of ICLGa28, where interposition of the compound between the Cterminus and ICL3 could restrict the movement of both regions and directly
impede the cleft which would be occupied by bound Gai.

ICLGa compound binding alters the conformation of the extracellular and
intracellular surfaces of CXCR4.
Given the interactions of the ICLGa compounds with the intracellular
surface of CXCR4, we sought to investigate what effect inhibitor binding could
have on overall receptor conformation. To do this, we sought to compare the
structure of the ICLGa complexed conformations of CXCR4 to the inactive native
conformation and the constitutively active N119S conformations of the protein.
The extracellular surface of CXCR4 is highly conserved between ICLGa8 and
native CXCR4. Although the structure of the loops is conserved between the
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three conformations, there are several differences in positioning. In the Nterminal region, the anti-parallel

~-sheet

is more compact and the distance

between ECL 1 and the N-terminal region is decreased, mimicking the N119S
conformation, while the entire region is displaced away from the extracellular
surface of the TM regions. ECL2 retains the native conformation and positioning,
while ECL3 is outwardly displaced from the center of the receptor. At the
intracellular surface of CXCR4, the ICLGa conformation retains the native
conformation and position of ICL 1, ICL2 and the C-terminus. A loss of one turn of
helical structure at the cytoplasmic surface of TM5 produces a displacement of
ICL3 towards the C-terminal tail in the ICLGaB complexed structure.
Several significant structural changes characterize the extracellular
surface the ICLGa12 complex conformation. In the N-terminal region, the threestrand

~

sheet of the native conformation is converted into a two-strand sheet by

extension at ThrB rather than flexion. The proximal portion of the N-terminus also
takes on an additional turn of a-helical structure. ECL 1 and ECL2 adopt the
native conformation of the loops, while the apex of the ECL3 loop is displaced
towards the base of the N-terminal strand as in the constitutively active N119S
conformation. At the intracellular surface of the receptor, ICL 1 adopts the native
conformation, while the plane of the ICL2 loop is inclined towards the center of
the receptor, rather than away from the center as in the native conformation.
ICL3 adopts the unkinked structure of the native conformation, and is displaced
away from the center of the receptor as in the N119S conformation of CXCR4.
Helix B structure and positioning is conserved between ICLGa12 and native,

292

while a section of the C-terminal tail between Ser319 and Ser330 takes on a
more helical conformation and is inclined towards the center of the receptor when
compared to the native conformation.
The extracellular surface of CXCR4 is highly conserved between ICLGa25
and native CXCR4. The structures of the N-terminal region and the three ECL
structures are nearly identical to that of the native conformation. However at the
ICL surface, while ICL 1 structure is conserved between the ICLGa25 and native
conformations of the receptors, significant differences are apparent for the other
intracellular structures. The apex of ICL2 is located at the midpoint of the loop as
in the native conformation, while the angle of inclination of ICL2 is closer towards
the center of the receptor as in the N 119S conformation. The distance between
the apex of ICL3 and Helix 8 is also significantly decreased when compared to
the native structure. Finally, the tail of the C-terminal region is in a more vertical
orientation than in the native or N119S conformations.
Several significant structural changes characterize the extracellular
surface the ICLGa28 complex conformation. The N-terminal j3-sheet is more
compactly packed in the ICLGa28 complexed conformation as in the N119S
structure. The proximal portion of the N-terminal tail is displaced towards ECL3.
ECI1, ECL2 and ECL3 strongly conserve the native conformation. At the
intracellular surface of the receptor, ICL 1 maintains the native conformation,
while the apexes of ICL2 and ICL3 are displaced towards the center of the
receptor, and Helix 8 is outwardly displaced from the cytoplasmic terminal of
TM1.
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The extracellular surface of CXCR4 is highly conserved between ICLGa29
and native CXCR4. The structures and positioning of the N-terminal region,
ECL2 and ECL3 maintain the native conformation of the receptor. There is also a
slight displacement of ECL 1 towards the N-terminal region. At the intracellular
surface of the receptor, ICL 1 conformation and positioning maintains the native
conformation, while the angle of inclination for ICL2 is decreased, displacing the
apex of this loop towards the center of the receptor. ICL3 adopts the linear
conformation of the native receptor, while the apex of ICL3 is displaced towards
the apex of ICL2. Finally, although the structure of the C-terminal tail is largely
preserved between the ICLGa29 complexed conformation and the native
structure, the distal portion of the tail is brought into close contact with the
apexes of ICL2 and ICL3.
The extracellular surface of CXCR4 is highly conserved between ICLGa37
and native CXCR4. The distal N-terminal I)-sheet adopts the compact
conformation of the N119S structure, and the proximal region adopts the
displacement towards ICL 1 as in the N119S conformation. ECL2 is maintained in
the native conformation, while ECL3 is outwardly displaced from the center of the
receptor. At the intracellular surface of the receptor, ICL 1 and C-terminal region
conformation and positioning largely maintains the native structure. The angle of
inclination for ICL2 is decreased, displacing the apex of this loop towards the
center of the receptor and the apex of ICL3 is displaced away from the center of
the receptor.
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The overall implication from these ICLGa complex conformations is that
the receptor adopts either the inactive native conformation (ICLGa25, ICLGa29)
or an intermediary structure between the inactive and active conformations
(ICLGa8, ICLGa12, ICL28, ICLGa37).
ICLGa compound binding alters the conformation of the transmembrane
helixes of CXCR4.
Given the interactions of the ICLGa compounds with the intracellular
surface of CXCR4 and the altered conformations of the intracellular and
extracellular surfaces, we investigated the effect of inhibitor binding on the
structure of the helixes. To do this, we compared the reduced representations of
the transmembrane helices for each of the ICLGa complexed conformations of
CXCR4 to the inactive native conformation and the constitutively active N119S
conformation of the protein. Comparison of multiple receptor conformations to the
native CXCR4 structure and the constitutively active N119S variant was
facilitated by the helixanal program developed by Dr. Trent.
In investigating the reduced representations of the transmembrane region
of the complexes produced by ICLGa8, ICLGa12, ICLGa25, ICLGa29, and
ICLGa37, we found that they were similar in conformation to native CXCR4 as
depicted in Figure 73. The N-terminal portion of the TM region is highly
conserved compared to the native structure, and as a consequence, there are
multiple deviations by the complexed structures from the structure of the
constitutively active N119S mutant. The bulge of TM5 produced by loss of helical
character between residues Val206 and lIe215 present in the native conformation
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Figure 73: Transmembrane regions of ICLGa compound-CXCR4 complexes
adopt a similar conformation to native CXCR4. Reduced representations of
receptor transmembrane helices are presented: native CXCR4 in green, N119S
in red, and the ICLGa8 conformation in teal, ICLGa12 conformation in magenta,
ICLGa25 conformation in orange, ICLGa28 conformation in yellow, ICLGa29
conformation in white, ICLGa37 conformation in purple. The ICLGa8, ICLGa12,
ICLGa25, ICLGa29, and ICLGa37 conformations adopt the transmembrane
structure of the native receptor. The ICLGa28 conformation adopts an
intermediate conformation between the active and inactive conformations of the
receptor.
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Figure 73: Transmembrane regions of ICLGa compound-CXCR4 complexes
adopt a similar conformation to native CXCR4.
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was present in the complexed structures. Conversely, the kink of TM1 at Va154,
the more linear conformation of TM2, the outward flexion of TM3, the greater
angle of inclination of TM4, the axial rotation of TM6, and the outward shift of
TM7 present in the N119S conformation were not present in the complexed
structures. This suggests that ICLGa8, ICLGa12, ICLGa25, ICLGa29 and
ICLGa37 stabilize the TM structures in the inactive native conformation of the
receptor potentially acting as inverse agonists.
The transmembrane region of the complex produced by ICLGa28 seems
to be an intermediate form of the receptor between the native and N119S
conformations as depicted in Figure 73. TM1 is more linear in the complexed
conformation and lacks a kink at Ser46 present in the native conformation. TM2
and TM3 structure and positioning is conserved between the complexed
conformation and the native form. The complexed TM4 and TM6 structures are
more closely aligned with the structure of the N119S active conformation. The
TM5 bulge present in the native structure is present in the complexed structure,
but the helix seems to be rotated towards TM3. Finally, the cytoplasmic portion of
TM7 is rotated outward from the center of the receptor. In total, ICLGa28 drives
CXCR4 into an intermediate conformation with elements of the inactive native
structure and the active N119S configuratio n, suggesting that this compound
may act as a weak partial agonist.
Further examination of the transmembrane helixes involved assessment
of the distances between the intracellular and extracellular termini of the
interhelical segments. At the extracellular surface, as seen in Table 16, variation
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Table 16: ICLGa induced conformations adopt native interhelical distances
at the extracellular surface of CXCR4. Interhelical distances measured at
extracellular termini of transmembrane domains of native CXCR4, constitutively
active N119s, and compound docked structures. Distances measured at the
extracellular termini of reduced representations of the averaged structures.
Illustrated interhelical distances demonstrate 1.5 angstrom or greater deviation
from N119S structure, demonstrating that at the extracellular surface, the bound
ICLGa structures maintain or induce the native conformation of CXCR4.
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Table 16: IClGa induced conformations adopt native interhelical distances
at the extracellular surface of CXCR4.

TMA TMB Native N119S ICl8 ICl12 ICl25 ICl28 ICl29 ICl37

5

6

11.2

13.1

11.4

11.9

11.3

11.3

11.7

11.6

4

7

14.3

17.5

14.4

14.9

14.3

14.2

14.6

13.8

1

7

15.8

14.6

15.9

15.9

15.5

16.0

16.3

16.6

3

7

18.8

21.3

18.6

18.7

18.8

18.3

19.3

18.5

5

7

21.4

24.7

20.9

21.3

21.4

21.0

21.3

21.3
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from N119S interhelical distance between TM7 and helices one, three, four and
five was a consistent finding in all of the active CXCR4 inhibitors investigated.
There was a similarly uniform decrease in the TM5-6 interhelical distance
when compared to N119S. All of these interhelical distances were compatible
with the expected distances for the native receptor. IClGa37 did produce a
unique 1.8 angstrom increase in the interhelical distance between TM1-2, which
is an unusual finding in that this is the shortest interhelical distance on the
receptor and is highly conserved across conformations. In this case it could
represent a shift between the native conformation of the N-terminal and ECl1
conformations and the N119S conformation. There was an additional decrease in
the interhelical distance in TM2-7 in the conformation of IClGa12. This decrease
could be the source of the altered conformation of ECl3.
At the intracellular surface, as seen in Table 17, several key similarities
are noted between the complexed conformations and the native structure of
CXCR4. The TM3-6 interhelical distance is uniformly decreased in all of the
active receptor structures. Interhelical distance between transmembrane regions
TM1-5, TM2-3, TM2-5, TM2-6, TM3-4, TM3-5, and TM4-6 is decreased
compared to the conformation of N119S, and reflects the expected difference
between the native conformation of the receptor and the N119S conformation.
This relationship is also reflected in the distance between TM1-7 in the
conformations produced by compounds IClGa8, IClGa12, IClGa25 and
IClGa37. These compounds all also exhibit an increased interhelical distance
between TM4-7 when compared to the native structure.
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Table 17: ICLGa induced conformations adopt native interhelical distances
at the intracellular surface of CXCR4. Interhelical distances measured at
cytoplasmic termini of transmembrane domains of native CXCR4, constitutively
active N119s, and compound docked structures. Distances measured at the
intracellular termini of reduced representations of the averaged structures.
Illustrated interhelical distances demonstrate 1.5 A or greater deviation from
either the Native or N119S structure.
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Table 17: IClGa induced conformations adopt native interhelical distances
at the intrace"ular surface of CXCR4.

TMA TMB

Native N119S ICl8 ICl12 ICl25 ICl28 ICl29 ICl37

2

6

10.7

12.9

11.1

10.9

10.8

10.3

10.7

10.7

3

5

11.5

16.5

11.6

11.9

12.0

11.6

11.8

11.2

3

6

12.0

13.4

11.3

11.1

11.2

11.1

11.4

11.8

1

7

12.2

13.6

12.1

12.3

12.6

13.7

13.4

12.1

2

3

15.6

17.9

15.4

15.3

15.2

15.9

15.8

15.6

3

4

16.0

12.6

16.2

15.9

16.0

15.1

15.5

15.6

4

6

19.5

17.6

20.1

19.2

19.3

17.9

18.7

19.2

4

7

22.3

21.0

22.5

23.1

23.1

24.2

25.2

21.9

2

5

22.5

25.3

23.3

22.6

22.7

22.8

22.9

22.7

1

5

32.2

33.9

31.5

32.1

31.5

32.4

32.4

31.8
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In addition to these alterations, compounds ICLGa28 and ICLGa29 also
produce additional alterations in the interhelical distances between TM7 and the
other helices as seen in Table 18. The interhelical distance between TM7 and
TM2, TM3, TM5 and TM6 was significantly increased compared to both native
and N119S conformations. The TM4-7 was also increased to a greater extent
than seen in the other compounds, while the TM1-7 interhelical distance in the
conformation produced by these two compounds closely reflects that of the
N119S conformation.
This data reflects that the majority of compound complex conformations
reflect the native conformation. In add ition , each of the compounds produced a
decrease in the interhelical distance between TM3-6 suggesting increased
stability of the inactive conformation. The complexed structures produced by
ICLGa28 and ICLGa29, produced significant variation in the position of TM7
reflecting significant structural variation from the native structure and N119S,
suggesting an intermediate conformation of the receptor.
Interhelical hydrogen bonding characterizes differences between ICLGa
compound binding.
To continue to investigate the differences in interhelical movements
produced by compound binding , receptor hydrogen bond ing was analyzed. As
the N119 residue was located on TM3, and we previously demonstrated
significant variation in the interhelical distances of TM7 , our efforts were focused
on the hydrogen bonds formed by TM3 and TM7. Hydrogen bonding in each of
the compound-CXCR4 complex molecular dynamics trajectories at equilibrium
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Table 18: ICLGa28 and ICLGa29 alter the position of TM7 at the intracellular
surface of CXCR4. Interhelical distances measured at cytoplasmic termini of
transmembrane domains of native CXCR4, constitutively active N119s, and
compound docked structures. Distances measured at the intracellular termini of
reduced representations of the averaged structures. Illustrated interhelical
distances demonstrate 1.5 angstrom or greater increase from the Native and
N119S structures, indicating significant alterations of the structure of TM7 by
compounds ICLGa28 and ICLGa29.
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Table 18: ICLGa induced conformations adopt native interhelical distances
at the intracellular surface of CXCR4.

TMA

TMB

Native

N1195

ICL28

ICL29

2

7

11.7

12.3

13.8

14.5

6

7

12.3

11.8

15.8

16.3

3

7

21.5

22.2

24.7

25.3

5

7

24.8

23.7

27.8

28.6

306

was determined using a PTRAJ program to process and analyze sets of 3-D
coordinates and trajectory files . Occupancy is defined as the prevalence of a
hydrogen bond across the 5 ns trajectory, as is used to quantify the influence of a
hydrogen bond on receptor structure.
The hydrogen bonding by TM7 residues in each of the compound-CXCR4
complexes was analyzed. Bonds between TM7 and TMs 2, 3, 6, and ECL2 were
identified for each of the conformations residues as illustrated in Table 19.
Hydrogen bonding between Asn298-Tyr76, Asp187-Ser285, and Asp187-Thr287
was consistent between all of the compound-CXCR4 complexes. Compounds
ICLGa12, ICLGa25, ICLGa28 and ICLGa29 each formed stable hydrogen bonds
between Asp84-Asn298 and Asn119-His294, but the hydrogen bond occupancy
of Asp84-Asn298 for ICLGa28 was significantly reduced as was the hydrogen
bond occupancy of Asn119-His294 for ICLGa25. In addition, the hydrogen bond
occupancy between Thr240 and Tyr302 was 70 .2% for the ICLGa25 complex
while this value was significantly reduced for ICLGa28 and ICLGa29, and there
was no bond at all in the ICLGa12 complex. Hydrogen bonding between Asn288
and Lys282 also significantly varied between compound complexes, with
ICLGa 12 and ICLGa28 producing almost full occupancy of this hydrogen bond
across the trajectory, whi le ICLGa25 and ICLGa29 produced significant
reductions in the occupancy of this hydrogen bond. ICLGa12, ICLGa25, ICLGa28
and ICLGa29 each exhibit hydrogen bonding between His294 and Trp252,
although this hydrogen bond is much more prevalent in the ICLGa28
conformation.
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Table 19: Hydrogen bonds formed by the side chains of TM7 in anti-CXCR4
compound bond molecular dynamics simulations. Hydrogen bonds mediated
by TM7 residues were found to be conserved in each of the derived
conformations. % indicates percent occupancy of the hydrogen bond.
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Table 19: Hydrogen bonds formed by the side chains of TM7 in anti-CXCR4
compound bond molecular dynamics simulations.
ICLGa12

ICLGa25

Donor

Acceptor

%

Donor

Acceptor

%

84001

298 N02

89.6

84001

298 N02

89.76

119001

294 NE2

73.12

119001

294 NE2

48.44

187002

2850G

99.6

187002

2850G

99.64

187002

2870G1

82.52

187002

2870G1

92.24

2880E2

282 NZ

53.56

2400G1

3020H

70.24

2880E2

282 NZ

35.2

2880E2

282 NZ

52.12

2880E2

282 NZ

8.44

2880E1

282 NZ

8.16

294 N01

252 NE1

28.4

294 N01

252 NE1

22.24

298001

760H

86.84

298001

760H

82.52

ICLGa28

ICLGa29

Donor

Acceptor

%

Donor

Acceptor

%

84001

298 N02

60.04

84001

298 N02

89.6

119001

294 NE2

80.6

119001

294 NE2

68.28

187002

2850G

99.88

187002

2850G

99.8

187002

2870G1

82.2

187002

2870G1

81.2

2400G1

3020H

17.4

2400G1

3020H

24.76

2880E2

282 NZ

41.08

2880E1

282 NZ

32

2880E2

282 NZ

32.24

2880E2

282 NZ

17.72

2880E2

282 NZ

17.84

294 N01

252 NE1

29.64

294 N01

252 NE1

57.56

298001

760H

81.76

298001

760H

89.16
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The hydrogen bonding by TM1 residues in each of the compound-CXCR4
complexes was also analyzed in Table 20 . Only one hydrogen bond involving
TM1 was present in all four complexed structures, the bond between TM1
residue Tyr65 and the C-terminus residue Ser319. Although present over 3040% of the trajectory for compounds ICLGa28 and ICLGa29, this bond was
nearly non-existent for residues ICLGa12 and ICLGa25.
Significant differences in TM3 mediated interhelical hydrogen bonding in
each of the compound-CXCR4 complexes is illustrated in Table 21 . Hydrogen
bonding between Asp171-His113 and Asp187-Tyr116 was consistent for all of
the residue complexes.
However hydrogen bond occupancy was reduced for the bonds between
Tyr116-Tyr255 and Asn119-His294 for compounds ICLGa25 and ICLGa29.
Occupancy of the Thr117 -Arg188 bond was increased for the ICLGa12 complex
and decreased for the ICLGa29 complex. Occupancy of the Tyr121-Ala188 bond
was

increas~d

by compounds ICLGa28 and ICLGa29. Finally, the occupancy

between Asp84-Asn119 was decreased by ICLGa12 and increased by ICLGa28.
Significant differences in TM4 mediated interhelical hydrogen bonding in
each of the compound-CXCR4 complexes is illustrated in Table 22 . All of the
complexes consistently formed hydrogen bonds between Glu153-Tyr157.
However, ICLGa28 produced a significantly greater occupancy of the hydrogen
bond between Tyr157-Lys75, a bond wh ich was barely present in the other
conformations. Also, hydrogen bonds between Asp171-His113 and Asp171Lys110 were occupied in the conformations produced by ICLGa12,
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Table 20: Hydrogen bonds formed by the side chains of TM1 in anti-CXCR4
compound bond molecular dynamics simulations. Hydrogen bonds mediated
by TM1 residues were found to be conserved in each of the derived
conformations. % indicates percent occupancy of the hydrogen bond.
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Table 20: Hydrogen bonds formed by the side chains of TM1 in anti-CXCR4
compound bond molecular dynamics simulations.
Donor

Acceptor

%

ICL 12

3190G

650H

0.04

ICL25

3190G

650H

0.08

ICL28

3190G

650H

41.72

ICL29

3190G

650H

30.44
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Table 21: Hydrogen bonds formed by the side chains of TM3 in anti-CXCR4
compound bond molecular dynamics simulations. Hydrogen bonds mediated
by TM3 residues were found to be conserved in each of the derived
conformations. % indicates percent occupancy of the hydrogen bond.
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Table 21: Hydrogen bonds formed by the side chains of TM3 in anti-CXCR4
compound bond molecular dynamics simulations.
ICLGa12

ICLGa25

Donor

Acceptor

%

Donor

Acceptor

%

84002

119 N02

49.72

84002

119 N02

34.24

84001

119 N02

14.64

84001

119 N02

26.24

84002

119 N02

3.76

84002

119 N02

13.88

1160H

2550H

77.52

1160H

2550H

51.4

1170G1

188 NE

48.28

1170G1

188 NH2

20.4

1170G1

188 NH2

3.16

1170G1

188 NE

3.52

119001

294 NE2

73.12

119001

294 NE2

48.44

1210H

188 NH2

2.36

1210H

188 NH2

2.52

1210H

188 NH1

1.64

1210H

188 NH2

1.04

171 002

113 NE2

15.52

171 002

113 NE2

16.8

187001

1160H

99.04

187001

1160H

99.32

ICLGa28

ICLGa29

Donor

Acceptor

%

Donor

Acceptor

%

84002

119 N02

92.76

84002

119 N02

57.6

84001

119 N02

1

84001

119 N02

11.24

84002

119 N02

0.44

84002

119 N02

5.2

1160H

2550H

69.72

1160H

2550H

59.72

1170G1

188 NE

20.16

1170G1

188 NE

0.28

119001

294 NE2

80.6

119001

294 NE2

68.28

1210H

188 NH2

21.32

1210H

188 NH1

42.16

1210H

188 NH2

2.04

1210H

188 NH2

2.36

171 002

113 NE2

21.16

171 002

113 NE2

17.24

187001

1160H

98.76

187001

1160H

95.32
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Table 22: Hydrogen bonds formed by the side chains of TM4 in anti-CXCR4
compound bond molecular dynamics simulations. Hydrogen bonds mediated
by TM4 residues were found to be conserved in each of the derived
conformations. % indicates percent occupancy of the hydrogen bond.
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Table 22: Hydrogen bonds formed by the side chains of TM4 in anti-CXCR4
compound bond molecular dynamics simulations.

Donor

ICLGa12
Acceptor

ICLGa25
Donor
Acceptor

1530E1

1570H

%
46.72

1530E2

1570H

52.8

1530E2

1570H

68.16

1570H

75 NZ

0.04

1570H

75 NZ

0.16

171 002

113 NE2

15.52

75 NZ

0.04

171 002

110 NZ

12.12

1570H
1570H

75 NZ

0.04

171 002

110 NZ

11.28

171 002

113 NE2

16.8

171 001
171 001

110 NZ
110 NZ

11.16

171 002
171 002

110 NZ

27.92

171 001
171 002

110 NZ
110 NZ

171 002

110 NZ
110 NZ

21
19.12

171 001

110 NZ

4

8.48
7.24
10.84

1530E1

1570H

%
31.24

171 001
171 001

1530E1

1570H

%
96.12

1530E2

1570H

0.56

110 NZ
2.88
110 NZ
2.56
ICLGa29
Acceptor
Donor
%
1530E1
1570H 41.56
1530E2
1570H 56.72

1570H
1570H

75 NZ
75 NZ

9.08

1570H

75 NZ

0.16

1570H
171 002

75 NZ
113 NE2

9
8.6

1570H
1570H

75 NZ
75 NZ

0.04
0.04

171 002

110 NZ

21.16
26.08

171 002
171 002

110 NZ
110 NZ

19.92
16.76

171 001

110 NZ

2.12

171 001

110 NZ

1.72

171 001

110 NZ

1.64

Donor

ICLGa28
Acceptor
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ICLGa25 and ICLGa28 but completely absent in the conformation formed by
ICLGa29.
This hydrogen bonding data suggests that movements of TM7 induced by
ICLGa28 and ICLGa29 produce an alteration of the hydrogen bonding network,
which is distinct from ICLGa12 and ICLGa25. The ICLGa28 and ICLGa29
hydrogen bonding networks may produce a CXCR4 conformation with less
internal stability due to decreased hydrogen bonding by TM3, TM4 and TM7.
Discussion
Our goal was to ta rget the CXCR4:G-protein interface to discover novel
small molecules which could selectively inhibit receptor function and be used as
scaffolds for development of clinically active anti-metastatic compounds. Initial
screening of the thirty-seven ICLGa compounds at 50 IJM identified twenty-four
compounds which inhibited chemotaxis (Figure 55). This hit rate of 64.9 % at 50
flM for initial screening of our thirty-seven ICLGA compounds represents a
significant increase over contemporary studies [314-316]. Ten of the twenty-four
active compounds had chemotaxis IC50 values of 10 IJM or less (Figure 56), for
an exceptional hit rate of 27% . Of the ten ICLGa compounds inhibiting CXCR4mediated chemotaxis at 10 IJM or less, only five exhibited any anti-BLT1 activity,
and none of these possessed an anti-BLT1 IC50 of less than 25 IJM, suggesting
that the most active compounds are highly specific.
Subsequent investigations of the impact of the ICLGa compounds on
signal transduction by CXCR4 revealed that twelve ICLGa compo unds produced
significant reductions in calcium release (Figure 58), and six of the twelve active
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compounds had calcium mobilization IC50 values of 10 IJM or less (Figure 59).
Selectivity screening of the ICLGa compou nds with anti-calcium release activity
revealed that six of the nine ICLGa compou nds with anti-BLT1 activity had IC50
values that were lower for BLT1 than for CXCR4, suggesting that the anticalcium release activity produced by these compounds was not specific for
CXCR4. However, three of the most active compounds had significantly greater
anti-CXCR4 activity than anti-BL T1 activity, suggesting that anti-calcium
mobilization activity in these compounds is selective for CXCR4.
The effects of the twenty-six active anti-CXCR4 compounds were
produced in the absence of significant cytotoxicity, as only seven of the
compounds produced elevated cytotoxicity at 50 IJM, and only four of these
compounds produced any cytotoxicity at less than 10 IJM.
Sorting of the thirteen ICLGa com pounds with anti-CXCR4 activity at 10
IJM or less in chemotaxis and calcium mobilization allows the compounds to be
divided into fou r categories (Table 23). Seven compounds exhibit CXCR4specific and exclusive anti-chemotaxis activity. Three compounds exhibit
CXCR4-specific anti-chemotaxis and anti-calcium mobilization activity. Two
compounds exhibit non-specific exclusive anti-calcium mobilization activity. The
remaining compound exhibits CXCR4-specific and exclusive anti-calcium
mobilization activity. The ICLGa compounds could be interfering with the
interaction between CXCR4 and Gai, completely preventing signal transmission
through the receptor inhibiting both chemotaxis and calcium mobilization as is the
case with ICLGa25, ICLGa28 and ICLGa36.
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Table 23: Classification of ICLGa Compounds with anti-CXCR4 activity of
10 IJM or less. ICLGa compounds with anti-CXCR4 activity can be classified by
their primary mode of inhibition; either chemotaxis or calcium mobilization.
Additional subclassification based on molecular dynamics studies suggest that
compounds which do not successfully interact with the native structure can be
classified as potential inverse agonists, while dynamically bound compounds can
be classified as potential antagonists or weak partial agonists.
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Table 23: Classification of compounds with anti-CXCR4 activity at 10 JJM or
less.
Calcium
IC50 (JJM)
35

Activity

Target

ICLGa4

Chemotaxis
IC50 (JJM)
10

Chemotaxis

Goi

ICLGa5

5

45

Chemotaxis

Goi

ICLGa8

3

--

Chemotaxis

CXCR4

ICLGa9

45

1

Calcium

CXCR4

ICLGa12

12.5

5

Calcium

CXCR4

ICLGa13

12.5

5

Calcium

CXCR4

ICLGa17

10

--

Chemotaxis

CXCR4

ICLGa22

10

--

Chemotaxis

Goi

ICLGa25

10

1

Dual

CXCR4

ICLGa28

1

10

Dual

CXCR4

ICLGa29

10

--

Chemotaxis

CXCR4

ICLGa36

1

6

Dual

CXCR4

ICLGa37

5

--

Chemotaxis

Goi

320

Mode

Inverse
Agonist
Weak Partial
Agonists
Inverse
Agonist
Weak Partial
Agonists
Inverse
Agonist
Inverse
Agonist
Inverse
Agonist
Antagonists
Weak Partial
Agonists
Antagonists
Inverse
Agonist
Weak Partial
Agonists

Assessment of inhibition of tumor proliferation by three of the most active
ICLGa compounds by MTT screening revealed that the three compounds
produce three different avenues of proliferation inhibition. ICLGa9 is generally
inhibitory, affecting both normal and cancer cells at levels lower than the
cytotoxicity levels seen in Figure 62 . ICL25 inhibited the growth of metastatic
cancer cell lines A549 and MDA-MB-231, but not normal cells or non-metastatic
MCF7 cells. Finally, ICL36 inhibited the growth of non-metastatic MCF7 cells,
metastatic cancer cell lines to a lesser extent, and did not inhibit proliferation of
H827 cells. These results are intriguing as a CXCR4 inhibitor need not be
cytotoxic to function, for instance ICL36 inhibits chemotaxis but does not affect
metastatic cell proliferation .
Of the twelve docked compounds, stable CXCR4: compound complexes
were generated for compounds ICLGa8, ICLGa12, ICLGa25, ICLGa28, ICLGa29
and ICLGa37. ICLGa5, ICLGa9, ICLGa13, ICLGa17, ICLGa22, and ICLGa36 did
not form stable complexes with the native conformation of CXCR4. As these
compounds were initially designed to target the constitutively active N 1198
conformation of CXCR4, it may be that ICLGa5, ICLGa9, ICLGa13, ICLGa17,
ICLGa22, and ICLGa36 are only capable of interacting with the receptor in active
conformation , suggesting that these compounds could be acting as inverse
agonists.
The bound ICLGa compounds were able to demonstrate several
significant differences in CXCR4 structure. All of the compounds interacted with
the aliphatic components of the side chains and backbones of ICL 1 and ICL2,
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suggesting that the compounds could act as bridging elements between these
two regions, stabilizing their position and preventing signal transduction or
producing a more closed intracellular surface potentially incapable of binding Gai.
Interaction by the compounds with the C-terminal region could potentially
stabilize TM?, or interfere with the interface between the C-terminus and Gai.
This could be especially true in the case of ICLGa28, where interposition of the
compound between the C-terminus and ICL3 could restrict the movement of both
regions and directly impede the cleft which would be occupied by bound Gai.
Comparisons of the intracellular and extracellular surfaces of CXCR4
produced by the ICLGa compounds revealed that the receptor adopts either the
native conformation (ICLGa25, ICLGa29) or an intermediary structure between
the inactive native conformation and the constitutively active conformation
(ICLGa8, ICLGa12, ICL28, ICLGa3?), suggesting that the receptor is being
stabilized in an inactive state by the ICLGa compounds, either by an inverse
agonist or by a weak partial agonist. This stabilization is further suggested by the
uniformly decreased interhelical distance TM3-6 in the compound conformations.
In prior lipid bilayer molecular dynamiCS simulations, a decrease in TM3-6
distance has been associated with T140 acting as an inverse agonist, while
AMD3100 acting as a weak partial agonist did not produce this effect [200]. This
suggests that these compounds are acting as inverse agonists, and producing
similar alterations to the inverse agonist T140.
Thus, we have developed a series of compounds with anti-CXCR4 activity
by targeting the intracellular CXCR4:Gai interface. This study represents the first
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successful attempt to generate potential pharmaceuticals by targeting this
interface that has produced phenotypical changes in the GPCR, rather than just
conformational changes of the receptor. Molecular dynamics demonstrated that
several of these compounds produced changes in CXCR4 consistent with
inverse agonist activity. As CXCR4 represents one of the central mechanisms in
cancer metastasis, these novel compounds could represent lead templates for
the possible treatment of metastatic disease.
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CHAPTER IV
VALIDATION OF INHIBITOR COMPOUNDS IDENTIFIED BY
VIRTUAL SCREENING

The process of structure based drug design

Although high-throughput screening methodologies have provided the
traditional pipeline for lead compounds for pharmaceutical development [322 ,
323], SBDD has produced some notable successes. Some of the most notable
successes have involved the development of the inhibitors targeting HIV
protease [324, 325] and the neuraminidase inhibitors for treating influenza [326].
SBDD is an iterative process, illustrated in Figure 74. The process begins
with identification of a structural basis for a pathological phenomenon.
Compounds are screened targeting this process, through high-throughput or
virtual screening to identify lead compo unds which modulate a phenotype. Active
compounds are then tested for toxicity and specificity. Compound and receptor
interactions are then modeled. The basic structure of the compound is then
investigated through the development of derivatives based on the initial model of
compound:receptor interaction. Quantitative structure activity relationship
analysis (QSAR) can then be developed to characterize compound activity based
on modifications to select structural regions . In addition , mutational analysis can
be used to determine particular regions of the target essential to compound
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Figure 74: Progression in the SBDD protocol for developing inhibitors of

CXCR4. Surflex-Dock was used to virtually re-dock ECLVS and ICLGa compounds
into their respective surfaces of CXCR4 to identify potential interaction residues between
the receptors and compounds . Molecular dynamics based on in silico mutants were
used to determine if structural modifications of the target sites would induce an altered
conformation of CXCR4. Site directed mutagenesis would also be used to develop
mutants to identify the in vitro effects of modification of the active site residues. Finally,
the most active anti-CXCR4 compounds will be tested in in vivo assays to determine if
they can inhibit metastasis.
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Figure 74: Progression in the SBOO protocol for developing inhibitors of

CXCR4.
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function or to further characterize the structure of the target. Additional
derivatives can be generated based on the regions described in QSAR analysis
to test a new hypothesis of interaction in an effort to uncover the mechanism of
action for the lead compounds. Well-characterized and strongly active
compounds can then be submitted for animal testing in an effort to translate
findings from the laboratory to the clinical setting.
In the case of our work, the identification of metastatic cells expressing
elevated concentrations of cell surface CXCR4, combined with migration by
these cells in relation to a CXCL 12 gradient by Muller [9], highlighted CXCR4 as
a potential target for inhibiting metastasis. We utilized virtual screening targeted
at separate regions or targets of CXCR4 to identify two series of active inhibitors
of the receptor, using CXCR4-mediated chemotaxis as a model for metastasis.
Our compounds are highly specific in their anti-CXCR4 activity, and lack nonspecific cytotoxicity, as discussed in Chapters II and III. Thus, continuing
development of our identified compounds will involve reflecting back on our
mechanistic model, as well as looking forward to testing of the compounds in vivo
in animal models of pathology.

In silico methods can be high-throughput methodologies for SBDD.
Virtual screening of compounds through molecular docking methods such
as Surflex[234], Autodock[227], and DOCK[226] is based on the theory that the
suggested compound placement produced by the docking program corresponds
to the compound conformation adopted in the cellular milieu. Several studies
have confirmed that virtual docking studies can reproduce the active site
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placement of the compounds seen in the crystal structure [327-329] with
particular success in carbohydrate ligands [330], factor Xa inhibitors [331],
acetylcholinesterase [332] and cytochrome P450 [333].
Evaluation of successful compound placement is largely based on
evaluation of electrostatic and hydrophobic interactions between the compound
and the receptor, as well as steric factors such as clash scores which quantify
penetration by the placement of the compound in the surface of the target
protein. The scores used to evaluate the docked conformations can either be
proprietary to the programs as in Surflex[234], DOCK[226] or Autodock[227] or
ligand conformations can be output by the docking program and a separate
scoring program such as FlexX[240], SCORE[226], and Ligandfit[241] can be
used to evaluate the compounds.
Surflex-Dock [234, 244] screening begins with the development of a
protomol, a series of pseudo-atoms used to define the target for the docking
sequence. Ligand based protomols based on ligands, inhibitors or partner protein
substructures allow specific interaction residues to be highlighted by the docking
process. The same is true for residue based protomols, which can be generated
based on series of defined residues to target specific regions of an active site.
Proper placement and focus of a target site for a virtual screening program can
make the difference between a screen that identifies active inhibitors and one
that returns nothing but false positives [334].
The results of a Surflex-Dock virtual screen are not simply a list of single
compounds with an associated score. The program generates multiple initial
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fragmentations of the compounds in its flexible docking protocol. These initial
fragments are scored and used as a starting position for construction of the full
virtual compound. Greater results variety and exploration of the space of the
active site can be achieved by randomizing the initial conformation of the
compound and varying the site for initial placement of the compound fragments.
Randomization of the compound starting conformation causes the docking
program to consider different fragmentation schemes, and thus attempts build
the flexible ligand in the active site in different fashions between different
conformations. Varying the initial starting position of the compound fragments
causes different chemical elements of the active site to come into play in building
the rest of the compound depending on where the process is begun. As a result
of this, hundreds of unique compound conformations can be produced for a
single compound, and by expanding the sampling pool the highest scoring
compound conformations from a true sampling of the entire space of the active
site can be identified.
Mutagenesis assays can be used to characterize receptor structure and
function.
SBDD can also be approached from the perspective of the receptor and
not just the compound, in order to gain greater understanding of receptor
structure. Mutagenesis studies have been extensively used to characterize
GPCR functional mechanisms. There are three primary mechanisms by which
mutation can alter receptor function: 1, the mutation can directly interfere with
ligand binding; 2, the mutation can result in a conformational shift altering the
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ligand binding pocket; and 3, the mutation can modulate allosteric movement
altering signal transduction.
One of the best examples of mutational studies directly interfering with
ligand binding corresponds to studies concerning the mechanism of ligand
binding for CCR5. CCR5 is the GPCR co-receptor used for plasma membrane
fusion in M-tropic strains of HIV-1 [335]. Scanning alanine site directed
mutagenesis has been used to identify acidic residues (Asp2, Asp11 and Glu18)
which are essential to chemokine and gp120 binding, and by extension, HIV
entry [336]. Further study of this region by this technique added the aromatic
residues Tyr3 and Tyr10 to the residues which are essential to chemokine and
gp120 binding [337, 338]. Further analysis of the extracellular surface of CCR5
including the extracellular loops identified Lys171 and Lys191 as essential
elements in the binding of ligands MIP-1a and RANTES [339].
In GPCRs, mutations modulating allosteric sites and preventing signal
transduction usually correspond to mutations of the TMs. Basu et al in the Trent
and Bodduluri laboratories utilized a series of mutants targeting the TM region of
the Leukotriene B4 receptor BLT1 to characterize the allosteric effects of that
mutations to this region had on receptor function. Mutations of the TM1 residue
Asn36, TM3 residue Asp64, and the TM7 residues Ser277, Ser278, Ser279 and
Asn281 produced a significant reduction in LTB4 mediated chemotaxis and
calcium mobilization. Specifically, mutation of these residues prevented
interactions between Asp64 and Asn281 as well as Asp64 and Asn36, which
were required for transition of the molecule to its active state [151]. Similar
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studies involving the thyrotropin receptor [340] and histamine H1 receptor [341]
revealed that mutation of TM regions could prevent transition of the receptors to
the active state.
Mutational analysis has helped to characterize the structure and function
of CXCR4. Chimeras replacing the extracellular domains of CXCR4 with
comparable domains of CXCR2 were used in some of the earliest studies of
CXCR4 structure to characterize interactions between the extracellular surface of
the receptor at the distal N-terminus and ECL3 and CXCL 12. [342] These studies
also demonstrated that the serine and threonine residues of the carboxyl
terminus were essential to CXCL 12-induced signaling, through a series of
truncation mutants, which reduced the length of the C-terminus. Mutational
analysis has also been used to characterize the antagonist binding site of antiCXCR4 compounds T140 and AMD3100 [200]. Alanine scanning mutations
identified Asp171 , Arg188, Tyr190 and Asp262 as essential to binding of T140 to
the extracellular surface of the CXCR4 at ECL2. Additional alanine scanning
mutations identified Phe189, Tyr190, Asp262 and Glu288 as essential to the
binding of AMD31 00 to the base of ECL3.
Biophysical studies can be used to characterize GPCR structure, but
analysis of transmembrane proteins remains difficult.
Biophysical analysis is another method which can be used to define and
develop characteristics of protein structure, although these methods are not
without their difficulties when applied to transmembrane proteins. Crystallography
remains the gold standard of biophysical and structural characterization of
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proteins. However, growth of well-ordered three dimensional crystals remains the
major constraint of generating high-resolution structural data. Novel
crystallization techniques have allowed the crystal structures of the

~2-adrenergic

receptor [108], a2A-adrenergic receptor [111] and recently, CXCR4 [257] to be
characterized. These techniques have essentially been designed to minimize the
mobility and flexibility of the protein including removal of the N-terminal and Cterminal subunits as well as substitution of ICL3 with T4L [109, 110] which
exchanges a mobile and flexible unit for a solid and immobile element which is a
desirable characteristic in the development of well-ordered three dimensional
crystals. In spite of the good resolution of these novel crystallization studies, one
has to question the impact of removing essential elements of protein structure,
and what impact this would have on the derived crystals of the remaining
structure.
Spin labeling is another method which can be used to monitoring the
structure and dynamics of soluble and membrane bound proteins. In this method,
sulfhydryl groups are modified by a nitroxide reagent to produce a nitroxide probe
on substructures of a larger group. This nitroxide probe possesses unique
paramagnetic properties which can be used in conjunction with electron
paramagnetic resonance spectroscopy to define the solvent accessibility,
mobility, polarity index of the adjacent environment, and the distance between
the probe and the paramagnetic center of the protein, all vital information for the
biophysical characterization of biomolecules [343]. Some of the earliest
characterizations of GPCR structure were derived from experimentation based
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on incorporation of rhodopsin into lipid bilayers with motion of TM segments
assessed by the spin-labeled phosphatidylcholine which made up the bilayers
[344]. Subsequent development of site-directed mutagenesis allowed
development of a site-directed spin labeling technique for assessing biophysical
properties of proteins [345]. In this method, site directed mutagenesis is used to
replace protein residues with cysteine, which can be subsequently used to react
with the nitroxide probe of the spin-labeling reaction allowing characterization of
specific protein subunits. The developer of this method, Dr. Wayne L Hubbell,
has utilized the method primarily to detect structural changes between the active
and inactive conformations of rhodopsin. Site directed spin labeling has been
used to characterize the mobility of the C-terminus region, describing the
structure as a disordered and dynamic unit tethered at one end of the protein,
with no additional stability provided by palmitoylation of the protein at residues
322 or 323 [346]. Spin-labeling of N-terminal and C-terminal elements allowed
the active state of the receptor to be characterized by movement of TM7 away
from TM1 when compared to the inactive state of the receptor [347]. This method
is not without its problems in assessing biophysical characteristics of
transmembrane proteins. As the paramagnetic signal is highly sensitive to its
surrounding environment, the protein should be placed in purified micelles rather
than the cell membrane to directly assess the influence of the protein on the
paramagnetic signal rather than the surrounding elements of the cellular milieu. It
is difficult to purify sufficient volumes of TM protein to perform these assays, as
well as place the proteins in micelles while maintaining some semblance of
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structural elements of an active receptor. In addition, as GPCR structure is highly
dependent on several conserved cysteine linkages, addition of other cysteine
elements could produce abnormal structural conformations by incorrect linkages
with substituted cysteine residues. The bulky nitroxide labels provide another
potential source of error in the form of disrupted native structure, and
conformational flexibility of the labels themselves leading to poor resolution [348].

In vivo analysis of inhibition of metastasis in animal models
Given the myriad factors and conditions involved in successful metastasis
of neoplastic cells, accurate in vivo models of metastasis are exceptionally
difficult to develop. In xenograft models, neoplastic cells are directly injected into
proposed sites of metastasis, such as long bones like the femur in an orthotopic
model [349] or into the mammary fat pad [350], and tumor growth in the novel
microenvironment is assessed. Non-small cell lung cancer (NSCLC) cells can
also be used in the assessment of metastasis. One such method injected A549
cells (a NSCLC cell line) directly into SCID mouse lung tissue and assessed
distant organ and contralateral lung metastasis development. Philips et al used
this method to identify increased cell surface expression of CXCR4 in A549 cells
with increased metastasis to distant organs and the contralateral lung, a process
which could be inhibited by knockdown of CXCL 12 expression [32]. Another
common model of metastasis used in conjunction with pharmaceutical
development is the tail vein injection method. In this method, severe combined
immune deficient mice are injected in their large diameter tail veins with cells
from tumor cell lines such as MDA-MB-231 [9,351]. This method was utilized in
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the MOiler paper to identify favorable microenvironments and homing locations
for metastatic cells expressing cell surface CXCR4. This method has also been
utilized to demonstrate the anti-metastatic properties of T140 derivative TN 14003
[351]. Other models of metastasis focus on the development of bone metastasis.
In this model, tumor cell lines such as MDA-231-BSC12 are directly injected into
the left ventricle of athymic mice and cells preferentially metastasize to sites in
the bone marrow [350]. This model has been successfully used to demonstrate
the anti-metastatic properties of anti-CXCR4 peptide CTCE-990B [350].
Tail vein injection remains one of the most popular methods for assessing

in vivo metastasis, primarily because of its ease of use and draw backs of the
other methods. Direct injection of cells into the lung parenchyma runs the risk of
producing pneumonia in the injected lung, and carries an increased risk of
bleeding and pneumothorax. Direct injection of cells into the left ventricle carries
its own difficulties, with an experienced and steady hand required to successfully
place the needle in the required location, and an increased risk of mortality in the
injected animals due to arrhythmia or cardiac tamponade due to disruption of the
ventricular chamber. Tail vein injections are not without their own drawbacks, as
they suffer from a significant first pass effect, as the cells must pass through the
portal and pulmonary circulation, increasing the risk of entrapment of tumor cells
in the attendant capillary beds of these systems. One of the main benefits of the
bone metastasis model is that it avoids this first pass effect by directly injecting
the cells into the systemic circulation, and thus provides at least one full pass of
the cells through the systemic circulation.
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In this chapter, we will seek to continue the SSOO process for our antiCXCR4 compounds targeting the extracellular and intracellular surfaces of the
receptor. We will use virtual screening in a novel manner, taking advantage of
the additional structural information gained from the virtual screening process, to
identify the sites of our targets on the extracellular and intracellular surfaces of
the receptor where our compounds most frequently interacted in virtual screens.
In this manner, we will identify the residues where interaction with the antiCXCR4 compounds produced an altered phenotype of the receptor. We will then
utilize molecular dynamics to demonstrate that alteration of these ECL2, ECL3,
ICL3 and C-terminal residues modulate the TM regions of the receptors, and
affect the conformation of CXCR4. We will then use mutatagenesis analysis to
determine the effects of these mutations on CXCR4 mediated signaling and
migration. We will also advance further in the SSOO process and test the antimetastatic activity of the compounds in in vivo metastatic models.
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Methods
Virtual re-docking
Surflex-Dock [234, 244] was used to generate high-accuracy docked
conformations of the ICLGa compounds, as well as the ECLVS and EVS14
compounds. Compound structures were generated in Sybyl (Tripos) and
subjected to 2500 iterations of steepest descent minimization. Compound
conformation was randomized using the Surflex-Dock "random" command to
generate ten random conformations of each compound . The ligand-based
protomol targeting the intracellular surface of the constitutively active N119S
CXCR4 described in the virtual screening protocol in Chapter III was reused for
this procedure for ICLGa compounds. A novel protomol targeting the residues
listed in Table 24 was designed to dock the compounds targeting the
extracellular surface of CXCR4. Surflex-Dock [234, 244] was used to dock the
ten random conformations of each com pound using 5 randomized starting
positions. The top 200 scored poses produced by the Surflex-Dock [234, 244]
protocol were collected for each compound . The top 5 for each compound were
then subjected to distance analysis on either the extracellular or intracellular
surface and used to identify CXCR4 residues within 3 A of the compounds.
Transfection and generation of 300.19 stable cell lines expressing
mutations of hCXCR4-GFP
Site-specific mutations of CXCR4 and their effects on inhibitor function
and cell phenotype were investigated using 300.19 cell lines overexpressing
stably transfected hCXCR4-GFP mutants. Residues identified in the virtual re-
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Table 24: Extracellular Residues of CXCR4 used in protomol development
in Surflex. Residues on CXCR4 within 15 A of a centroid placed on the
extracellular surface of CXCR4 were used to develop a residue based protomol
targeting the extracellular surface of the receptor.

338

Table 24: Extracellular Residues of CXCR4 used in protomol development
in Surflex.
Residue

1
2
3
4
5
21
22
23
24
25
26
27
28
29
31
102
104
105
106
107
109
110
113
116

Amino
Acid
Met
Glu
Gly
lie
Ser
Tyr
Asp
Ser
Met
Lys
Glu
Pro
Cys
Phe
Glu
Trp
Phe
Gly
Asn
Phe
Cys
Lys
His
Tyr

Residue

171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193

Amino
Acid
Asp
Phe
lie
Phe
Ala
Asn
Val
Ser
Glu
Ala
Asp
Asp
Arg
Tyr
lie
Cys
Asp
Arg
Phe
Tyr
Pro
Asn
Asp
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Residue

194
195
196
197
198
199
200
203
263
266
267
270
271
276
277
280
281
282
283
284
285
286
288

Amino
Acid
Leu
Trp
Val
Val
Val
Phe
Gin
His
Ser
Leu
Leu
lie
Lys
Phe
Glu
Val
His
Lys
Trp
lie
Ser
lie
Glu

screening protocol for site directed mutagenesis are listed in Table 25 . Additional
mutants were developed based on distance calculations between the intracellular
surface of CXCR4 and the comparable interface surface of Gai , which are also
listed in Table 25. PCR-based site- directed mutagenesis was utilized to
generate sequence confirmed plasm ids using primers listed in Tables 26 and 27.
PCR-based site-directed mutagenesis was carried out using the followed
parameters for each sample: 5 IJI 10X Thermo Pol Buffer, 1 IJI 100 mM MgS04,
2.5 mM dNTPs, 1 IJI Deep Vent Polymerase, 2 IJI 50 ng/IJI Template DNA, 1 IJI
each of Sense and Anti-sense primer and 31 IJI Millipore H20. PCR was run
using the following specifications: an initial denaturing step of 4 min at 95 °C,
followed by 20 repetitions of 45 s 95 °C, 1 min 54 °c , 6 min 72 °C, and a final
annealing step of 15 min at 72 °C. 300 .19 cells were maintained as suspension
cultures in RPMI supplemented with 10% FBS , 100 U/ml penicillin and 100 Ilg/ml
streptomycin , and 55 IlM of 2-mercaptoethanol. Transfections were performed by
electroporation . The stable cell lines are maintained in the presence of 1 mg/ml
of G418. Cells are cultured in complete medium for 24 hrs after transfection and
used for microscopy. The cell surface expression of hCXCR4 is also determined
by incubating receptor or parental cells with 12G5 Ab followed by PE labeled
secondary Ab as well as detection of protein GFP tag and expression was
analyzed by FACS (BD Biosciences).
Chemotaxis analysis
Chemotaxis analysis for suspension 300.19 cells expressing hCXCR4GFP mutants were performed as previously described in chapter 2.
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Table 25: Residues identified for SOM. Residues identified in the virtual
redocking protocol which established close contacts with the EClVS compounds
are listed in the first column. Close contact residues interacting with the IClVS
compounds are listed in the second column. Residues which were identified as
within 2

A of the Gai G-protein subunit in the N 119S-G-protein hetero trimer

homology model are listed in the third column.
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Table 25: Residues identified for SOM.

ECl

ICl

Gai

Val177

Lys239

Lys234

Ser178

Thr240

Arg322

Glu179

Ala307

Lys327

Phe189

Lys308

Lys333

Asn192

Phe309

Ser341

Leu194

Ser338

Ser351

Phe276

Ser352

His281
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Table 26: CXCR4 ECl SOM plasmids. Plasmids utilized in PCR based site
directed mutagenesis SOM of CXCR4 to mutate residues of the extracellular
region of CXCR4 identified by virtual redocking. Listed with mutant and sense
and anti-sense plasmids for development of SOM for each residue.

343

Table 26: CXCR4 ECLSDM plasm ids.
Mutant

Direction

Plasmid

Sense

5'-CTTIGCCAACGCCAGTGAGGCAGA-3'

Anti-sense

5'-TCT GCC TCA CTG GCG TTG GCA AAG-3'

Sense

5'-TIC TAC CCC GCT GAC TIG TGG GTG G-3'

Anti-sense

5'-CCA CCC ACA AGT CAG CGG GGT AGA A-3'

Sense

5'-GGT GTG AGG CTG AGA ACA CTG TGC A-3'

Anti-sense

5'-TGC ACA GTG TTC TCA GCC TCA CAC C-3'

Sense

5'-GAA CAC TGT GGC CAA GTG GAT TIC CA-3'

Anti-sense

5'-TGG AM TCC ACT TGG CCA CAG TGT TC-3'

Sense

5'-TTG CCA ACG TCG CTG CGG CAG ATG-3'

Anti-sense

5'-CAT CTG CCG CAG CGA CGT TGG CAA-3'

Sense

5'-GAC CGC GCC TAC CCC AAT GAC GCG TGG GTG-3'

Anti-sense

5'-CAC CCA CGC GTC ATT GGG GTA GGC GCG GTC-3'

V177A

N192A

F276A

H281A

S178AE179A
F189AL194A
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Table 27: CXCR4 ICL 80M plasmids. Plasmids utilized in PCR based site
directed mutagenesis SDM of CXCR4 to mutate residues of the intracellular
region of CXCR4 identified by virtual redocking. Listed with mutant and sense
and anti-sense plasm ids for development of SDM for each residue.
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Table 27: CXCR4 ICL 80M plasmids.
Mutant
K234A
K239A
K239AT240A
T240A
A307E
K308A
F309A
A307EK308A
K308AF309A
A307EK308AF309A
R322A
K327A
K333A
S338A
S341A
S351A
S352A
S351AS352A

Direction

Plasmid

Sense
Anti-sense
Sense
Anti-sense
Sense
Anti-sense
Sense
Anti-sense
Sense
Anti-sense
Sense
Anti-sense
Sense
Anti-sense
Sense
Anti-sense
Sense
Anti-sense
Sense

5'-GGC CAC CAG GCG CGC MG GCC CT-3'
5'-CCG GTG GTC CGC GCG TTC CGG GA-3'
5'-MG GCC CTC GCG ACC ACA ATC-3'
5'-TTC CGG GAG CGC TGG TGT TAG-3'
5'-GCG TTC CGG GAG CGC CGG TGT TAG TAG GGG TA-3'
5'-CGC MG GCC CTC GCG GCC ACA ATC ATC CCC AT-3'
5'-MG GCC CTC MG GCC ACA ATC ATC C-3'
5'-TTC CGG GAG TTC CGG TGT TAG TAG G-3'
5'-GCT TTC CTT GGA GAG AM TTT AM-3'
5'-CGA MG GM CCT CTC TTT AM TTT -3'
5'-TTC CTT GGA GCC GCA TTT AM ACC-3'
5'-MG GM CCT CGG CGT AM TTT TGG-3'
5'-TTG GAG CTA AGG CTA AM CCT CTC C-3'
5'-MC CTC GGC TTC GAT ATT GGA GAT G-3'
5'-TTT CCT TGG AGA GGC ATT TM MC CTC TGC CG-3'
5'-AM GGA ACC TCT CCG TMATT TTG GAG ACG GG-3'
5'-TTT CCT TGG AGC CGC AGC TM MC CTC TGC CC-3'
5'-AM GCA ACC TCG GCG TCG ATT TTG GAG ACG GG-3'
5'-TTT CCT TGG AGA GGC AGC TM MC CTC TGC CC-3'

Anti-sense

5'-AM GGA ACC TCT CCG TCG ATT TTG GAG ACG GG-3'

Sense
Anti-sense
Sense
Anti-sense
Sense
Anti-sense
Sense
Anti-sense
Sense
Anti-sense
Sense
Anti-sense
Sense
Anti-sense
Sense
Anti-sense

5'-GTG AGC GCA GGG TCC AGG CT-3'
5'-CAC TCG CGT CCC AGG TCG GA-3'
5'-GGG TCC AGC CTC GCG ATC CTC TCC AM-3'
5'-CCC AGG TCG GAG CGC TAG GAG AGG TTT-3'
5'-CCC AGG TCG GAG CGC TAG GAG AGG TTT-3'
5'-TAG GAG AGC --- CCT TTC GCT G-- -3'
5'-GGT GGA CAT GCA TCT GTT TCC ACT -3'
5'-CCA CCT GTA CGT AGA CM AGG TGA-3'
5'-TCA TCT GTT GCC ACT GAG TCT G-3'
5'-AGT AGA CM CGG TGA CTC AGA C-3'
5'-AGT TTT CAC GCC AGC CTA CG-3'
5'-TCA AM CTG CGG TCG GAT GT-3'
5'-TTT CAC TCC GCC CTA CAT CAT -3'
5'-AM GTG AGG CGG GAT GTA GTA-3'
5'-CM GTT TTC ACG CCG CCC TAC ATC ATC AT -3'
5'-GTT CM MG TGC GGC GGG ATG TAG TAG TA-3'
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Cell signaling analysis
Cell signaling by CXCR4 was investigated by assessment of intracellular
calcium mobilization as seen in chapter 2.
Molecular dynamics
Fully solvated lipid bilayer molecular dynamics simulations of mutated
CXCR4 structures were performed using the AMBER suite of programs using the
parm99 force field [284]. As previously described in chapter 2. Calculations were
performed on servers from the Cardinal Research Cluster.
Development of animal model for CXCR4 dependent cancer metastasis in
lungs.
Lewis lung carcinoma, B16F10 melanoma and TC-1 cervical cancer
carcinoma, mouse cell lines known to metastasize to lungs in mice models, were
screened for CXCR4 cell surface expression using flow cytometry based surface
receptor staining using a flurochrome labeled antibody to mouse CXCR4
receptor. TC-1 cervical cancer carcinoma cell lines were selected for tail vein
injection studies.
Toxicity of lead compounds was assessed by intraperitoneal injection of
compounds at an initial dose of 5 mg kg- 1 body weight, followed by a second
dose two days later of either 20 mg kg- 1 body weight or 40 mg kg- 1 body weight.
Toxicity was assessed by loss of body weight and development of signs of
physical distress including lethargy and signs of illness over a period of 3 weeks.
Antimetastatic compound activity was assessed using a mouse pulmonary
metastatic cancer model. In this model, 21 days of daily intra-peritoneal injection
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of AMD3100, ECLVS14, ICLGa28 or ICLGa36 (5 mg kg- 1 body weight) were
followed by injection of 5 x 105 TC-1 cells intravenously into tail veins of C57BI/6
mice. On day 21 post tumor challenge, mice were sacrificed and lungs were
perfused and stored in formalin for 16 hours prior to transfer to 70% ethanol.
Tumors were counted by magnifying glass, microscopy and size was measured
by digital caliper. The total number of tumors counted in all the five lung lobes of
an individual mouse was presented as tumor incidence and addition of the mean
tumor sizes were done to calculate cumulative tumor size which was presented
as tumor burden for each mouse.
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Results
Virtual Re-docking analysis identifies potential critical residues on the
extracellular and intracellular surfaces of CXCR4.
Virtual screening can produce more information than just the placement of
a single compound in a binding site. The results of a virtual screen are frequently
presented by the program as a list of the top scored conformations of the
individual compounds, but the number of compounds returned in a given screen
is a variable that can be set by the user. As can be seen in Figure 75, there is
significant diversity in the poses produced by docking a single compound into a
receptor. Our hypothesis is that by docking multiple conformations of active
compounds into the active site of the receptors, we will be able to identify specific
sites which are essential to receptor activity. In essence we will be virtually
screening the residues of the active sites to identify potential targets for site
directed mutagenesis analysis under the assumption that because the natural
function of these residues is interrupted by the anti-CXCR4 compounds, their
interruption by site directed mutagenesis could produce similar results.
To this end, we employed a high-intensity docking protocol using SurflexDock [234, 244] to identify CXCR4 amino acid residues within two

A of the

top

five scored conformations of each compound. The high-intensity docking protocol
incorporated ten randomized starting conformations for each compound and five
unique starting positions for the initial fragment placement in the flexible docking
protocol of Surflex-Dock. The extracellular-targeted compounds most frequently
interacted with nine residues illustrated in Figure 76. Compounds primarily
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Figure 75: Virtual screening can be used to assess the interaction of
multiple conformations of a single compound within an active site. By
inspecting the position of multiple compounds in an active site, additional
information about the receptor can obtained, identifying specific interaction
residues which can affect phenotypical changes through many different
compounds. A) The top 10 scored conformations of ECLVS14 produced by
Surflex-Dock, placed in the extracellular surface of the receptor. B) The top 10
scored conformations of ICLGa36 produced by Surflex-Dock, placed in the
extracellular surface of the receptor.
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Figure 75: Virtual screening can be used to assess the interaction of
multiple conformations of a single compound within an active site.
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Figure 76: Virtual rescreening of extracellular loop targeted compounds
identifies specific contact residues. Scores are presented as percentage of
compound poses within two

A of the residue for the entire set of compounds (in

blue), those with anti-chemotaxis activity (in red) and those with anti-calcium
mobilization activity (in green). Compounds primarily interacted with nine specific
residues of ECL2 and ECL3.
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Figure 76: Virtual rescreening of extracellular loop targeted compounds
identifies specific contact residues.
100

90

80
70

~------------~~

__~------~__~~__~------~----~__-------

60

~r-----------~~

__

50

~------------~~

__~--__~~__~~__~------~----~__-------

40

~~----------~~

__~--__~~__~~__~------~----~__~-----

30

~------------~~

__

20

~-.-----.----~~__

~------~

~--

__

~~

__

~~

__

~------~----~

__-------

____

10

I

o

•

I

~El TYR SER/VIE PRO~SN VAL SER GLU ALA ARGASP PHE PRC ASN LEU TRP VAL LYS PHE GLU VAL HIS LYS ILE SER

1

21 23

24 27 176 177 178 179 180 183 187 189 191 192 194 195 196 271 276 277 280 281 282 284 285

- Full

- Chemotaxis

353

- Calcium

contacted the second and third extracellular loops along with the N-terminal
methionine. The most frequently interacting residues were Va1177, Ser178,
Glu179 on the N-terminal side of the second extracellular loop and Phe189,
Pro191, Asn192 and Leu 194 on the C-terminal side of the loop. Phe276 and
His281 on the third extracellular loop also frequently interacted with the
compounds. It is important to note that there was relatively little overlap between
the compounds with anti-chemotaxis activity and those with anti-calcium
signaling activity.
The intracellular-targeted compounds primarily interacted with six residues
illustrated in Figure 77. The six most common contact points were located on 3
regions of the intracellular surface. Lys239 and Thr240 were located on the
intracellular surface of TM6. Ala307, Lys308 and Phe309 are located on the
intracellular surface of TM7. Ser338 was located on the C-terminal tail of CXCR4.
As these compounds represent a structurally diverse initial virtual screen , the
contact frequencies seen in the virtual re-docking were substantially decreased
when compared to screening results of the structurally similar extracellulartargeting compounds. There is a wider diversity in contact residues between
compounds with anti-chemotaxis activity and anti-calcium signaling , with anticalcium signaling compounds coming into more frequent contact with Lys239,
Ala307 and Phe309. In contrast, contact with residues Lys308 and Ser338
seems to favor anti-chemotaxis activity. It is also important to note that the
docked position of these compounds is in direct conflict with the docked position
of a key projection of G-protein Gai into the intracellular surface of CXCR4.
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Figure 77: Virtual rescreening of intracellular loop targeted compounds
identifies specific contact residues. Scores are presented as percentage of
compound poses within two

A of the residue for the entire set of compounds (in

Blue), those with anti-chemotaxis activity (in Red) and those with anti-calcium
mobilization activity (in Green). Compounds primarily interacted with six residues
on the intracellular surface of TM6 and TM7 and the C-terminal tail of the protein .
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Figure 77: Virtual rescreening of intracellular loop targeted compounds
identifies specific contact residues.
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We also sought to investigate the interaction between CXCR4 and Gai.
Using the model developed for th is interaction, we sought to identify close
contact residues of CXCR4 important to the interaction of the two proteins.
Seven CXCR4 residues were identified that were within 2

A of Gai: ICL3 residue

Lys 234, and C-terminus residues Arg322, Lys327, Lys333, Ser 341, Ser 351 ,
and Ser 352.
Analysis of CXCR4 mutants through molecular dynamics simulations

The virtual redocking protocol identified several amino acid residues which
were consistent interaction points for our anti-CXCR4 compounds. Modulation of
CXCR4 through interaction with these residues produced significant alterations in
the phenotype of the receptor. Thus, in line with our SSOO method , we sought to
further investigate and characterize the structure of our receptor by in silico
mutagenesis of the native structure of CXCR4, to investigate whether mutations
of these residues would similarly alter its conformation. As mentioned in
Chapters II and III , the native CXCR4 and N 119S structures were developed by
Dr. Napier via homology modeling based upon the high resolution crystal
structure of rhodopsin [288].
Molecular Dynamics simulations of intracellular CXCR4 mutants

We hypothesize that disruption of residues which are purported to interact
with compounds targeting the intracellular and extracellular surfaces of the
receptor as well as the residues identified as being within binding distance of the
Gai G-protein subunit will produce significant alteration of the structure of
CXCR4. To investigate this hypothesis, mutations of the native CXCR4 structure
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were investigated by molecular dynamics as described in Chapters II and III.
However, rather than the ten 500 ps production runs conducted in the compound
docking dynamics studies in the previous Chapters, twenty production runs of
500 ps were conducted for a 10 ns total production run for each mutant to assess
structural conformation .
Molecular dynamics simulations of CXCR4 intracellular and extracellular
surface residue mutations form stable conformations of the receptor.
The final averaged structures of the mutated CXCR4 conformations from
the 10 ns molecular dynamics simulations are shown in Figure 78 along with the
location of the mutated residues. The mutated CXCR4 conformations were
energetically stable throughout the production run (data not shown), indicating
that the simulation was well-equilib rated prior to production analysis.
Conformational stability of the mutated CXCR4 structures were investigated
using root mean square deviation (RMSD) analysis, (data not shown). RMSD
values as measured at the Ca position remained stable for the majority of the
production runs , with the final average structure representative of the trajectory
after approximately 1.5 ns. The helical domains were stable through the
production run , and the majority of structural variation was in the loop regions.
Conformation of the mutant receptors will be presented in reference to the
inactive native structure and the constitutively active N119S conformations. As
discussed in Chapters II and III , significant differences exist between these
structures. Briefly, the N-terminall3-sheet is more compact for N119S than
native. The proximal portion the N-terminus is displaced towards ECl1 for
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Figure 78: Final averaged structures of molecular dynamics of mutated
CXCR4. Average structure of CXCR4 presented in cyan ribbon . Mutant residues
are highlighted in ball-stick rendering . A) V177A S) S178A C) E179A D) F189A
E) N192A F) L 194A G) K234A H) K239A I) T240A J) F276A K) H281A L) A307E
M) K308A N) R322A 0) K327A P) K333A Q) S338A R) S341A S) S351A T)
S352A U) V177 A-F189A-L 194A V) V177A-F189A-L 194A-F276A W) V177 AF276A X) S 178A-E 179A Y) S 178A-E 179A-H281 A Z) S 178A-E 179A-N 192A AA)
S178A-E179A-N192A-H281A AS) F189A-L 194A AC) F189A-L 194A-F276A AD)
N192A-H281A AE) K239A-T240A AF) A307E-K308A AG) A307E-F309A AH)
A307E-K308A-F309A AI) K308A-F309A AJ) S351A-S352A
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Figure 78: Final averaged structure of molecular dynamics of mutated
CXCR4. A) V177A B) S178A C) E179A D) F189A E) N192A F) L 194A G)
K234A H) K239A I) T240A J) F276A K) H281A L) A307E M) K308A N) R322A

0) K327A P) K333A Q) S338A R) S341A S) S351A T) S352A U) V177AF189A-L 194A V) V177 A-F189A-L 194A-F276A W) V177 A-F276A X) S178AE179A Y) S178A-E179A-H281A Z) S178A-E179A-N192A AA) S178A-E179AN192A-H281A AB) F189A-L 194A AC) F189A-L 194A-F276A AD) N192AH281A AE) K239A-T240A AF) A307E-K308A AG) A307E-F309A AH) A307EK308A-F309A AI) K308A-F309A AJ) S351A-S352A

360

361

362

363

364

365

366

367

368

369

N119S. ECl1 is conserved as a short bridging loop between TM2 and TM3 and
ECl2 is conserved as a two-stranded anti-parallel

~-sheet

structure. ECl3 is a

disordered loop between TM6 and TM7. The apex of this loop is in close
proximity to the distal

~

sheet structure of the N-terminus in the native

conformation, but is displaced towards the proximal portion of the N-terminus in
the N11 9S conformation. As a result, constitutively-active N11 9S is more open at
the extracellular surface, allowing greater access to the acidic residues of the
extracellular termini of the TM regions. ICl1 forms a short loop joining TM1 and
TM2, and the apex is displaced towards the cytoplasmic terminus of TM3 for
N119S. ICl2 is a more extended loop that joins TM3 and TM4, with an apex that
occurs towards the midpoint of the loop in the native conformation and more
proximally in the N11 9S conformation. The apex of the loop is oriented towards
ICl1 in the native conformation, but is displaced away from the center of the
receptor in the N119S conformation. Kinks in the structure of ICl3 in the N119S
conformation produce increased angles at residues lys 230 and Ala 237,
causing the apex of ICl3 to be displaced upward and away from the center of the
receptor. The C-terminal region produces an eighth helix aligned perpendicular to
the rest of the helices and parallel with the lipid surface. In the N11 9S
conformation torsion at Ser313 causes this eighth helix to lose a-helix
conformation, and the distal C-terminal is brought into much closer contact with
the cytoplasmic termini of TM1 and TM4.
Mutation of the distal end of ICl3 alters CXCR4 structure.
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Significant variations characterized the four mutants targeting ICL3:
K234A, K239A, T240A and K239A-T240A. Although the majority of the structure
mirrored the native conformation of the receptor, the mutants exhibited
differences in the structure and positioning of the N-terminus, ICL 1, ICL2, ICL3
and ECL3. The N-terminus of the K234A mutant adopted the more compact
structure and orientation. This region in the K239 mutant was more distended
than the native structure converting the three strand anti-parallel terminal portion
of the structure to adopt a two strand anti-parallel conformation. The T240 mutant
N-terminus was displaced towards ECL3 as in the N119S conformation, but the
p-sheet adopted the native conformation. The mutants primarily maintained the
conserved ICL 1 loop, although the K239A-T240A mutant shifted the apex of this
loop towards the center of the receptor. K234A and K239A-T240A mutants
maintained the native conformation of ICL2, but the apex of the loop was shifted
towards ICL 1 by K239A and T240A. The T240A mutant shifted the apex of ICL3
towards the C-terminus and the center of the receptor, while the K234A, K239A,
and K239A-T240 mutants shifted the apex of this loop away from the C-terminal
region and towards ICL2. Finally, the K239A-T240A mutant shifted the apex of
ECL3 towards the N-terminal region, while T240A caused an opposite effect,
shifting the Apex of the loop away from the N-terminus of the receptor.
These surface changes of the receptor suggest that the mutations are
causing CXCR4 to adopt different conformations. There were relatively few
modifications of receptor structure caused by the K234A mutation, but those
changes resulted in a more compact N-terminus producing a more exposed
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CXCL 12 binding site and a more open Gai binding site at the intracellular
surface. The K239A mutation seemed to primarily affect the N-terminal region of
the receptor, resulting in a more open intracellular surface, but primarily
maintaining the native conformation. The T240A mutation seems to drive CXCR4
more towards a more inactive form, shifting the N-terminus and ECL3 to produce
a distortion of the extracellular surface, but producing greater shifting of the
intracellular loops toward ICL 1 and the center of the receptor than in the native
receptor, producing obstructions to G-protein binding. K239A-T240A mutation
produces greater interaction between the N-terminus and ECL3, producing
greater exposure of the CXCL 12 ligand binding surface, but greater interaction
between ICL2 and ICL3, suggesting that while the extracellular surface is more
receptive to ligand binding, the intracellular surface would be less receptive to
signal transduction.
Conformational differences were noted with respect to the
intermembranous segments of the mutant CXCR4 structures as well. Although
the conformations primarily conformed to the native structure of the receptor,
several key differences were apparent. As depicted in Figure 79a , the K234A
mutant produced no gross deviations from native CXCR4 TM structure. The
same was true for the K239A mutant shown in Figure 79b, which aside from a
more linear TM4 conformation produced little variation from the native structure.
The T240A and K239A-T240A mutants produced more significant variations in
Figure 79c-79d . The T240A mutant produced a shift at the apex of TM4 though
additional angularity of the helix at Thr168. An additiona l kink in TM5 was
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Figure 79: Transmembrane regions of the ICL3 mutants adopt a similar
conformation to native CXCR4. Reduced representations of receptor
transmembrane helices are presented: native CXCR4 in green, N119S in red, the
K234A conformation in teal, K239A conformation in white, T240A conformation in
magenta, and the K239A-T240A conformation in blue. A) K234A, 8) K239A, C)
T240A, D) K239A-T240A
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Figure 79: Transmembrane regions of the ICL3 mutants adopt a similar
conformation to native CXCR4. A) K234A B) K239A C) T240A D) K239AT240A
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produced at Pro211 while in the K239A-T240A mutant this helix was tiled
towards TM4. The basal termini of TM6 and TM7 in both mutants were shifted
towards the intracellular surface of the membrane.
The TM regions of the receptors were further characterized by
measurement of interhelical distances as depicted in Table 28 . At the
extracellular surface, K234A mutation primarily altered TM1 and TM5 positioning ,
modulating distances based on these TM regions and reproducing the N119S
interhelical distance for TM1-2 , TM1-3 , and TM1-4. K239A mutation seemed to
have widespread effects, modulating interhelical distances corresponding to
TM1 , TM4 and TM6, reproducing the N119S interhelical distance for TM1-2 ,
TM1 -4, TM1-5, TM2-4, and TM5-6. T240A and K239A-T240A did not produce as
much change at the extracellular surface of the receptor, primarily modulating
TM6 position.
Interhelical distances at the intracellular surface of the receptor are
illustrated in Table 29 . K234A mutation had relatively few effects on intracellular
interhelical distances, decreasing the TM4-7 distance compared to native and
causing TM1-6 to approach the N119S interhelical distance. K239A produced
similar light effects at the intracellular surface, causing a mild increase in TM6-7
distance, and a decrease in the TM5-6 distance. A more substantial difference
was noted in the T240A mutant, where mutation produced increased interhelical
distances forTM1-7 , TM2-7, and TM6-7 , and decreases in the TM5-6 distance.
Very substantial modifications were noted with the K239A-T240A mutant, as this
mutant produced significant alteration in the positioning of TM7, leading to an
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Table 28: Interhelical distances at the extracellular surface for the ICL3
mutants. Interhelical distances measured at extracellular termini of
transmembrane domains of native CXCR4, constitutively active N119s, and ICL3
mutant structures measured in averaged conformations of dynamically
determined structures. At the extracellular surface, the K234A and K239A
mutants alter the position of TM1.
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Table 28: Interhelical distances at the extracellular surface for the lel3
mutants.
Native

N119S

K234A

K239A

T240A

K239A-T240A

TM1-2

6.5

7.6

7.7

7.4

7.1

6.9

TM 1-3

20.9

22.2

22.4

21.5

21.4

21.7

TM 1-4

21.9

23.3

23.1

23.6

22.7

22.3

TM 1-5

33.6

34.8

33.6

34.5

33.5

34.6

TM 1-6

26.0

25.4

26.7

26.3

26.4

27.6

TM 1-7

15.8

14.6

17.1

17.2

15.3

16.2

TM 2-6

28.7

28.0

28.6

29.3

29.3

29.9

TM 4-6

15.9

15.4

16.7

17.1

17.0

16.3

TM 5-6

11.2

13.1

11.4

12.8

12.3

11.3

TM 6-7

12.1

13.1

11.4

11.1

12.3

12.8
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Table 29: Interhelical distances at the intracellular surface for the lel3
mutants. Interhelical distances measured at intracellular termini of
transmembrane domains of native CXCR4, constitutively active N11 9s, and ICL3
mutant structures of averaged structures dynamically determined structures.
Mutations of residues 239 and 240 altered the position of TM6 and TM?
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Table 29: Interhelical distances at the extracellular surface for the lel3
mutants.
Native

N119S

K234A

K239

T240A

K239A-T240A

TM 1-5

32.2

33.9

32.7

30.8

31.9

33.6

TM 1-6

20.5

21.3

21.2

20.3

20.7

21.3

TM 1-7

12.2

13.6

11.5

11.9

13.1

13.1

TM 2-5

22.5

25.3

23.0

22.4

23.1

23.8

TM 2-7

11.7

12.3

10.4

11.9

12.7

14.3

TM 3-4

16.0

12.6

15.7

16.2

15.8

14.8

TM 3-6

12.0

13.4

11.6

11.4

11.2

10.7

TM 3-7

21.5

22.2

20.6

21.8

24.3

26.0

TM 4-7

22.3

21.0

20.4

22.3

23.7

24.6

TM 5-6

13.3

12.7

13.3

12.7

12.8

13.1

TM 5-7

24.8

23.7

24.8

24.6

27.3

29.6

TM 6-7

12.3

11.8

12.6

13.4

15.1

17.5
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average increase of 3.4

A for the interhelical distances involving this helix when

compared to the native conformation. This effect seems to correlate across the
mutants, as the interhelical distance between TM6-7 for the K239A mutant
exhibited a mild increase, which was greater in the T240A mutant and greater
still in the double mutant. This suggests that the base of TM6 where K239 and
T240 are located is essential to the maintenance of TM7 position and that these
modifications do substantially affect CXCR4 structure.
Mutations proximal to Helix eight alter TM7 position.
Mutations of the proximal portion of the C-terminal region corresponding to
the beginning of helix eight primarily adopt the native conformation of the
receptor, including maintenance of helical structure in helix 8 in all mutants.
There were a few notable exceptions to conservation of native conformation. At
the N-terminus the A307E mutant adopted a more extended conformation of the
~

sheet, while the A307E-F309A mutant adopts a more compact conformation.

Several of the mutants also altered the conformation of ECl1 , with the A307E
mutant producing a shift of the apex of the loop towards the N-terminus and the
center of the receptor. The K308A mutant adopted a similar conformation,
although the apex of the loop was directed more towards the base of the Nterminus rather than the center of the receptor. Finally, the A307E-K308A mutant
shifted ECl1 opposite the other two mutants and outward from the center of the
receptor. ECl3 was altered in the A307E, A307E-F309A, K308A, and K308AF309A mutants to adopt a conformation more in line with the N11 9S mutant but
shifted away from the n-terminus and outward from the center of the receptor.
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Thus, while the majority of the structures of the extracellular terminus are
maintained in their native conformation in many of the mutants, the A307EF309A, K30BA, and K30BA-F309A produce a mild distortion of the CXCL 12
binding site by altering the position of ECL3. The A307E mutant also seems to
adopt a more inactive conformation, with distortions of the l3-sheet structure of
the N-terminus in addition to the distortion of ECL3 conformation.
On the intracellular surface of the receptor, mutants K30BA, A307EF309A, A307E-K30BA and K30BA-F309A all shifted the apex of ICL2 opposite of
the N119S conformation and towards ICL 1 rather than ICL3 and the C-terminus.
The A307E-K30BA, K30BA-F309A and A307E-K30BA-F309A mutants shifted the
apex of ICL3 away from the C-terminus and towards ICL2, while the K30BA
mutant shifted the apex of the ICL3 loop towards the C-terminus and the center
of the receptor. The structure of the intracellular surface of the mutant
conformations once again primarily maintained the native conformation of the
receptor with a few key differences. The A307E-K30BA and K30BA-F309A
mutants shifted both ICL2 and ICL3 away from the C-terminal region, suggesting
that the G-protein binding site would be more open. K30BA shifted ICL2 away
from the C-terminus but ICL3 towards the C-terminus, distorting the G-protein
binding site.
Structural modifications were seen on the TM regions of CXCR4 in several
of the Helix B mutants illustrated in Figure BO. In TM1 of the K30BA-F309A
conformation, the base of the helix is displaced by an additional kink at Asn56.
The TM4 of the A307E-K30BA mutant adopted an intermediate conformation
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Figure 80: Transmembrane regions of the proximal C-terminal mutants
adopt a similar conformation to native CXCR4. Reduced representations of
receptor transmembrane helices are presented: native CXCR4 in green, N119S
in red, the A307E conformation in white, K30BA conformation in blue, A307EK30BA conformation in orange, A307E-F309A conformation in magenta, K30BAF309A conformation in yellow, and the A307E-K30BA-F309A conformation in tan.
The A307E conformation adopts alterations of TM5 and TM6. The K30BA
conformation adopts alterations of TM1. The A307E-K30BA conformation adopts
alterations of TM4 and TM5. The A307E-F309A conformation adopts alterations
of TM5 and TM6. The K30BA-F309A conformation adopts alterations of TM4 and
TM6. The A307E-K30BA-F309A conformation adopts the transmembrane
structure of the native receptor. A) A307E 8) K30BA C) A307E-K30BA D) A307EF309A E) K30BA-F309A F) A307E-K30BA-F309A
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Figure

so: Transmembrane regions of the proximal C-terminal mutants

adopt a similar conformation to native CXCR4. A} A307E B) K30SA C)
A307E-K30SA D) A307E-F309A E) K30SA-F309A F) A307E-K30SA-F309A
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between that of the native and N 119S conformations of the receptor, while an
additional kink displaced the base of the helix in the K30BA-F309A mutant. The
characteristic bulge of TMS was rotated in the A307E , A307E-F309A and A307EK30BA mutants, suggesting rotation of the helix as a whole. TM6 in the A307E
and A307E-F309A mutants was in a more linear conformation than the native
TM6 , while the apex of the helix was shifted towards TMS in the K30BA-F309A
mutant. Given their proximity to the base of TM7, it was interesting that none of
these mutants produced any gross deviation of this helix.
The interhelical distances of the proximal C-terminal mutants measured at
the extracellular surface are depicted in Table 30 . The A307E mutation produced
the most significant variation from the native conformation, primarily altering
increasing interhelical distances or shifting them to coincide with the expected
value for the N119S conformation by altering positioning of TM1 and TM2. Less
substantial alterations were seen for the K30BA mutation which only increased
the interhelical distances between TM4-6 and decreased the TM4-S distance to
coincide with the N119S conformation. The A307E-K30BA mutant primarily
modulated the TM6 position , increasing the interhelical distance for TM4-6, TM16, and TM2-6. The A307E-F309A mutation shifted the interhelical distances of
TM1-2 and TMS-6 to coincide with the N119S conformation. The K30BA-F309A
mutation acted primarily by modulating the position of TM1, resulting in increased
interhelical distances between TM1-2 , TM1-7 and TM1-6. A307E-K30BA-F309A
produced only minor variations of the extracellular surfaces of the TM regions,
increasing TM4-6 and decreasing TMS-7 and TM6-7.
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Table 30: Interhelical distances at the extracellular surface for the helix 8
mutants. Interhelical distances measured at extracellular termini of
transmembrane domains of native CXCR4, constitutively active N119s, and helix
B mutant structures measured in averaged conformations of dynamically
determined structures. At the extracellular surface, A307E altered TM1 and TM2,
A307E-K30BA altered TM6, K30BA-F309A altered TM1 and A307E-K30BAF309A altered TM6.
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Table 30: Interhelical distances at the extracellular surface for the lel3
mutants.
A307EF309A

K308AF309A

A307EK308AF309A

TM

Native

N119S

A307E

K308A

A307EK308A

1-2

6.5

7.6

7.6

6.7

6.8

7.6

7.3

6.7

5-6

11.2

13.1

12.2

11.2

11.3

13.0

11.4

12.1

6-7

12.1

13.1

12.0

12.2

12.8

11.7

12.7

11.2

1-7

15.8

14.6

17.0

15.7

17.8

15.5

16.7

16.2

4-6

15.9

15.4

15.4

16.6

16.9

15.3

15.9

17.1

4-5

16.8

15.6

15.7

15.7

17.3

16.8

16.4

16.3

2-4

20.6

21.6

22.3

21.0

22.1

20.9

21.3

20.9

1-3

20.9

22.2

22.7

21.3

21.0

20.3

20.8

21.8

5-7

21.4

24.7

21.8

20.7

21.8

22.9

21.8

20.3

1-6

26.0

25.4

27.8

26.6

27.7

24.4

27.1

25.8

2-6

28.7

28.0

30.5

29.6

30.3

28.2

30.1

28.6

386

The interhelical distances of the proximal C-terminal mutants measured at
the intracellular surface are depicted in Table 31 . The A307E mutation had
relatively few effects on interhelical distances, increasing TM6-7 and decreasing
TM1-4 to coincide with the N119S conformation . The K30BA mutant primarily
altered TM7 position, increasing TM3-7, TM4-7, TM5-7, and TM6-7 interhelical
distances. The A307E-K30BA mutation mildly altered TM1 position , resulting in
decreases of the TM1-4 and TM1-5 interhelical distances. The A307E-F309A
mutant primarily altered TM7 position , increasing TM3-7, TM5-7 and TM6-7
interhelical distances, and decreasing the TM1-7 distance. K30Ba-F309A
mutation primarily altered TM6 position, increasing interhelical distance of TM1-6,
TM2-6 , TM4-6 and TM6-7. The A307E-K30BA-F309A mutant produced
significant variation of TM6 and TM7 position , increasing the distances of TM1-7,
TM2-7, TM3-7, and TM4-7 and decreasing the distance of TM2-6 andTM4-6.
Helix B mutations primarily maintained the inactive conformation of the
receptor, although several of the mutations possessed alterations of TM
structures. At the extracellular surface, A307E altered TM1 and TM2 , A307EK30BA altered TM6, K30BA-F309A altered TM1 and A307E-K30BA-F309A
altered TM6. At the intracellular surface, K30BA, A307E-F309A altered TM7,
A307E-K30BA altered TM1 , K30BA-F309A altered TM6 and A307E-K30BAF309A altered TM6 and TM7 .This suggests that the conformations adopted by
the mutant structures cou ld be more inactivated than the native structure due to
altered interhelical distances, especially in mutants A307E-F309A and A307EK30BA-F309A where disruption of TM7 could alter signal transduction.
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Table 31: Interhelical distances at the intracellular surface for the helix 8
mutants. Interhelical distances measured at intracellular termini of
transmembrane domains of native CXCR4, constitutively active N119s, and helix
B mutant structures of averaged structures dynamically determined structures. At
the intracellular surface, K30BA, A307E-F309A altered TM7, A307E-K30BA
altered TM1, K30BA-F309A altered TM6 and A307E-K30BA-F309A altered TM6
and TM7.
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Table 31: Interhelical distances at the intracellular surface for the helix 8
mutants.
A307EF309A

K308AF309A

A307EK308AF309A

TM

Native

N119S

A307E

K308A

A307EK308A

2-6

10.7

12.9

10.5

10.9

10.7

11.3

13.4

8.9

2-7

11.7

12.3

12.0

15.4

11.6

11.8

13.0

12.9

3-6

12.0

13.4

11.4

11.3

11.2

11.3

11.4

13.2

1-7

12.2

13.6

12.3

12.5

11.6

11.2

12.7

13.2

6-7

12.3

11.8

13.3

17.6

12.8

15.1

14.0

12.7

1-4

18.2

17.7

17.3

17.4

17.5

17.4

18.2

16.8

4-6

19.5

17.6

18.3

18.6

18.9

19.0

21.3

17.9

1-6

20.5

21.3

20.7

19.9

20.5

21.1

21.7

18.5

3-7

21.5

22.2

21.5

26.7

20.4

23.2

22.6

24.4

4-7

22.3

21.0

22.0

25.4

21.5

22.1

23.5

23.8

5-7

24.8

23.7

24.4

28.6

24.4

26.9

25.2

24.7

1-5

32.2

33.9

31.9

30.7

30.9

32.6

31.6

30.3
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Mutations of the distal C-terminus alter the structure of CXCR4 at TM7.
Mutations of the distal tail of the C-terminus primarily preserved the
structure of the native receptor. However, several of the mutants produced
variations of the native conformation at the extracellular and intracellular surfaces
of the receptor. The N-terminus of the receptor was predominantly preserved
amongst the distal C-terminal mutants, except for the R322A mutant who altered
the N-terminal

~-sheet

to a more compact structure, much like the N119S

conformation. ECl1 was also altered by several of the mutants, with the apex of
the loop being repositioned towards the apex of TM1 in the S338A mutant. The
S341A and S351A mutants both shifted the apex of the loop towards the Nterminus, while the S351A-S352A mutant shifted the apex of this loop away from
the N-terminus. In addition, K327A, S351A, S352A, and S351A-S352A mutants
all caused ECl3 to adopt a conformation reminiscent of the N119S conformation,
but shifted away from the N-terminus. Thus, K327 A and S352A feature disruption
of the CXCl12 binding pocket by distortion of ECl3, while S351A and S351AS352A also disrupt this structure while also modulating ECl1 structure,
producing a more open, but potentially more unstable extracellular surface.
At the intracellular surface of the receptor, K333A shifts the apex of ICl1
downwards while S351A-S352A displaces the apex of the loop towards the Cterminus. ICl2 adopts a variety of conformations in the different mutants. R322A
and S341 A shift the apex of ICl2 into a conformation opposite that of the N119S
structure, and away from ICl3. K327A, K333A and S352A all feature a more
compact conformation of the loop, which is displaced downwards from the native

390

position. There is a similar variety of positions for ICL3, with K327 A, R322A, and
K333A shifting the apex of the loop towards the C-terminus and the center of the
receptor, while S338A, S351A, and S352A each shift the apex of the loop away
from the C-terminus and towards ICL2. Finally, mutants R322A, S341A, S351A,
and S351A-S352A produce an increased angle in Helix 8, shifting the distal end
of the helix away from the cell membrane, and displacing the loop outwards from
the native conformation.
Modifications of CXCR4 structure were also seen in the TM regions of the
distal C-terminal mutations depicted in Figure 81. In the TM1 of the R322A
mutant, the apex of the helix was displaced by a kink at Asn56, while the S352A
mutant TM1 was displaced towards TM2. TM2 is also modulated by several of
the mutants. In the confo rmation of the S338A mutant, the apex of the helix is
shifted outwards away from the center of the receptor. In the S352A mutant
conformation, the helix is more bowed in the direction ofTM4. In the S351A and
S351A-S352A mutant conformations, the base of the helix aligns with the native
conformation, but the apex of the helix is aligned with the N119S conformation . In
the conformation of TM4 in the R322A mutant, a kink displaces the base of the
helix, while an increased angle of TM4 at Leu165 results in an outward
displacement of the helix in the S338A and S341A mutants. The position ofTM7
is shifted towards TM1 in the S338A mutant.
The interhelical distances of the native, N119S and distal C-terminal
mutants at the extracellular surface are listed in Table 32 . The R322A mutant
had almost no position on the interhelical distances, essentially maintaining the
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Figure 81: Transmembrane regions of the C-terminal mutants adopt a
similar conformation to native CXCR4. Reduced representations of receptor
transmembrane helices are presented: native CXCR4 in green, N119S in red, the
R322A conformation in teal, K327 A conformation in magenta , K333A
conformation in white, S338A conformation in yellow, S341 A conformation in
orange, S351A conformation in blue, S352A conformation in tan, and the S351AS352A conformation in violet. The R322A, K327 A, K333A, S338A, S341 A,
S351A, S352A, and S351A-S352A mutant conformations adopt the
transmembrane structure of the native receptor. A) R322A 8) K327A C) K333A
D) S338A E) S341A F) S351A G) S352A H) S351A-S352A
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Figure 81: Transmembrane reg ions of the C-terminal mutants adopt a
similar conformation to native CXCR4. A) R322A B) K327 A C) K333A D)
5338A E) 5341A F) 5351A G) 5352A H) 5351A-5352A
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Table 32: Interhelical distances at the extracellular surface for the distal C
terminus mutants. Interhelical distances measured at extracellular termini of
transmembrane domains of native CXCR4, constitutively active N119s, and
distal C terminus mutant structures measured in averaged conformations of
dynamically determined structures. At the extracellular surface, K237 A altered
TM1 and TM2, K333A alter TM1, S338A alters TM1 and TM2, S341 A alters TM3,
S351A alters TM1 and TM2, S351A-S352A alters TM1 and TM2.
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Table 32: Interhelical distances at the extracellular surface for the distal C
terminus mutants.

5351 A-

TM

Native

N1195

R322A

K327A

K333A

5338A

5341A

5351A

5352A

1-2

6.5

7.6

6.7

8.0

6.9

7.3

7.1

10.8

7.0

8.6

1-7

15.8

14.6

16.6

16.5

17.0

19.4

16.4

16.6

16.1

18.2

2-3

18.3

18.6

18.4

18.8

18.0

20.0

19.1

18.1

18.4

18.1

2-7

19.1

19.3

19.8

20.5

19.7

22.6

19.9

21.8

19.7

22.2

2-4

20.6

21.6

21.1

20.8

21.1

23.6

21.4

20.9

20.9

21.0

1-3

20.9

22.2

21.0

22.3

21.5

22.6

21.8

22.5

21.5

22.1

1-4

21.9

23.3

22.3

22.4

23.0

24.8

22.7

22.8

22.4

22.8

1-6

26.0

25.4

26.7

26.7

26.4

28.6

26.5

27.6

27.2

27.1

2-6

28.7

28.0

29.2

29.8

28.7

31.3

29.3

31.6

29.8

30.0

1-5

33.6

34.8

34.3

34.8

33.2

36.0

34.4

35.0

33.8

34.2
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5352A

native conformation of the receptor. More substantial alterations were seen in the
K237A mutant, where TM1 and TM2 were displaced to produce increased
distances in TM1-2, TM1-3 , TM1-5 , TM2-6 , and TM2-7. K333A mutation altered
TM1 position, increasing the TM1-4 and TM1-7 distance. S338A significantly
altered the extracellular termini of TM1 and TM2 , producing an average
increased interhelical distance of 2.5 A for each of the helices involving TM1 and
TM2. S341 A mutation altered the position of TM3, increasing the distance of
TM1-3 and TM2-3. S351A mutation altered the positions of TM1 and TM2,
increasing the distance ofTM1-2 , TM1-3, TM1-5, TM1-6 , TM2-6 and TM2-7.
S352A mutation had only minor effects on the extracellular surface of the
receptor, increasing the distance only for TM1-6. S351A-S352A mutation altered
the positions of TM 1 and TM2 in a manner similar to the S351 A mutant,
increasing the distance of TM1-2 , TM1-3 , TM1 -6, TM1-7, TM2-6 and TM2-7.
The interhelical distances of the native, N119S and distal C-terminal
mutants at the intracellular surface are listed in Table 33. Two of the mutants
produced relatively little alteration of interhelical distance at the intracellular
surface. The K327 A mutant primarily altered the position of TM6, producing
increased interhelical distances for TM3-6, TM5-6 and TM3-7, while the K333
mutant increased the interhelical distance of TM1-6, while decreasing the
interhelical distance of TM4-7. The rest of the distal C-terminal mutants altered
the position of TM7, producing significant interhelical distance variation between
TM7 and each of the other helices.
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Table 33: Interhelical distances at the intracellular surface for the distal C
terminus mutants. Interhelical distances measured at extracellular termini of
transmembrane domains of native CXCR4, constitutively active N119s, and distal
C terminus mutant structures measured in averaged conformations of
dynamically determined structures. At the intracellular surface, R322A, S338A,
S341A, S351A, S352A and S351A-S352A alter TM7.
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Table 33: Interhelical distances at the intracellular surface for the distal C
terminus mutants

TM

Native

N1195

R322A

K327A

K333A

5338A

5341A

5351A

5352A

5351A5352A

1-4

18.2

17.7

17.0

17.5

17.9

18.3

17.5

17.9

18.2

19.2

1-6

20.5

21.3

21.2

19.5

21.3

21.9

21.1

21.2

21.3

21.0

2-7

11.7

12.3

12.4

12.1

10.9

14.1

12.5

13.7

13.2

13.1

3-6

12.0

13.4

11.1

13.2

11.4

11.2

11.4

11.5

11.4

11.4

3-7

21.5

22.2

22.5

22.4

19.7

25.6

22.4

25.1

25.2

22.1

4-7

22.3

21.0

22.0

22.3

21.0

24.4

22.7

23.9

24.0

23.9

5-6

13.3

12.7

12.6

14.3

12.9

13.3

13.1

12.6

12.6

12.8

5-7

24.8

23.7

25.5

25.5

23.5

29.7

26.5

28.2

27.6

25.5

6-7

12.3

11.8

14.4

12.2

12.2

17.2

14.6

16.6

16.2

13.9
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While the distal C-terminal mutants maintain the native conformation of
the receptor, the increased distance between TM7 and the other helices
suggests that the receptor may have difficulty successfully transducing signals
from the extracellular surface to the intracellular surface due to displacement of
the TM7.

Mutations of polar extracellular mutants alter the intracellular position of
TM7 and the extracellular position of TM1 and TM2
Mutations of the polar and charged groups of the extracellular surface of
CXCR4 produced significant alteration of several facets of the extracellular
surface. Mutation of E179A and S178A produced a more compact N-terminal
conformation matching the N119S conformation the receptor. In contrast, S 178AE179A mutation produced a less compact conformation than the native receptor.
The N192A-H281A mutation produced a compact N-terminal region matching the
N119S conformation, as well as displacing the N-terminus of the receptor
towards the extracellular surface of the TM region as in the N119S conformation.
The E179A, H281 A, N 192A-H281 A, S 178A and S 178A-E 179A-N 192A-H281 A
mutations shifted the apex of ECL3 away from the N-terminus and outward from
the center of the receptor.
Several mutations of the polar and charged extracellular residues were
demonstrated to produce a shift of the first intracellular loop towards the Cterminus of the receptor, including mutations involving S178A and E179A, and
the N 192A-H281 A mutations. E 179A, H281 A, N 192A-H281 A, S 178A-E 179A,
S178A-E179A-N192A and S178A-E179A-N192A-H281A mutations shifted the
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apex of the ICL2 away from the C-terminus and towards TM1, in a conformation
that seems to be opposite of the N119S conformation. Two different
conformations of ICL3 were also seen in the mutations of the polar and charged
residues. The E 179A, H281 A and S 178A-E 179A-N 192A-H281 A mutations each
shifted ICL3 towards the C-terminus and the center of the receptor. In contrast,
the N 192A, N 192A-H281 A, S 178A, S 178A-E 179A, S 178A-E 179A-N 192A and
S 178A-E 179A-H281 A mutations caused ICL3 to be shifted away from the Cterminus and downward away from the cytoplasmic membrane. Finally, mutants
H281A, N192A-H281A and S178A produce an increased angle in Helix 8,
shifting the distal end of the helix away from the cell membrane, and displacing
the loop outwards from the native conformation.
Alterations of the conformation of the TM regions are also seen in the
mutants of the charged and polar extracellular residues, as seen in Figure 82.
Mutation of E179A alters TM1 such that there is increased angularity at residues
Tyr45 and Gly55 producing angularity of the base and apex of the helix. The
S178A mutation produces a more extended conformation of TM1. The H281A
and N192A mutations cause the apex of TM2 to be displaced towards TM2, while
the N 192A-H281 A and E 179A mutants possess decreased angularity at Asp84,
producing a displacement of the apical portion of the helix. Decreased angularity
at Leu120 displaces the base of TM3 in the E179A mutant, while the Apex of the
mutant is displace towards TM4 in the S 178A-E 179A-N 192A mutant. The
N 192A, H281 A, S 178A-E 179A-N 192A and S 178A-E 179A-H281 A mutations each
produce an outward tilt of TM4. Multiple conformations of tTM5 are adopted by
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Figure 82: Transmembrane regions of the polar/charged ECl mutants
adopt a similar conformation to native CXCR4. Reduced representations of
receptor transmembrane helices are presented: native CXCR4 in green, N119S
in red, S178A conformation in yellow, E179A conformation in teal, N192A
conformation in white, H281A conformation in blue, S178A-E179A conformation
in tan, S178A-E179A-N192A conformation in teal, S178A-E179A-H281A
conformation in yellow, S 178A-E 179A-N 192A-H281 A conformation in teal, and
the N 192A-H281 A conformation in white. The S 178A, E 179A, N 192A, H281 A,
S178A-E179A,S178A-E179A-N192A,S178A-E179A-H281A,S178A-E179AN192A-H281A, and N192A-H281A conformations adopt the transmembrane
structure of the native receptor. A) S178A 8) E179A C) N192A D) H281A E)
S178A-E179A F) S178A-E179A-N192A G) S178A-E179A-H281A H) S178AE 179A-N 192A-H281 A I) N 192A-H281 A
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Figure 82: Transmembrane regions of the polar/charged ECl mutants
adopt a similar conformation to native CXCR4. A) 5178A B) E179A C)
N192A D) H281A E) 5178A-E179A F) 5178A-E179A-N192A G) 5178A-E179AH281A H) 5178A-E179A-N192A-H281A I) N192A-H281A
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the polar extracellular mutants. An additional kink at Pro211 displaces the apex
of TM5 outwards in the S 178A-E 179A-H281 A mutant, while the entire helix is
displaced towards TM4 in the S178A-E179A mutant. The H281A and S178AE179A-N192A-H281A mutations each cause the TM5 bulge to reproduce the
more extended structure of the N119S conformation . In contrast, the N192A and
S178A mutants cause the TM5 bulge to adopt a tighter conformation than the
native structure, producing outward displacement of the apical and basal termini
of the helix. Modulation of TM6 structure is also affected by the mutants. S178A,
N 192A, H281 A, S 178A-E 179A-N 192A and S 178A-E 179A-H281 A mutations are
characterized by an additional kink at the base of the helix, shifting the terminus
towards TM5. The S178A-E179A and N192A-H281A mutations each produced
an additional angularity at Tyr255 , shifting the apex of the helix towards TM5 and
producing a more complex apical loop. S178A, E179A, S178A-E179A, N192A,
S 178A-E 179A-N 192A and S 178A-E 179A-H281 A mutants each featured and
additional angularity of the base of TM7 producing an outward displacement of
the terminus.
Several of the mutations of polar extracellular residues produced relatively
little impact on the intrahelical distances at the extracellular termini of the TM
regions as seen in Table 34. S178A produced increases of the TM1-2 and TM1-3
distances, and a decrease of the TM3-5 distance, causing these distances to
coincide with the expected interhelical distance of N119S. S178A-E179A-H281A
and S 178A-E 179A-N 192A-H281 A had similar sparse influence on the
extracellular termini of the helices, in the case of S 178A-E 179A-H281 A
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Table 34: Interhelical distances at the extracellular surface for the polar
extracellular mutants. Interhelical distances measured at extracellular termini of
transmembrane domains of native CXCR4, constitutively active N119s, and polar
extracellular mutant structures measured in averaged conformations of
dynamically determined structures. At the extracellular surface, K237 A altered
TM1 and TM2, K333A alter TM1, S338A alters TM1 and TM2, S341A alters TM3,
S351A alters TM1 and TM2, S351A-S352A alters TM1 and TM2.
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Table 34: Interhelical distances at the extracellular surface for the polar
extracellular mutants.
S178A
E179A
N192A

TM

Native

N119S

S178A

E179A

N192A

H281A

S178AE179A

N192AH281A

1-2

6.5

7.6

7.8

8.8

7.9

6.9

8.2

11.9

7.5

1-3

20.9

22.2

22.2

22.3

21.5

21.6

20.7

22.0

22.0

1-4

21.9

23.3

22.6

22.4

22.3

22.7

22.4

23.5

23.3

1-5

33.6

34.8

34.1

34.8

34.3

35.6

34.2

34.1

32.5

1-6

26.0

25.4

27.0

27.7

25.3

27.6

26.8

27.7

25.6

1-7

15.8

14.6

15.6

17.0

16.2

15.2

17.9

17.7

15.9

2-3

18.3

18.6

18.6

19.8

20.9

18.7

17.9

18.1

18.8

2-4

20.6

21.6

20.8

22.1

23.9

21.5

21.3

21.2

21.4

2-5

34.5

34.9

34.2

36.2

37.6

36.4

35.5

34.9

33.0

2-6

28.7

28.0

29.4

31.7

30.8

30.3

30.2

32.3

28.5

2-7

19.1

19.3

19.2

22.3

22.2

19.0

21.7

23.1

19.5
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increasing TM2-7, but decreasing TM3-5, while S178A-E179A-N192A-H281A
decreased TM2-5 and increased TM4-6 to coincide with the N119S distances.
In contrast several other mutations significantly altered these interhelical
distances. E179A mutation significantly altered the position of TM1 and TM2,
producing an average deviation of the interhelical distances involving these to
helices by 1.6 and 2.2

A respectively. Similar effects were seen

in N192A, where

alteration of TM2 position increased the interhelical distances involving this helix
by an average of 2.6

A.

H281 altered the TM5 and TM6, increasing TM1-5 and

TM2-5 by an average of 2 A, and TM1-6, TM2-6, and TM6-7 by an average of
1.5 A. S178A-E179A mutation caused TM1-2 , TM1-7, TM2-6 and TM2-7 to
increase by an average of 2 A. The N192A-H281A mutation significantly altered
TM1 at the extracellular surface, increasing interhelical distances involving this
helix by an average of 2.3 A. S178A-E179A-N192A seemed to have a different
effect from the rest of the mutations, in that it modulated TM5 position, producing
and average decrease in interhelical distance of this helix by 1.8

A.

Alterations of the interhelical distances at the intracellular surface are
listed in Table 35. S178A, N192A, S178A-S179A, S178A-E179A-N192A, S178AE179A-H281 and S178A-E179A-N192A-H281A alter the position of the base of
TM7, altering the average interhelical distance involving this helix by 2.9 A, 4.5

A, 2.9 A, -1.4 A, 3.1 A and 2.6 A, respectively.
This suggests that mutations of the extracellular polar residues alter the
conformation of CXCR4, primarily by displacing TM7 at the intracellular surface,
and displacement of TM1 and TM2 at the extracellular surface.
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Table 35: Interhelical distances at the intracellular surface for the polar
extracellular mutants. Interhelical distances measured at intracellular termini of

transmembrane domains of native CXCR4, constitutively active N119s, and polar
extracellular mutant structures measured in averaged conformations of
dynamically determined structures. At the intracellular surface, N192A altered
TM6 and TM7, H281A altered TM3 and TM6, N192A-H281A altered TM1,

S178A,S178A-E179A,S178A-E179A-H281A,S178A-E179A-N192A,and
S178A-E179A-N192A-H281 altered TM7.
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Table 35: Interhelical distances at the intracellular surface for the polar
extracellular mutants.

N192A
H281A

S178A
E179A
H281A

S178A
E179A
N192A

S178A
E179A
N192A
H281A

TM

Native

N119S

S178A

E179A

N192

H281A

S178A
E179A

1-4

18.2

17.7

17.8

18.4

17.2

16.7

18.8

17.1

18.0

18.0

17.6

1-6

20.5

21.3

21.7

20.7

22.4

20.7

20.5

21.7

21.8

21.0

20.0

2-7

11.7

12.3

11.3

11.5

12.6

11.2

13.5

11.8

10.5

12.9

13.1

3-5

11.5

16.5

11.7

11.5

11.9

14.3

12.4

11.5

11.5

12.2

11.7

3-7

21.5

22.2

23.3

21.2

25.2

20.5

24.3

21.3

19.9

25.5

25.0

4-6

19.5

17.6

18.7

18.5

19.0

20.1

19.1

19.5

19.1

17.7

18.4

4-7

22.3

21.0

21.8

21.9

22.7

21.1

24.4

21.5

20.8

23.3

24.4

5-7

24.8

23.7

28.4

25.8

29.5

25.0

28.2

25.0

24.1

28.1

27.1

6-7

12.3

11.8

15.6

12.5

17.3

13.1

15.6

13.3

12.3

16.3

16.0
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Mutations of non-polar extracellular mutants alter the extracellular
positions of TMs.
Mutations of the polar and charged groups of the extracellular surface of
CXCR4 produced significant alteration of several facets of the extracellular and
intracellular surface. V177 A-F276A, F189A-L 194A, V177 A-F189A-L 194A,
V177A-F189A-L 194A-F276A mutations produced a more compact distal Nterminus resembling the N119S conformation. The L 194A, V177 A and F189AL 194A mutations each shifted the apex of ECL 1 towards the N-terminus.
Substantial modifications of ECL3 were noted in conjunction with the V177 AF276A, F189A-L 194A, V177 A-F189A-L 194A, V177A-F189A-L 194A-F276A
mutations, shifting the apex of the loop away from the N-terminus and outwards
from the center of the receptor.
At the intracellular surface of the receptor, mutations altered the
positioning of several loop regions. V177 A, F189A, L 194A, F189A-L 194A,
V177 A-F189A-L 194A and V177 A-F276A mutations produced a shift of ICL2
tangential to the TM helices, but in the opposite direction from the N119S
mutation. F276A or F189A-L 194A-F276A mutation produces an intermediate
conformation for this loop between the native and N119S positions, while
directing the apex of the loop towards ICL3. The F189A, L 194A, F189A-L 194A
and V177 A-F189A-L 194A mutations each shifted the apex of ICL3 towards the
C-terminus and the center of the receptor. In contrast, V177 A, F276A, F189AL 194A-F276A and V177A-F189A-L 194A-F276A mutations shifted the apex of
ICL3 away from the C-terminus and downward away from the cytoplasmic
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membrane. V177 A mutation was associated with a more extended and distended
C-terminal region. F189A, L 194A, V177 A-F276A and V177 A-F189A-L 194A
mutations were also associated with and increased angle in Helix 8, shifting the
distal end of the helix away from the cell membrane, and displacing the loop
outwards from the native conformation.
These mutations also significantly altered the conformations of the TM
regions , as depicted in Figure 83. The F189A and V177 A-F276A mutations
produced greater displacement of TM1 towa rds TM2 . In the F276A and V177 AF189A-L 194A mutations, decreased angularity of Asp84 at the base of the helix
displaces the apical termini. Several of the mutations, including V177 A, L 194A,
F276A, F189A-L 194A, F189A-L 194A- F276A, V177 A-F276A and V177 A-F189AL 194A-F276A displaced the apex and base of TM4 by producing an increased
outward tilt of the helix. In the L 194A and F276A mutations, the bulge of TMS
was in a tighter conformation than the native , producing an outward displacement
of the basal terminus. In contrast, the F189A-L 194A-F276A mutation produced a
more extended bulge in the mode of N1 19S . The F276A and F189A-L 194A
mutations exhibited increased at Tyr2SS , shifting the apex of the helix towards
TMS . L 194A and V177 A-F276A mutations exhibited an additional angularity of
Phe249 , shifting the base of the helix towards TMS. Finally, V177 A, F189A,
L 194A, F276A, V177 A-F189A-L 194A and F189A, L 194A, V177 A-F276A
mutations exhibited an additional angularity at Pro299 , shifting the base of the
helix outwards from the center of the receptor.
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Figure 83: Transmembrane regions of the non-polar ECl mutants adopt a
similar conformation to native CXCR4. Reduced representations of receptor
transmembrane helices are presented: native CXCR4 in green, N119S in red, the
V177A conformation in teal, F189A conformation in yellow, L 194A conformation
in white, F276A conformation in magenta, V177 A-F276A conformation in orange,
V177A-F189A-L 194A conformation in teal , V177 A-F189A-L 194A-F276A
conformation in tan, F189A-L 194A conformation in violet, and the F189A-L 194AF276A conformation in aqua. The V177 A, F189A, L 194A, F276A, V177 A-F276A,
V177 A-F189A-L 194A, V177 A-F189A-L 194A-F276A, F189A-L 194A, and F189AL 194A-F276A conformations adopt the transmembrane structure of the native
receptor. A) V177A 8) F189A C) L 194A D) F276A E) V177A-F276A F) V177AF189A-L 194A G) V177A-F189A-L 194A-F276A H) F189A-L 194A I) F189AL 194A-F276A
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Figure 83: Transmembrane regions of the non·polar ECl mutants adopt a
similar conformation to native CXCR4. A) V177A B) F189A C) l194A D)
F276A E) V177A·F276A F) V177A·F189A·l194A G) V177A·F189A·l194A·
F276A H) F189A·l194A I) F189A·l194A·F276A
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Several of the mutations of non-polar extracellular residues significantly
altered intra helical distances at the extracellular termini of the TM regions as
seen in Table 36. Apical TM1 position was altered by the V177 A, L 194A, V177 AF276A and V177 A-F189A-L 194A-F276A mutations producing an average
increase in interhelical distance of 1.5, 1.9, 1.8, and 2.3 A, respectively. The apex
of TM2 was significantly altered by the F189A-L 194A mutation increasing the
intrahelical distances by an average of 1.8 A. The F189A and F189A-L 194AF276A mutations each altered the apical position of TM5 , decreasing interhelical
distances by 1.3 and 1.2 A, while L 194A mutation increased the interhelical
distances involving TM5 by an average of 2
Interhelical distances produced

A.

by the

non-polar mutants at the

intracellular surface are depicted in Table 37. Mutation of V177 A produces an
average decrease of interhelical distances involving TM3 of 1.5

A. The mutation

of F276A modulates the position of TM5 , increasing interhelical distances
involving this helix by an average of 2.1

A. The F189A mutation displaces TM7 to

increase its interhelical distances by an average of 3.4

A. In contrast, L194A and

V177 A-F189A-L 194A-F276A mutations each decrease the TM7 associated
interhelical distances by 2.1 and 1.2

A respectively.

The remaining mutants

maintain the native interhelical distances.
Although the non-polar mutants of the extracellular surface of CXCR4
mutants primarily maintain the native conformation of the receptor, several key
differences exist. Although the conformations of the extracellular loops and
transmembrane helixes are primarily in the native conformation, several of the
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Table 36: Interhelical distances at the extracellular surface for the nonpolar extracellular mutants. Interhelical distances measured at extracellular
termini of transmembrane domains of native CXCR4, constitutively active N119s,
and non-polar extracellular mutant structures measured in averaged
conformations of dynamically determined structures. A) V177A, L 194A, F189AL 194A, V177 A-F276A, and V177 A-F189A-L 194A-F276A alter TM1 conformation.
S) F189A, L 194A, F276A, F189A-L 194A, V177A-F276A, F189A-L 194A-F276A,
V177A-F189A-L 194A, and V177 A-F189A-L 194A-F276A alter TM5 conformation.
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Table 36A: Interhelical distances at the extracellular surface for the polar
extracellular mutants.

TM

Native

N119S

V177A

L194A

F189AL194A

V177AF276A

V177AF189AL194AF276A

1-2

13.4

11.9

13.4

13.3

12.3

13.7

13.5

1-3

24.6

25.7

23.0

24.1

24.2

24.6

24.2

1-4

18.2

17.7

17.8

18.0

16.9

18.2

16.7

1-5

32.2

33.9

31.0

31.9

31.4

32.2

31.3

1-6

20.5

21.3

20.2

21.0

20.6

20.9

20.7

1-7

12.2

13.6

12.0

12.0

12.2

11.8

12.7
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Table 36B: Interhelical distances at the extracellular surface for the polar
extracellular mutants.

TM

Native

N119S

F189A

L194A

F276A

F189A
L194A

V177A
F276A

F189A
L194A
F276A

V177AF189AL194A

V177AF189AL194AF276A

1-5

33.6

34.8

33.1

36.1

33.6

33.5

35.8

32.6

33.9

33.4

3-5

20.5

19.9

19.1

20.7

19.1

18.5

19.5

19.4

19.2

19.0

4-5

16.8

15.6

15.6

17.4

15.9

16.0

16.7

16.4

17.4

16.1

5-7

21.4

24.7

20.7

23.2

22.3

20.1

21.3

20.0

22.2

20.9
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Table 37: Interhelical distances at the intracellular surface for the non-polar
extracellular mutants. Interhelical distances measured at extracellular termini of
transmembrane domains of native CXCR4, constitutively active N119s, and nonpolar extracellular mutant structures measured in averaged conformations of
dynamically determined structures. A) V177 A, V177A-F189A-L 194A-F276A,
F189A, F189A-L 194A, F189A-L 194A-F276A, and F276A each alter the position
of TM1. 8) V177A, F189A-L 194A, F189A-L 194A-F276A, F276A, F189A, L 194A,
and V177 A-F189A-L 194A-F276A each alter the position of TM7.
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Table 37A: Altered TM1 interhelical distances at the extracellular surface
for the polar extracellular mutants.

TM

Native

N119S

V177A

V177A
F189A
L194A
F276A

1-4

18.2

17.7

17.8

16.7

17.2

16.9

18.1

18.0

17.9

1-5

32.2

33.9

31.0

31.3

30.7

31.4

31.8

31.9

34.6

1-6

20.5

21.3

20.2

20.7

21.0

20.6

21.6

21.0

22.1

F189A

F189AL194A

F189A
L194A
F276A

L194A

F276A
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Table 378: Altered TM7 interhelical distances at the extracellular surface
for the polar extracellular mutants.
F189A
L194A
F276A

F276A

F189A

L194A

V177A
F189A
L194A
F276A

TM

Native

N119S

V177A

F189A
L194A

2-7

11.7

12.3

11.8

12.6

11.5

11.5

14.9

11.0

10.6

3-7

21.5

22.2

20.1

22.7

20.4

21.8

25.3

19.1

20.4

4-7

22.3

21.0

22.0

22.4

21.8

21.5

25.0

21.5

20.9

5-7

24.8

23.7

24.0

25.3

24.5

27.6

27.3

22.9

23.3

6-7

12.3

11.8

12.3

13.9

12.7

14.0

16.8

12.0

11.6
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loops are modified the conformations of the extracellular and intracellular loops.
The cases of the F189A, l1 94A, V177 A-F276A and V177 A-F189A-l 194A
mutations are particularly interesting as these mutations result in a significant
increase in the angularity of Helix 8, shifting the base of the helix away from the
intracellular surface of the receptor. These changes are reflected in alterations of
the interhelical distances of the TM1 and TM5 of the extracellular surface of the
receptor, and Tm1 and Tm7 on the intracellular surface of the receptor.

Influence of ECl Mutants on CXCl12-mediated chemotaxis.
In light of the modifications of native CXCR4 structure produced by the
mutations of ECl residues, we attempted to generate stable cell lines expressing
mutated strains of CXCR4 by site directed mutagenesis. Unfortunately, we were
only able to generate stably transfected cell lines for the N192A, F276A, H281A,
V177A-F276A, V177A-F189A-l194A, S178A-E179A-H281A, and S178A-E179AN192A-H281A mutants.
We did find that several of these mutants displayed significant reductions
in chemotaxis as seen in Table 38 . Dose response analysis of the mutant
CXCR4 expressing cell lines to treatment with CXCl12, demonstrated that the
maximal chemotaxis of the V177 A-F276A, S 178A-E 179A-H281 A, S 178A-E 179AN192A-H281A, N192A and H281A each produced significant reductions in
chemotaxis when compared to wild type CXCR4. Maximal chemotaxis response
of the N192A mutant was produced by treatment with 10 nM treatment with
CXCl12, producing a maximal response 37% of the wild type maximal response.
Maximal chemotaxis response of the V177A-F276A, S 178A-E 179A-H281 A and

422

Table 38: Mutation of extracellular residues of CXCR4 alters chemotaxis.
Significant reductions of CXCL 12-induced chemotaxis were produced by V177 AF276A, S 178A-E 179A-H281 A, S 178A-E 179A-N 192A-H281 A, and N 192A
mutations. V177A-F189A-L 194A, F276A, and H281A mutations maintained WT
amplitude of chemotaxis ..
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Table 38: Mutation of extracellular residues of CXCR4 alters chemotaxis.
Strain

Maximal
Concentration

Chemotaxis
index

St. Dev.

WT

10

1

0.27

V177 A-F189A-L 194A

20

1.01

0.19

V177 A-F276A

20

0.20

0.19

S178A-E179A-H281A

20

0.44

0.014

S178A-E179A-N192A-H281A

20

0.10

0.13

N192A

10

0.37

0.17

F276A

20

1.47

1.32

H281A

10

1.29

0.82
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S178A-E179A-N192A-H281A mutants was achieved with 20 nM of CXCL 12,
producing a response which was 17%, 44% and 12% of WT. Each of these
mutations had produced alterations of TM7 interhelical distances at the
intracellular surface of the receptor suggesting impaired signal transduction
capabilities in the molecular dynamics studies.
These poor chemotaxis responses were in contrast to the results seen for
the V177A-F189A-L 194A, F276A, and H281A mutations. In these cases,
maximal chemotaxis response at 20 nM produced migrations of 100%, 125%,
and 150% of wild type. In the case of H281A, this mutant shared many dynamics
characteristics with the inactive S 178A-E 179A-N 192A-H281 A in that both
mutants primarily maintained the native conformation of the receptor and shifted
the apex of ICL3 towards the C-terminus and the center of the receptor. The only
noted differences were that H281A shifted the apex of the N-terminus outwards
from the center of the receptor and away from the N-terminus and the angle
taken at the origin of Helix 8 shifted the base of that helix away from the
cytoplasmic membrane. The V177A-F189A-L 194A and F276A mutants did not
share any common features in the dynamics simulations either.
Effects of ICL mutants on CXCL 12-mediated chemotaxis.

We also attempted to generate site directed mutations of ICL residues
highlighted in the virtual redocking program. However, difficulties in plasmid
generation, and cell line stability meant that the mutated cell lines available for
initial CXCL 12 dose response testing were limited to K234A, K239A, K239AT240A, A307E-K308A, A307E-K308A-F309A, S341A, S351A and S351A-S352A.
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Several of these mutants were found to have a significantly reduced
chemotaxis response to CXCL 12, as seen in Table 39 . The K234A, K239AT240A, A307E-K30BA, A307E-K30BA-F309A, and

S351A

mutants

each

expressed significant reduction in chemotaxis response when compared to WT.
The

A307E-K30BA

and

S351A-S352A

mutants

produced

no

significant

chemotaxis at any of the screened concentrations of CXCL 12.
The C-terminal serine residues are essential to CXCR4 function through
truncation mutants [342] and site directed mutagenesis [352] , so it is not
surprising that loss of these residues would impair chemotaxis. Mutations of helix
eight have not been demonstrated to adversely affect CXCR4 function, and in
fact disruption of this helix is one of the characteristics of the constitutively active
mutants. But perhaps it is because in the constitutively active mutants the center
of the helix is disrupted, while the mutations of the apex of the helix near the
base of TM7 continue to maintain helical conformation.
The K234A, K239A-T240A and A307E-K30BA-F309A mutants each
migrate in response to CXCL 12 although at a much reduced rate compared to
the WT strain , with maximal chemotaxis at 20 nM CXCL 12 producing chemotaxis
which was only 40 % and 5% of WT for the K234A and A307E-K30BA-F309A
mutants and maximal response at 10 nM for the K239A-T240A of only 20% of
WT. This suggests that ICL2 residues K234, K239 and T240 playa significant
role in transduceing the signal from the extracellular surface to the intracellular.
Effects of CXCR4 mutants on CXCL 12-mediated calcium mobilization.
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Table 39: Mutation of intracellular residues of CXCR4 alters chemotaxis.
Significant reductions of CXCL 12-induced chemotaxis were produced by K234A,
K239A-T240A, A307E-K308A, A307E-K308A-F309A, and S351A mutations.
K239A mutation maintained the amplitude of the CXCL 12-induced chemotaxis
response, while S341A and S351A-S352A mutation significantly increased
CXCL 12 induced Chemotaxis.
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Table 39: Mutation of extracellular residues of CXCR4 alters chemotaxis.

Strain

Maximal
Concentration

Chemotaxis
index

St. Dev.

WT

10

1

0.27

K234A

20

0.40

0.30

K239A

20

1.1

0.7B

K239A-T240A

10

0.20

0.063

A307E-K30BA

20

0.0053

0.0033

A307E-K30BA-F309A

10

0.054

0.060

8341A

10

4.30

0.93

8351A

1

0.095

0.14

8351 A-8352A

10

1.53

0.20
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Several hCXCR4-GFP mutants were generated targeting

residues

identified in the virtual re-docking analysis to see what impact loss of these
contact residues would have on the activity of active CXCR4 inhibitors. We
investigated the impact of these mutations on cell signaling via intracellular
calcium mobilization. We were able to generate cell lines and perform
intracellular calcium mobilization testing for the following extracellular hCXCR4GFP mutants: N192A, F276A, H281A, V177A-F276A, V177A-F189A-L 194A,
S179A-E179A-H281A, and S179A-E179A-N192A-H281A. We were also able to
generate cell lines and perform intracellular ca lcium mobilization testing for the
following intracellular mutants: K234A, K239A, K239A-T240A, A307E-K308A,
A307E-K308A-F309A, S341A, S351A and S351A-S352A.

The impact of the

extracellular mutants on CXCL 12 mediated signaling was assessed in terms of
signal amplitude and maximal CXCL 12 concentration. Table 40 depicts the
maximal CXCL 12 concentrations and invoked calcium responses for the
extracellular mutants. Three of these mutants, N 192A, F276A and V177 AF189A-L 194A, maintained a maximal CXCL 12 concentration of 10 nM. The
H281 A, V177 A-F276A, S 179A-E 179A-H281 A and S 179A-E 179A-N 192A-H281 A
mutations each increased maximal CXCL 12 concentration to 20 nM. Calcium
response was then assessed, and normalized to the maximal response produced
by WT CXCR4. Maximal calcium response was reduced by the N192A, F276A,
V177A-F276A, S179A-E179A-H281A and S179A-E179A-N192A-H281A. The
H281A and

V177A-F189A-L 194A mutants

mobilization of WT CXCR4.
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both

maintained

the

calcium

Table 40: Mutation of extracellular residues of CXCR4 alters CXCL 12induced calcium mobilization. Calcium response is presented as maximum
amplitude of calcium signal normalized to the maximal response of WT CXCR4.
Calcium response was reduced by N192A, F276A, V177A-F276A, S179AE 179A-H281 A and S 179A-E 179A-N 192A-H281 A mutations. H281 A and V177 AF189A-L 194A mutants both maintained the calcium mobilization of WT CXCR4.
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Table 40: Mutation of extracellular residues of CXCR4 alters CXCL 12induced calcium mobilization.
Mutant

Maximal
Calcium
concentration Mobilization

St. Dev.

WT

10

0.92

0.22

N192A

10

0.37

0.17

F276A

10

0.78

0.46

H281A

20

1.24

1.15

V177 A-F276A

10

0.26

0.18

V177 A-F189A-L 194A

20

1.01

0.19

S179A-E179A-H281A

20

0.44

0.01

S179A-E179A-N192AH281A

20

0.10

0.13
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The impact of the intracellular mutants on CXCL 12 mediated signaling
was assessed in terms of signal amplitude and maximal CXCL 12 concentration .
Table 41 depicts the maximal CXCL 12 concentrations and invoked calcium
responses for the extracellular mutants. Three of these mutants, K239A-T240A,
A307E-K308A-F309A and

S351A-S352A maintained

a maximal CXCL 12

concentration of 10 nM. The H K234A, K239A, A307E-K308A, S341A and S351A
mutations each increased maximal CXCL 12 concentration to 20 nM. Calcium
response was then assessed , and normalized to the maximal response produced
by WT CXCR4. Maximal calcium response was reduced by the K234A, K239A,
K239A-T240A, and A307E-K308A-F309A. The S341A and S351A-S352A
mutants both enhanced calcium mobilization when compared to WT CXCR4.
A307E-K308A and S351A mutants did not effectively transmit calcium signaling.
The impact of hCXCR4-GFP extracellular mutants on the activity of active
CXCR4 inhibitors of intracellular calcium mobilization was then assessed.
Compounds were tested using the maximal CXCL 12 concentration for each
mutant, and results were normalized fo r each mutant to a DMSO alone control.
Results were prepared for available mutants; however, due to difficulty in
successful generation of PCR based site directed mutant plasmid generation and
difficulties in generation and maintenance of single cell derived cell lines stably
expressing the plasmid protein, only select mutants were available for study.
The

V177 A-F276A

mutation

produced

an

interesting

phenotypical

difference when compared to wild type, as depicted in Figure 84. Mutation of
these two residues resulted in active inhibition of intracellular calcium
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Table 41: Mutation of intracellular residues of CXCR4 alters calcium
mobilization. Significant reductions of CXCL 12-induced chemotaxis were
produced by K234A, K239A-T240A, A307E-K308A, A307E-K308A-F309A, and
S351A mutations. K239A mutation maintained the amplitude of the CXCL 12induced chemotaxis response, while S341A and S351A-S352A mutation
significantly increased CXCL 12 induced Chemotaxis.
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Table 41: Mutation of intracellular residues of CXCR4 alters calcium
mobilization.
Mutant

Maximal
concentration

Calcium
Mobilization

St. Dev.

WT

10

0.92

0.22

K234A

20

0.40

0.30

K239A

20

0.65

0.19

K239A-T240A

10

0.1B

O.OB

A307E-K30BA

20

0.01

0.00

A307E-K30BA-F309A

10

0.05

0.06

S341A

20

2.07

0.41

S351A

20

0.01

0.00

S351 A-S352A

10

1.53

0.20
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Figure 84: ECLV514 and EV514·2·AB produce greater calcium inhibition in
V177 A·F276A mutant CXCR4. V177 A-F276A mutation produces greater
inhibition of calcium mobilization by ECLVS14 and EVS14-2-AB. EVS-2-AB
demonstrated a significant reduction in intracellular calcium mobilization, with a
nearly two-fold decrease in signaling at 50 !-1M. Unpaired samples denoted by *
have no WT counterpart because lack of screening activity did not warrant dose
response testing.
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Figure 84: ECLVS14 and EVS14·2·AB produce greater calcium inhibition in
V177 A·F276A mutant CXCR4.
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mobilization by EClVS14, a compound with no such activity in wild type cells. In
V177 A-F276A CXCR4 cells, the IC50 of this activity is roughly 40 I-IM, compared
to no significant inhibition in Wild type cells, suggesting that interaction with the
valine and phenylalanine residues in the wild type protein influences the manner
in which EClVS14 alters downstream signaling. Similarly, while not achieving
significant inhibition of intracellular calcium mobilization, the V177 A-F276A
mutation produced a greater than two fold decrease in signal amplitude for
compound EVS14-2-AB at 50 I-IM. In contrast, EClVS59 and EClVS82 both
inhibited intracellular calcium mobilization in V177 A-F276A CXCR4 cells, while
neither EVS14-21 nor EVS14-22 displayed a substantial increase in inhibition.
The

V177 A-F189A-l 194A

mutation

produced

several

noteworthy

phenotypical alterations, as depicted in Figure 85 . Unlike the V177 A-F276A
mutation, this mutation did not produce significant inhibition of intracellular
calcium mobilization by EClVS14, although signaling was reduced almost twofold by V177 A-F189A-l 194A mutation. A similar increase in compound mediated
inhibition was seen for EVS-2-AB, ·with an almost two fold increase in signaling
inhibition, but no significant inhibition of intracellular calcium mobilization.
Conversely, th is mutation caused compound EVS-21 to produce a significant
increase in intracellular calcium mobilization , with a greater than 2.5

fold

increase in signaling compared to DMSO alone control. This mutation also
produced a reduction in activity of compound EClVS59 , which while remaining a
significant inhibitor of calcium mobilization, saw a decrease in IC50 from 5 I-IM for
Wild type CXCR4 to 10 I-IM for the V177 A-F189A-l 194A mutant.
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Figure 85: EVS14-21 produces greater calcium mobilization in V177AF189A-L 194A mutant CXCR4. EVS14-21 treatment in cells expressing the
V177A-F189A-L 194A mutant produce an almost two and a half fold increase in
CXCL 12-induced signaling. Inhibitory activity of ECLVS14 and EVS-2-AB is
increased almost two-fold compared to WT. Unpaired samples denoted by * have
no WT counterpart because lack of high concentration activity did not warrant
dose response testing .
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Figure 85: EVS14-21 produces greater calcium mobilization in V177AF189A-l194A mutant CXCR4.
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N192A mutation produced relatively few phenotypic changes in compound
function , as depicted in Figure 86 . The only two differences involved improved
but still not significant inhibition of intracellular calcium mobilization by EClVS 14
and EVS-2-AB. Mutation of this residue produced a roughly 1.5 fold decrease in
signaling for EClVS14 and a roughly 2.5 fold decrease in signaling for EVS-2AB .
F276A mutation produced relatively few phenotypic changes in compound
function , as depicted in Figure 87. Two differences involved improved but still not
significant inhibition of intracellular calcium mobilization by EClVS14 and EVS-2AB . Mutation of this residue produced a roughly 1.5 fold decrease in signaling for
EClVS14 and a roughly 2 fold decrease in signaling for EVS-2-AB.
H281A mutation produced relatively few phenotypic changes in compound
function , as depicted in Figure 88 . Two differences involved improved but still not
significant inhibition of intracellular calcium mobilization by EClVS 14 and EVS-2AB . Mutation of this residue produced a ro ughly 2 fold decrease in signaling for
EClVS14 and a roughly 2.5 fold decrease in signaling for EVS-2-AB.
S178A-E179A-N192A-H281A

mutation

produced

several

interesting

alterations in compound phenotypes, as depicted in Figure 89 . While compound
EClVS59 activity remained relatively consistent between mutant and wild type,
inhibition by EClVS14, EVS-21 , EVS-22, and EVS-2-AB was significantly
enhanced , such that all four compounds produced significant inhibition of
intracellular calcium mobilization, when compared to DMSO alone control.
EClVS14 exhibited an IC50 of - 35, and EVS-21 , EVS-22 , and EVS-2-AB
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Figure 86: ECLVS14 and EVS14-2-AB produce greater inhibition of calcium
mobilization in N192A mutant CXCR4. ECLVS14 and EVS-2-AB achieve an
over one and a half fold reduction in CXCL 12 induced calcium signaling and a
nearly three-fold reduction in signaling for EVS-2-AB. Unpaired samples denoted
by * have no WT counterpart because lack of high concentration activity did not
warrant dose response testing.
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Figure 86: ECLVS14 and EVS14-2-AB produce greater inhibition of calcium
mobilization in N192A mutant CXCR4.
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Figure 87: ECLV514, EV514-21, EV514-22, and EV514-2-AB produce
greater inhibition of calcium mobilization in 5178A-E179A-N192A-H281A
mutant CXCR4. EClVS14, EVS-21 , EVS-22 , and EVS-2-AB achieve significant
inhibition of CXCl12-mediated intracellular calcium mobilization in cells
expressing S 178A-E 179A-N 192A-H281 A mutant CXCR4. ECl VS 14 was
improved to an IC5a of 35IJM while EVS-21 , EVS-22 and EVS-2-AB each
displayed IC5a values of less than 1a IJM. Unpaired samples denoted by * have
no WT counterpart because lack of high concentration activity did not warrant
dose response testing.
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Figure 87: ECLV514, EV514-21, EV514-22, and EV514-2-AB produce
greater inhibition of calcium mobilization in 5178A-E179A-N192A-H281A
mutant CXCR4.
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Figure 88: ECLVS14 and EVS14-2-AB produce greater inhibition of calcium
mobilization in F276A mutant CXCR4. EClVS14 and EVS-2-AB achieve
significant inhibition of CXCl12-mediated intracellular calcium mobilization in
cells expressing F276A mutant CXCR4. EClVS 14 and EVS-2-AB achieve a
nearly two-fold reduction in signaling for EClVS 14, and a two-fold reduction in
signaling for EVS-2-AB. Unpaired samples denoted by * have no WT counterpart
because lack of high concentration activity did not warrant dose response testing.
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Figure 88: EC LVS14 and EVS14-2-AB produce greater inhibition of calcium
mobilization in F276A mutant CXCR4.
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Figure 89: EVS14-2-AB produce greater inhibition of calcium mobilization
in H281A mutant CXCR4. EVS-2-AB achieves an over two and a half fold
reduction in CXCL 12 signaling. Unpaired samples denoted by * have no WT
counterpart because lack of high concentration activity did not warrant dose
response testing
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Figure 89: EVS14·2·AB produce greater inhibition of calcium mobilization
in H281A mutant CXCR4.
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produced IC50 values of 10 !-1M or less. loss of the charged contact residues in
the S 178A-E 179A-N 192A-H281 A mutation allows EClVS 14 and its derived
compounds to inhibit intracellular calcium mobilization to a substantially greater
degree than seen in wild type CXCR4, suggesting that interaction with these
residues influences the magnitude of the inhibition by these compounds, as well
as the specificity of their activity.
Difficulty in successful generation of site-directed mutant plasmids and
stably transfected cell lines meant that only one of the six desired intracellular
mutant cell lines, K239A, was generated for compound testing as depicted in
Figure 90 . There was no significant difference in IClGa9 , IClGa13 or IClGa36
mediated inhibition of intracellular calcium mobilization in K239A or WT cells.
However, K239A mutation produced a 2.4 fold decrease in IClGa12 activity at
50 !-1M, and a 2.7 fold decrease in IClGa12 activity at 10 !-1M. From

this

limited

data, it suggests that lyseine 239 on the second intracellular loop is important to
IClGa12-mediated inhibition of intracellular calcium mobilization.
Due to difficulty in producing stable CXCR4 mutants, there is a limited
volume of mutations from which to compare the data between the experimental
protocols exploring the effect of mutation of CXCR4 on chemotaxis and calcium
mobilization. However, some important conclusions can be drawn, as can be
seen in Table 42 . The S341A and S351A-S352A mutants each produced
increased amplitude of response to CXCl12 induced chemotaxis and calcium
mobilization. Like many of the inactive mutations, these mutants featured a
displacement of TM7, and helix eight adopted an angle, displacing the distal
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Figure 90: ICLGa12 produces greater inhibition of calcium mobilization in
K239A mutant CXCR4. Mutation of this residue significantly increased CXCL 12induced signaling for ICL VS 12 at 10 IJM and 50 IJM, increasing the IC50 of this
compound from 5 IJM in WT CXCR4 to 35 IJM in the K239A strain .
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Figure 90: ICLGa12 produces greater inhibition of calcium mobilization in
K239A mutant CXCR4.
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Table 42: Comparison of Mutant Molecular Dynamics and Experimental
data. Comparing the molecular dynamics and experimental data for the CXCR4
mutants developed by site directed mutagenesis, we find that while the mutants
primarily maintained the native conformation of CXCR4, each of the mutants
produced alteration of the dynamically determined structure of CXCR4. Of the
mutants developed by SDM , only the V177 A-F189A-L194A and H281 A mutants
reproduced WT chemotaxis and calcium mobilization activity. Two of the mutants
were hypersensitive to CXCL 12, two displayed no activity in Chemotaxis or
Calcium mobilization , and the remaining mutants displayed reduced CXCR4
activity.
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Table 42: Comparison of Mutant Molecular Dynamics and Experimental data.
Molecular Dynamics

Experimental

Mutant

Primary
Conformation

ECl

ICl

EC
TM

IC
TM

Chemotaxis

Calcium
Flux

Vl77AFl89All94A

Native

N-term,
ECl3

ICl3,
C-term

TM5

none

WT

WT

Vl77AF276A

Native

N-term,
ECLl,
ECl3

ICl2,
Helix 8

TM 1

TM l

decreased

decreased

Native

N-term,
ECLl

ICI2,
ICl3

none

TM7

decreased

decreased

Native

none

ICLl,
ICl2,
ICl3

none

TM7

decreased

decreased

Nl92A

Native

ECll

ICl3

TM2

TM6,
TM7

decreased

decreased

F276A

Native

none

ICLl,
ICl2,
ICl3

TM5

none

WT

decreased

H28lA

Native

ECl3

ICl2,
ICl3,
Helix 8

TM3,
TM4

TM5,
TM6

WT

WT

K234A

Native

N-term

ICl3

TMl,
TM5

none

decreased

decreased

none

TMl,
TM4,
TM6

WT

decreased

Sl78AE179AH28lA
Sl78AEl79ANl92AH28lA

K239A

Native

N-term

ICl2,
ICl3

K239AT240A

Native

ECl3

ICLl,
ICl2,
ICl3

TM6

TM6,
TM7

decreased

decreased

Native

ECLl

ICl2,
ICl3

TM6

TMl

Inactive

Inactive

Native

None

ICl3

TM7

TM6,
TM7

Inactive

Inactive

S34lA

Native

ECLl,

Helix 8

TM3

TM7

Increased

Increased

S35lA

Native

ECLl

ICl2,
ICl3,
Helix 8

TM 1,
TM2

TM7

Inactive

Inactive

S35lAS352A

Native

ElC3

ICLl,
Helix 8

TM1,
TM2

TM7

Increased

Increased

A307EK308A
A307EK308AF309A
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portion of the helix away from the cyto plasmic membrane. However, in contrast
to many of the other inactive mutants, these two preserved the structure and
conformation of their intracellular loops with minimal displacement from the
native conformation. Decreased chemotaxis and calcium mobilization activity. In
many of the mutants is associated with alteration of the ICL conformations from
the native.

In vivo testing of anti-CXCR4 compounds in a metastatic model reveals
significant anti-metastatic activity.
Experiments conducted by Dr. Rajesh Sharma sought to establish the
activity of anti-CXCR4 compounds in a CXCR4 dependant lung tumor metastasis
model. Initial development of the model centered on identifying CXCR4 cell
surface expression by a series of metastatic cell lines including Lewis lung
carcinoma cells, B16F10 melanoma cells, and TC-1 cervical carcinoma cells. Of
these, TC-1 cells expressed the most cell-surface CXCR4, as illustrated in Figure
91 a. This result is in line with prior research , demonstrating cidofovir antimetastatic activity in TC-1 cells via inhibition of CXCR4 signaling [353]. Lewis
lung carcinoma cells did not express elevated cell surface concentrations of
CXCR4, also illustrated in Figure 91 b.
Three compounds, ECLVS14, ICLGa28, and ICLGa36 were initially
assessed for in vivo cytotoxicity. These three represented the best of the antiCXCR4 compounds targeting the extracellular and intracellular surface of the
receptor. All three produced almost no cytotoxicity and selectively inhibited
CXCR4 mediated chemotaxis with chemotaxis IC50 values of 5 IJM for
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Figure 91: TC-1 cells express increased cell surface CXCR4. TC-1 cells (A)
express increased cell surface CXCR4 when compared to Lewis Lung carcinoma
cells (8). Expression of CXCR4 expression of 50 for TC-1 cells compared to 10
for Lewis Lung carcinoma cells suggests that TC-1 cells would be more
responsive the CXCR4 targeted inhibitors than Lewis Lung carcinoma cells.
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Figure 91: TC-1 cells express increased cell surface CXCR4.
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ECLVS14, 1 IJM for ICLGa28 and 1 IJM for ICLGa36. ICLGa28 and ICLGa36
also significantly inhibited CXCL 12-induced intracellular calcium mobilization with
IC50 values of 10 IJM and 6 IJM respectively. In vivo cytotoxicity was initially
assessed at 5 mg/kg body weight, 20 mg/kg body weight, and 40 mg/kg body
weight. None of these concentrations produced gross toxicity, as would be
exhibited by weight loss, physiological distress, overt illness, or lethargy over a
period of three weeks.
Further investigation using the Lewis lung carcinoma model revealed that
in a cell line with reduced surface expression of CXCR4, anti-CXCR4 compounds
do not inhibit metastasis (Figure 92 ). Investigation of the anti-CXCR4 compounds
using the TC-1 metastasis model compared ECLVS14, ICLGa28 and ICLGa36
mediated inhibition of tumor incidence and lung tumor burden to known inhibitor,
AMD31 00. As seen in Figure 93, all three compounds significantly reduced tumor
incidence and tumor burden. ECLVS 14 produced a roughly 60% improvement in
tumor incidence when compared to AMD31 DO , while ICLGa28 and ICLGa36
produced roughly equivalent reductions in incidence. Average tumor burden in
ECLVS14 treated mice was reduced by more than 60%, while reduction in tumor
burden was reduced by nearly 50% for AMD31 DO , ICLGa28 and ICLGa36. This
data confirms that these compounds are effective inhibitors of metastasis.
Summary

In the SBDD process, identification and characterization of active
compounds, illustrated in Chapters II and III , is followed by rationalization of
target protein structure and testing of lead compounds in in vivo models to
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Figure 92: Lewis lung cancer cell metastasis is not altered by anti-CXCR4
compounds. Usage of Lewis lung cancer cells in an in vivo metastasis model
reveals that treatment with anti-CXCR4 compound AMD3100 does not alter
tumor incidence or tumor burden.
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Figure 92: Lewis lung cancer cell metastasis is not altered by anti-CXCR4
compounds.
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Figure 93: Treatment with lead compounds ECLVS14, ICLGa28 and
ICLGa36 each reduce tumor incidence and tumor burden of TC-1 cells in a
syngenic mouse model of lung cancer metastasis. ECLVS14 reduced tumor
burden and incidence to a 60 % greater extent than AMD3100. ICLGa28 and
ICLGa36 each inhibited tumor incidence and burden to the same extent as
AMD3100, with each compound reducing tumor incidence and tumor burden by

50 %.
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Figure 93: Treatment with lead compounds ECLVS14, ICLGa28 and
ICLGa36 each reduce tumor incidence and tumor burden of TC·1 cells in a
syngenic mouse model of lung cancer metastasis.
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potentially translate the research from the laboratory to the clinic. In this chapter,
we have used a virtual redocking protocol based on Surflex-Dock to identify
residues of CXCR4 where interaction with active anti-CXCR4 compounds could
elicit a modification of phenotype. We sought to mutate these residues, in silico
through molecular dynamics simulations and in vitro through site directed
mutagenesis, to investigate whether or not mutations of these residues could
induce a change in structural conformation or an altered phenotype of CXCR4.
Virtual redocking identified eight contact residues for the ECl VS compounds,
and six contact residues for the IClGa compounds. Additional intracellular
mutants were generated based on contact residues between CXCR4 and Gai
identified in the dynamically docked structure of the two proteins. Stable
conformations of thirty-six total mutant structures of CXCR4 were generated to
investigate whether mutation of the identified residues in and of themselves could
induce an altered conformation of CXCR4.
Overall, the dynamically determined structures of the CXCR4 mutants
primarily adopted the conformation of the inactive native receptor, with no gross
deviations of transmembrane structure and maintenance of the helical
conformation of Helix eight. However, several key differences were noted in
some of the mutant structures. The mutations of ICl3 residues K239 and K240
altered the conformations of ICl2 and ICl3 as well as the base of TM6 and the
position of the intrahelical terminus of TM?, suggesting that these residues are
essential to the maintenance of TM? position and that mutation substantially
affects CXCR4 structure.
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Mutations of the initial portion of helix eight were not found to disturb
helical character of this region; however, several of the mutations produced
alterations of the conformation of ICl3, as well as the position of TM? Both of
the mutants developed by SOM targeting this region, A30?E-K308A and A30?EK308A-F309A were inactive and failed to produce a significant response to
CXCl12. This suggests that the apex of helix 8 at the base of the C-terminus is
essential to CXCR4 function.
Mutations of the distal C-terminus were found to predominantly maintain
the native structure of the receptor. However, several of the mutations altered
TM? position, as well as the angle of helix 8 in relation to the cytoplasmic
membrane. Interestingly, two of the mutants developed by SOM targeting this
region displayed hypersensitivity to CXCl12 in the form of increased response in
chemotaxis and calcium mobilization. One of these hypersensitive mutants,
S341A, produced a unique series of conformational changes in CXCR4 with
modulation of ECl1, helix 8, the extracellular terminus of TM3, and the
intracellular terminus of TM? Further exploration of these mutations would be
needed to determine the extent of their hypersensitivity.
Mutations of the extracellular surface of CXCR4 produced a variety of
alterations in CXCR4 conformation in molecular dynamics screening. In SOM
analysis, these mutants decreased CXCR4 response to CXCl12 in the form of
reduced chemotaxis and calcium mobilization. In total, this mutagenesis analysis
suggests that the altered CXCR4 conformations produced by mutation of target
site residues, that the target sites are essential to CXCR4 function.
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Perhaps the most important finding of this chapter though, came in the in
vivo testing of three of the most active anti-CXCR4 compounds identified in
Chapters II and III in a mouse model of pulmonary metastasis. In this assay, we
determined that ICLGa28 and ICLGa36 decreased both tumor incidence and
tumor burden to the same extent as AMD3100, without any of the associated
toxicity seen with the bicyclam compounds [160]. ECLVS14 produced even
greater inhibition of both pulmonary tumor development and tumor proliferation,
resulting in incidence and burden values of only 40 % of the values elicited by
AMD3100. By comparison, testing of anti-CXCR4 palindromic peptide CTCE9908 in a similar model of pulmonary metastasis produced a 50% reduction in
tumor incidence and tumor burden [176]. An 4F-Benzoyl derivative of T140, 4FBenzoyl-TN140003, was also found to decrease tumor burden by 37% in a
similar study [30]. Thus, these studies demonstrate that the ICLGa compounds
ICLGa28 and ICLGa36 each potentially inhibit CXCR4 mediated metastasis to
the same extent as existing CXCR4 inhibitors. This is the first evidence that
targeting the intracellular surface of a GPCR in order to inhibit G-protein binding
can be as effective inhibiting protein function as targeting the extracellular
surface. In addition, the 60% increase in inhibition of tumor burden and tumor
incidence marks ECLVS14 as one of the most active inhibitors of CXCR4mediated metastasis developed. In a clinical environment where there are
currently no anti-metastatic compounds in clinical trials, development of a nontoxic selective inhibitor of metastasis is a significant development.
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CHAPTER V: SUMMARY
Tumor metastasis represents a significant portion of the morbidity and
mortality attributable to neoplasia. Bone metastasis is present in 30-50% of
patients with highly metastatic visceral cancers such as breast, prostate, and
non-small cell lung cancer. The diffuse and systemic nature of metastatic disease
renders many conventional treatment modalities ineffective, presenting a
particularly perplexing predicament for treatment. Unfortunately there are no
primary anti-metastatic treatments approved by the FDA or in clinical trials.
Muller ef a/ proposed a theory of metastasis centered on chemoattraction.
In this theory, elevated CXCR4 surface expression by neoplastic cells coupled
with expression of the ligand of CXCR4, CXCL 12, in lung, lymph node, brain,
bone marrow and liver tissue, leads to directed migration of neoplastic cells to
these tissues. In these tissues, the neoplastic cells find favorable
microenvironments from which to spawn new metastatic foci. Elevated CXCR4
expression has been detected in over twenty three varieties of neoplastic cells
and is frequently associated with a more aggressive and metastatic phenotype
leading to greater patient morbidity and mortality.
CXCR4 is a G-Protein coupled receptor involved in signal transduction
and cell migration. It is essential in brain and heart development in the embryo,
and plays a critical role in the immune system, governing stem cell migration and
sequestration in the bone marrow and the development of lymphocytes and
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leukocytes. CXCR4 is also central to the process of HIV-1 infection, as one of the
primary coreceptors for HIV-1 entry into T-Iymphocytes.
One of the goals of SBDD is to identify structural targets which can be
used as a basis for inhibiting a pathological process. There are five available
target sites to inhibit a GPCR's signaling. The ligand can be sequestered or
inactivated or the ligand interaction surface of the receptor can be altered to
prevent interaction. The transmembrane regions of the receptor responsible for
signal transduction from the extracellular to the intracellular surface of the cell
membrane can be disrupted, or held in an inactive position. Finally, the
intracellular surface of the receptor can be prevented from interacting with the
coupled G-protein, either by altering or obstructing the intracellular surface of the
receptor or the complimentary interacting surface of the G-proteins. Inhibitory
efforts targeting CXCR4 have targeted just the extracellular surface of the
receptor. The remaining four targets remain largely unexplored. The hypothesis
of our research is that inhibition of CXCR4 can result in inhibition of metastasis,
and that this inhibition can be effected by targeting multiple sites of CXCR4, both
on the intracellular and extracellular surface of the receptor. The goals of this
research were to utilize SBDD to rationally target specific sites of CXCR4 to
develop inhibitors of metastasis. In this process, we would gain a greater
understanding of chemical elements which could induce phenotypical changes
produced by inhibitors through the use of QSAR analysis. We would also gain
insight into the structural changes elicited in the receptor by interactions between
active inhibitors and their targets through the use of molecular dynamics
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simulations. We would additionally gain insight into the receptor targets
themselves through the use of virtual screening in conjunction with molecular
dynamics and site directed mutagenesis.
Our analysis of compounds targeting the extracellular surface of the
receptor identified three compounds which inhibited CXCR4 at 10 IJM or less.
ECl VS 14 stands out amongst these compounds as a selective inhibitor of
CXCR4 with minimal cytotoxicity. Subsequent QSAR analysis of EClVS14
revealed that although conversion of the hydrazine-alkyl linker group increased
anti-CXCR4 activity, it also increased cytotoxicity. lengthening of the hydrazinealkyl linker moiety was found to reduce anti-CXCR4 activity, as did removal of the
1-BPMAM moiety. Modification of the terminal benzene group by addition of
electronegative substituents also decreased the anti-CXCR4 activity of the parent
compound. EClVS14 is unique in its inability to modify calcium signaling, a
characteristic that is not shared by any other CXCR4 inhibitors [289-291],
including T140 [195] and AMD3100 [275].
Our five ns molecular dynamics simulations have allowed us to gain a
finer mechanistic understanding of the interaction between CXCR4 and
EClVS14. We have found that EClVS14 drives CXCR4 into a unique
conformation which seems to be more open at the extracellular surface than
seen in the native conformation, but less open than seen in the N119S
conformation.
Targeting the interface between the intracellular surface of CXCR4 and
the G protein subunit Gai with virtual screening allowed us to identify twenty-four
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compounds which significantly inhibited CXCR4-mediated chemotaxis. This initial
hit rate of 64.9 % at 50 IlM represents a significant increase over contemporary
virtual screening and high-throughput studies. Ten of these compounds inhibited
CXCR4 mediated chemotaxis at 10 IlM or less, and only 5 of these compounds
displayed any activity in fellow class A GPCR BLT1 demonstrating that the
compounds were highly selective for the intracellular interface of CXCR4. Three
of the ICLGa compounds were also found to inhibit tumor cell proliferation, an
intriguing result, as a CXCR4 inhibitor need not be cytotoxic to function as a
metastatic agent, for instance ICLGa36 inhibits chemotaxis but does not affect
metastatic cell proliferation.
Molecular dynamics analysis revealed that several of the compounds
interacted with components of the side chains and backbones of ICL 1 and ICL2,
suggesting that the compounds could act as bridging elements between these
two regions, stabilizing their position and preventing signal transduction or
producing a more closed intracellular surface potentially incapable of binding Gai.
Interaction by the compounds with the C-terminal region could potentially
stabilize TM?, or interfere with the interface between the C-terminus and Gai.
This could be especially true in the case of ICLGa28, where interposition of the
compound between the C-terminus and ICL3 could restrict the movement of both
regions and directly impede the cleft which would be occupied by bound Gai.
This study represents the first attempt of structure based drug design to
successfully target the intracellular surface of a GPCR. Further, we demonstrate
that selective inhibition of GPCR function need not only target the extracellular
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CXCl12 interface, as has been the objective of all other anti-CXCR4 compound
development, but rather that CXCR4 can be effectively inhibited by interfering
with the entire sequence of events of its signal transduction apparatus.
Further examination of CXCR4 structure through in silico mutation of
target site residues identified by our virtual rescreening protocol determined that
while the receptors predominantly maintained in the inactive native conformation
several significant differences between native and mutant structures were
detected. These differences were corroborated by our admittedly limited in vitro
analysis of mutations of the target site residues produced by site directed
mutagenesis. All but two of these mutants displayed reductions of chemotaxis
and calcium mobilization by 50% or greater when compared to the wild type
receptor. The remaining two mutants were hypersensitive to CXCl12
administration, producing elevated chemotaxis and calcium mobilization
responses. This suggests that the target sites selected are essential for CXCR4
function and that compound interactions modulating these sites, could potentially
alter the CXCR4 phenotype.
Perhaps the most important findings of this dissertation came in the in vivo
testing of three of the most active anti-CXCR4 compounds, EClVS 14, IClGa28
and IClGa36 in a mouse model of pulmonary metastasis. In finding that
IClGa28 and IClGa36 both decreased both tumor incidence and tumor burden
by 50 %, we demonstrated for the first time that the anti-CXCR4 compounds
targeting the intracellular surface could inhibit metastasis to the same extent as
extracellular inhibitors of CXCR4 AMD3100, CTCE-9908 and T140 derivative,
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4F-Benzoyl-TN140003. In addition, the almost 80% decrease of tumor incidence
and tumor burden produced by ECl VS 14 represented highly significant inhibition
of tumor burden and incidence, a 60% increase over the inhibition produced by
the most advanced CXCR4 inhibitor, AMD31 00. All three of the screened
compounds produced no detectable toxic side effects. In a clinical environment
where there are currently limited anti-metastatic compounds in clinical trials,
development of three non-toxic selective inhibitors of metastasis is a significant
development.
The findings presented in this dissertation provide insight into the process
of SBDD targeting a GPCR. We have successfully demonstrated that metastasis
can be inhibited by targeting multiple regions of CXCR4. We have used drug
discovery to develop sixteen lead compounds which have great potential as
scaffolds for inhibiting CXCR4. Building upon these results, further drug
discovery focusing on optimization of the lead compounds could allow
characterization of essential pharmacophores for lead compound activity. The
impact of the compounds on different mechanisms of CXCR4 signaling could
further characterize the mechanism of action for each of the lead compounds.
Development of additional mutants based on the interaction residues identified in
the molecular dynamics study could also allow us to confirm the dynamically
determined interaction site for the compounds. Further virtual screening could
attempt to develop CXCR4 inhibitors targeting the remaining two potential
regions of CXCR4: the intrahelical regions of CXCR4 as well as the CXCl12
interface with the extracellular surface of CXCR4.
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